Acetamide Compounds as Fungicides

ABSTRACT

Compounds of the general formula (I); wherein the substituents are as defined in claim  1 , are useful as fungicides.

This invention relates to novel N-substituted-2-alkylthio-2-(substitutedaryloxy and heteroaryloxy)alkylamides and to their sulphinyl andsulphonyl derivatives. It also relates to processes for preparing them,to compositions containing them and to methods of using them to combatfungi, especially fungal infections of plants.

Certain pyridyloxy(thio)alkanoic and heteroaryloxy(thio)alkanoic acidamide derivatives and their use as agricultural and horticulturalbactericides are disclosed in WO 99/33810 and JP 2001-89453. Certainsubstituted phenoxybutyramides and their use as mildewicides aredescribed in EP 0,001,721. Certain phenoxy and pyridyloxy alkanoic acidamides and their use as fungicides are described in WO 04/047537, WO04/048316, WO 04/048315 and WO 03/048128. Certain phenoxy andheteroaryloxy alkoxy acetamide derivatives and their use as fungicidesare disclosed in WO 04/052100, WO 04/048337 and WO 04/047538. The use ofcertain substituted 2-alkylsulphonyl-2-phenoxyalkylanilides asphotographic materials is disclosed in JP 61,86702 and in U.S. Pat. No.4,286,053.

The present invention is concerned with the provision of particularN-substituted-2-alkylthio-2-(substituted aryloxy andheteroaryloxy)alkylamides and their sulphinyl and sulphonyl derivativesfor use mainly as plant fungicides.

Thus according to the present invention there is provided a compound ofthe general formula (1):

whereinAr is aryl (e.g. phenyl, naphthyl), heteroaryl (5-membered heteroaryle.g. pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl,thiadiazolyl, tetrazolyl; 6-membered heteroaryl e.g. pyridyl,pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl; 5-membered heteroarylfused to benzene e.g. indolyl, benzofuranyl, benzothienyl,benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl,benzisothiazolyl, indazolyl, benzoxadiazolyl, benzothiadiazolyl,benzotriazolyl; 5-membered heteroaryl fused to two benzene rings e.g.dibenzofuranyl, dibenzothienyl; 5-membered heteroaryl fused to onebenzene ring and one pyridine ring e.g. benzofuropyridyl,benzothienopyridyl; 6-membered heteroaryl fused to benzene e.g.quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl), or a partially orfully saturated cyclyl optionally containing one or two heteroatomsindependently selected from N, O or S (e.g. 9H-fluorenyl,1,2,3,4-tetrahydronaphthyl, indanyl, 1,3-benzodioxolyl,1,3-benzoxathiolyl, 1,3-benzodithiolyl),the aryl, heteroaryl or partially or fully saturated cyclyl beingoptionally substituted with one, two, three, four or five substitutentsindependently selected from halo (e.g. fluoro, chloro, bromo, iodo),cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl), halo(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo-(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g. phenoxy),aryl(C₁₋₆)alkyl (e.g. benzyl), aryl(C₁₋₆)alkoxy (e.g. benzyloxy),heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl-(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy(e.g. pyridylmethoxy), —SF₅, —S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethyl-sulphonyloxy), —CONR^(u)R^(v), —COR^(u), —CO₂R^(u),—CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NR^(u)CO₂R^(v),—SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted;R¹ is C₁₋₄ alkyl (e.g. methyl, ethyl), halo(C₁₋₄)alkyl (e.g. CF₃, CF₂H,CF₂Cl, CH₂CH₂F) or C₃₋₄ cycloalkyl;R² is H, C₁₋₈ alkyl (e.g. methyl, ethyl, iso-propyl), C₃₋₄ cycloalkyl(e.g. cyclopropyl), C₂₋₈ alkenyl (e.g. allyl, 3-methyl-but-2-enyl,4-methyl-pent-2-enyl), cyano(C₁₋₄)alkyl (e.g. cyanomethyl, cyanoethyl),C₁₋₄ alkoxy(C₁₋₄)alkyl (e.g. methoxymethyl, ethoxyethyl), C₁₋₄alkoxy(C₁₋₄)alkoxy(C₁₋₄)alkyl (e.g methoxyethoxymethyl) orbenzyloxy(C₁₋₄)alkyl (e.g. benzyloxymethyl) in which the phenyl ring ofthe benzyl moiety is optionally substituted with C₁₋₄ alkoxy;R³ is (CR^(a)R^(b))_(p)(CR^(c)R^(d))_(q)(X)_(r)(CR^(e)R^(f))_(s)R⁴,whereinR^(a). R^(b), R^(c), R^(d), R^(e) and R^(f) are independently H, C₁₋₄alkyl (e.g. methyl), halo (e.g. chloro), cyano, hydroxy, C₁₋₄ alkoxy(e.g. methoxy) or C₁₋₄ alkoxycarbonyl (e.g. ethoxycarbonyl), orR^(a)R^(b), R^(c)R^(d) or R^(e)R^(f) may join to form a 3-8 memberedring optionally containing an oxygen, sulfur or nitrogen atom,X is (CO), (CO)O, O(CO), O, S(O)_(t) wherein t is 0, 1 or 2, NH orN(C₁₋₆)alkyl,p, r and s are 0 or 1,q is 0, 1 or 2,R⁴ is C₁₋₆ alkyl (e.g. methyl, ethyl, iso-propyl, n-butyl, tert-butyl)optionally substituted with one, two or three substituents independentlyselected from halo (e.g. fluoro, chloro), cyano or hydroxy, C₁₋₄alkoxy(C₁₋₄)alkyl (e.g. methoxymethyl, ethoxyethyl), C₁₋₄alkoxy-(C₁₋₄)alkoxy(C₁₋₄)alkyl (e.g methoxyethoxymethyl),benzyloxy(C₁₋₄)alkyl (e.g. benzyloxymethyl), C₂₋₆ alkenyloxy (e.g.allyloxy), —S(O)_(x)(C₁₋₆)alkyl wherein x is 0, 1 or 2 and the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.2,2,2-trifluoroethylthio), mono- or di-(C₁₋₆)alkylamino (e.g.N-methylamino, N,N-dimethylamino) or tri(C₁₋₄)alkylsilyl (e.g.trimethylsilyl), orR⁴ is C₂₋₆ alkenyl (e.g. ethenyl, allyl) optionally substituted withone, two or three substituents independently selected from halo (e.g.chloro), cyano, hydroxy, C₁₋₆ alkoxy (e.g. methoxy), C₁₋₆ alkylcarbonyl(e.g. acetyl), C₁₋₆ alkoxycarbonyl (e.g. methoxycarbonyl), phenyloptionally substituted with C₁₋₄ alkoxy, orR⁴ is —CH₂—C≡C—R⁵, whereinR⁵ is H, C₁₋₈ alkyl, C₃₋₆ cycloalkyl or C₃₋₆ cycloalkyl(C₁₋₄)alkyl inwhich the alkyl or cycloalkyl group is optionally substituted with halo,hydroxy, C₁₋₆ alkoxy, C₁₋₃ alkoxy-(C₁₋₃)alkoxy, cyano, C₁₋₄alkylcarbonyloxy, aminocarbonyloxy or mono- ordi(C₁₋₄)alkyl-aminocarbonyloxy, tri(C₁₋₄)alkylsilyloxy,—S(O)_(g)(C₁₋₆)alkyl where g is 0, 1 or 2, or R⁵ is optionallysubstituted aryl (e.g. phenyl), optionally substituted aryl(C₁₋₄)alkyl(e.g. benzyl), optionally substituted aryloxy(C₁₋₄)alkyl (e.g.phenoxymethyl), optionally substituted aryl(C₁₋₄)alkoxy(C₁₋₄)alkyl (e.g.benzyloxymethyl), optionally substituted heteroaryl (e.g. pyridyl,thienyl, pyrazolyl, imidazolyl, triazolyl) or optionally substitutedheteroaryl(C₁₋₄)alkyl (e.g. pyridylmethyl, phthalimidoethyl), optionallysubstituted heteroaryloxy(C₁₋₄)alkyl (e.g. thienyloxymethyl) oroptionally substituted heteroaryl-(C₁₋₄)alkoxy(C₁₋₄)alkyl (e.g.thienylmethoxymethyl),in which the optionally substituted aryl and heteroaryl rings ormoieties of the R₅ values are optionally substituted with one, two orthree substituents independently selected from halo (e.g. fluoro,chloro, bromo, iodo), cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl),halo(C₁₋₆)alkyl (e.g. trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl,C₂₋₆ alkynyl (e.g. propargyl), halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g.methoxy), halo(C₁₋₆)alkoxy (e.g. trifluoromethoxy), C₂₋₆ alkenyloxy(e.g. allyloxy), halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g.propargyloxy), halo(C₂₋₆)-alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g.phenoxy), aryl(C₁₋₆)alkyl (e.g. benzyl), aryl-(C₁₋₆)alkoxy (e.g.benzyloxy), heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy (e.g.pyridylmethoxy), —SF₅, —S(O)_(g)(C₁₋₄)alkyl wherein g is 0, 1 or 2 andthe alkyl is optionally substituted with halo (particularly fluoro, e.g.trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkyl group isoptionally substituted with halo (particularly fluoro, e.g.trifluoromethylsulphonyloxy), —CONR^(g)R^(h), —COR^(g), —CO₂R^(g),—CR^(g)═NR^(h), —NR^(g)R^(h), —NR^(g)COR^(h), —NR^(g)CO₂R^(h),—SO₂NR^(g)R^(h) or —NR^(g)SO₂R^(i) where R^(i) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(g) and R^(h) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(g)R^(h) or —SO₂NR^(g)R^(h), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted, orR⁴ is C₃₋₆ cycloalkyl (e.g. cyclopropyl, cyclopentyl, cyclohexyl), C₅₋₆cycloalkenyl (e.g. cyclopentenyl, cyclohexenyl), aryl (e.g. phenyl,naphthyl), heteroaryl (5 membered heteroaryl e.g. pyrrolyl, furyl,thienyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl,isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl;6-membered heteroaryl e.g. pyridyl, pyridazinyl, pyrimidyl, pyrazinyl,triazinyl), or a partially or fully saturated cyclyl optionallycontaining one or two heteroatoms independently selected from N, O or S(e.g. pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl, piperidyl,dioxolanyl, morpholino, thiadiazinyl, 1,2,3,4-tetrahydronaphthyl,2,3-dihydrobenzo-furanyl), the aryl, heteroaryl or partially or fullysaturated cyclyl being optionally substituted with one, two or threesubstituents independently selected from halo (e.g. fluoro, chloro,bromo, iodo), cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl, n-pentyl),halo(C₁₋₆)alkyl (e.g. trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl,C₂₋₆ alkynyl (e.g. propargyl), halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g.methoxy), halo(C₁₋₆)alkoxy (e.g. difluoromethoxy, trifluoromethoxy),C₂₋₆ alkenyloxy (e.g. allyloxy), halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy(e.g. propargyloxy), halo(C₂₋₆)-alkynyloxy, —SF₅, —S(O)_(x)(C₁₋₆)alkylwherein x is 0, 1 or 2 and the alkyl group is optionally substitutedwith halo (particularly fluoro, e.g. trifluoromethylsulphonyl),—OSO₂(C₁₋₄)alkyl where the alkyl group is optionally substituted withhalo (particularly fluoro, e.g. trifluoromethylsulphonyloxy),—CONR^(x)R^(y), —CON(OR^(x))R^(y), —COR^(x), —CO₂R^(x), —CR^(x)═NR^(y),—NR^(x)R^(y), —NR^(x)COR^(y), —NR^(x)CO₂R^(y), —SO₂NR^(x)R^(y) or—NR^(x)SO₂R^(z) where R^(z) is C₁₋₈ alkyl optionally substituted withhalogen and R^(x) and R^(y) are independently H or C₁₋₆ alkyl optionallysubstituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂), orR² and R³ may join to form a saturated or unsaturated 5- or 6-memberedring optionally containing an O or S atom (e.g. tetrahydropyrrolyl,thiazolidinyl, piperidino, morpholino, thiomorpholino, 2,5dihydropyrrolyl) and optionally substituted with one, two or three halo(e.g. chloro), C₁₋₄ alkyl (e.g. methyl, ethyl) or mono- ordi-(C₁₋₄)alkylamino-carbonyl, or optionally containing an N atom (e.g.piperazinyl) which is optionally substituted on the N atom with C₁₋₄alkyl optionally substituted with halo, C₁₋₆ alkoxy or cyano, or phenyloptionally substituted with nitro, C₁₋₄ alkyl, halo(C₁₋₄)alkyl (e.g.trifluoromethyl), C₁₋₄ alkylcarbonyl (e.g. acetyl) or heteroaryl (e.g.pyridyl), or R² and R³ may join to form a 6,6-membered saturated bicycle(e.g. decahydro-isoquinoline); wherein any of the foregoing alkyl,cycloalkyl, alkenyl, alkynyl, aryl or heteroaryl groups or moieties areoptionally substituted;

L is O or S; and

n is 0, 1 or 2.

The compounds of the invention contain at least one asymmetric carbonatom and may exist as enantiomers (or as pairs of diastereoisomers) oras mixtures of such. Further, when n is 1, the compounds of theinvention are sulphoxides, which can exists in two enantiomeric forms,and the adjacent carbon can also exists in two enantiomeric forms.Compounds of general formula (1) can therefore exist as racemates,diastereoisomers, or single enantiomers, and the invention includes allpossible isomers or isomer mixtures in all proportions. It is to beexpected that for any given compound, one isomer may be morefungicidally active than another.

Except where otherwise stated, alkyl groups and alkyl moieties ofalkoxy, alkylthio, etc., suitably contain from 1 to 6, typically from 1to 4, carbon atoms in the form of straight or branched chains. Examplesare methyl, ethyl, n- and iso-propyl and n-, sec-, iso- and tert-butyl.Where alkyl moieties contain 5 or 6 carbon atoms, examples are n-pentyland n-hexyl. Examples of suitable optional substituents of alkyl groupsand moieties include halo, hydroxy, C₁₋₄ alkoxy and C₁₋₄alkoxy(C₁₋₄)alkoxy, optionally substituted aryl and optionallysubstituted heteroaryl. Where the optional substituent is halo, thehaloalkyl group or moiety is typically trichloromethyl ortrifluoromethyl.

Except where otherwise stated, alkenyl and alkynyl moieties alsosuitably contain from 2 to 6, typically from 2 to 4, carbon atoms in theform of straight or branched chains. Examples are allyl, ethynyl andpropargyl. Optional substituents include halo.

Halo includes fluoro, chloro, bromo and iodo. Most commonly it isfluoro, chloro or bromo and usually fluoro or chloro

Aryl is usually phenyl but also includes naphthyl, anthryl andphenanthryl.

Heteroaryl is typically a 5- or 6-membered aromatic ring containing oneor more O, N or S heteroatoms, which may be fused to one or more otheraromatic or hetero-aromatic rings, such as a benzene ring. Examples arethienyl, furyl, pyrrolyl, isoxazolyl, oxazolyl, thiazolyl, oxadiazolyl,pyrazolyl, imidazolyl, triazolyl, isothiazolyl, tetrazolyl,thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl,benzofuranyl, benzo-thienyl, dibenzofuranyl, dibenzothienyl,benzothiazolyl, benzoxazolyl, benzimidazolyl, indolyl, quinolyl,isoquinolyl, quinazolinyl and quinoxalinyl groups and, whereappropriate, N-oxides and salts thereof. Any of the aryl or heteroarylvalues are optionally substituted. Except where otherwise stated,substituents which may be present include one or more of the following:halo, hydroxy, mercapto, C₁₋₆ alkyl (especially methyl and ethyl), C₂₋₆alkenyl (especially allyl), C₂₋₆ alkynyl (especially propargyl), C₁₋₆alkoxy (especially methoxy), C₂₋₆ alkenyloxy (especially allyloxy), C₂₋₆alkynyloxy (especially propargyloxy), halo (C₁₋₆)alkyl (especiallytrifluoromethyl), halo(C₁₋₆)alkoxy (especially trifluoromethoxy),—S(O)_(m)(C₁₋₆)alkyl wherein m is 0, 1 or 2 and the alkyl is optionallysubstituted with halo, hydroxy(C₁₋₆)alkyl, C₁₋₄ alkoxy(C₁₋₄)alkyl,C₁₋₄alkoxy(C₁₋₄)alkoxy, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl,optionally substituted aryl (especially optionally substituted phenyl),optionally substituted heteroaryl (especially optionally substitutedpyridyl or pyrimidinyl), optionally substituted aryloxy (especiallyoptionally substituted phenoxy), optionally substituted heteroaryloxy(especially optionally substituted pyridyloxy or pyrimidinyloxy),optionally substituted —S(O)_(m)aryl wherein m is 0, 1 or 2 (especiallyoptionally substituted phenylthio), optionally substituted—S(O)_(m)heteroaryl wherein m is 0, 1 or 2 (especially optionallysubstituted pyridylthio or pyrimidinylthio), optionally substitutedaryl(C₁₋₄)alkyl (especially optionally substituted benzyl, optionallysubstituted phenethyl and optionally substituted phenyl n-propyl) inwhich the alkyl moiety is optionally substituted with hydroxy,optionally substituted heteroaryl(C₁₋₄)alkyl (especially optionallysubstituted pyridyl- or pyrimidinyl(C₁₋₄)alkyl), optionally substitutedaryl(C₂₋₄)alkenyl (especially optionally substituted phenylethenyl),optionally substituted heteroaryl(C₂₋₄)alkenyl (especially optionallysubstituted pyridylethenyl or pyrimidinylethenyl), optionallysubstituted aryl(C₁₋₄)alkoxy (especially optionally substitutedbenzyloxy and phenethyloxy), optionally substitutedheteroaryl(C₁₋₄)alkoxy (especially optionally substitutedpyridyl(C₁₋₄)alkoxy or pyrimidinyl(C₁₋₄)alkoxy), optionally substitutedaryloxy(C₁₋₄)alkyl (especially phenoxymethyl), optionally substitutedheteroaryloxy-(C₁₋₄)alkyl (especially optionally substituted pyridyloxyor pyrimidinyloxy(C₁₋₄)alkyl), optionally substituted—S(O)_(m)(C₁₋₄)alkylaryl wherein m is 0, 1 or 2 (especially optionallysubstituted benzylthio and phenethylthio), optionally substituted—S(O)_(m)(C₁₋₄)alkyl-heteroaryl wherein m is 0, 1 or 2 (especiallyoptionally substituted pyridyl(C₁₋₄)alkylthio orpyrimidinyl(C₁₋₄)alkylthio), optionally substituted—(C₁₋₄)alkylS(O)_(m)aryl wherein m is 0, 1 or 2 (especiallyphenylthiomethyl), optionally substituted —(C₁₋₄)alkylS(O)_(m)heteroaryl wherein m is 0, 1 or 2 (especially optionallysubstituted pyridylthio(C₁₋₄)alkyl or pyrimidinylthio(C₁₋₄)alkyl),acyloxy, including C₁₋₄ alkanoyloxy (especially acetyloxy) andbenzoyloxy, cyano, isocyano, thiocyanato, isothiocyanato, nitro,NR^(g)R^(h), —NHCOR^(g), —NHCONR^(g)R^(h), —CONR^(g)R^(h), —CO₂R^(g),—SO₂R^(i), —OSO₂R^(i), —COR^(g), —CR^(g)═NR^(h) or —N═CR^(g)R^(h) inwhich R^(i) is C₁₋₄ alkyl, halo(C₁₋₄)alkyl, C₁₋₄ alkoxy,halo(C₁₋₄)alkoxy, C₁₋₄ alkylthio, C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, phenyl or benzyl, the phenyl and benzyl groupsbeing optionally substituted with halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy andR^(g) and R^(h) are independently hydrogen, C₁₋₄ alkyl, halo(C₁₋₄)alkyl,C₁₋₄ alkoxy, halo(C₁₋₄)alkoxy, C₁₋₄ alkylthio, C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, phenyl or benzyl, the phenyl and benzyl groupsbeing optionally substituted with halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy.

Of particular interest are compounds (1) where Ar is aryl (e.g. phenyl,naphthyl), heteroaryl (5-membered heteroaryl e.g. pyrrolyl, furyl,thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl,isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl;6-membered heteroaryl e.g. pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,triazinyl; 5-membered heteroaryl fused to benzene e.g. indolyl,benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl,benzisoxazolyl, benzothiazolyl, benzisothiazolyl, indazolyl,benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl; 5-memberedheteroaryl fused to two benzene rings e.g. dibenzofuranyl,dibenzothienyl; 5-membered heteroaryl fused to one benzene ring and onepyridine ring e.g. benzofuropyridyl, benzothienopyridyl; 6-memberedheteroaryl fused to benzene e.g. quinolyl, isoquinolyl, quinazolinyl,quinoxalinyl), or a partially or fully saturated cyclyl optionallycontaining one or two heteroatoms independently selected from N, O or S(e.g. 9H-fluorenyl, 1,2,3,4-tetrahydronaphthyl, indanyl,1,3-benzodioxolyl, 1,3-benzoxathiolyl, 1,3-benzodithiolyl),

the aryl, heteroaryl or partially or fully saturated cyclyl beingoptionally substituted with one, two, three, four or five substitutentsindependently selected from halo (e.g. fluoro, chloro, bromo, iodo),cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl), halo(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo-(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g. phenoxy),aryl(C₁₋₆)alkyl (e.g. benzyl), aryl(C₁₋₆)alkoxy (e.g. benzyloxy),heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl-(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy(e.g. pyridylmethoxy), —SF₅, —S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethyl-sulphonyloxy), —CONR^(u)R^(v) , —COR^(u), —CO₂R^(u),—CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NR^(u)CO₂R^(v),—SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted;R¹ is C₁₋₄ alkyl (e.g. methyl, ethyl), halo(C₁₋₄)alkyl (e.g. CF₃, CF₂H,CF₂Cl, CH₂CH₂F) or C₃₋₄ cycloalkyl;R² is H, C₁₋₈ alkyl (e.g. methyl, ethyl, iso-propyl), C₃₋₄ cycloalkyl(e.g. cyclopropyl), C₂₋₈ alkenyl (e.g. allyl, 3-methyl-but-2-enyl,4-methyl-pent-2-enyl), cyano(C₁₋₄)alkyl (e.g. cyanomethyl, cyanoethyl),C₁₋₄ alkoxy(C₁₋₄)alkyl (e.g. methoxymethyl, ethoxyethyl), C₁₋₄alkoxy(C₁₋₄)alkoxy(C₁₋₄)alkyl (e.g methoxyethoxymethyl) orbenzyloxy(C₁₋₄)alkyl (e.g. benzyloxymethyl) in which the phenyl ring ofthe benzyl moiety is optionally substituted with C₁₋₄ alkoxy;R³ is (CR^(a)R^(b))_(p)(CR^(c)R^(d))_(q)(X)_(r)(CR^(e)R^(f))_(s)R⁴,whereinR^(a), R^(b), R^(c), R^(d), R^(e) and R^(f) are independently H, C₁₋₄alkyl (e.g. methyl), halo (e.g. chloro), cyano, hydroxy, C₁₋₄ alkoxy(e.g. methoxy) or C₁₋₄ alkoxycarbonyl (e.g. ethoxycarbonyl), orR^(a)R^(b), R^(c)R^(d) or R^(e)R^(f) may join to form a 3-8 memberedring optionally containing an oxygen, sulfur or nitrogen atom,X is (CO), (CO)O, O(CO), O, S(O)_(t) wherein t is 0, 1 or 2, NH orN(C₁₋₆)alkyl,p, r and s are 0 or 1,q is 0, 1 or 2,R⁴ is C₁₋₆ alkyl (e.g. methyl, ethyl, iso-propyl, n-butyl, tert-butyl)optionally substituted with one, two or three substituents independentlyselected from halo (e.g. fluoro, chloro), cyano or hydroxy, C₁₋₄alkoxy(C₁₋₄)alkyl (e.g. methoxymethyl, ethoxyethyl), C₁₋₄alkoxy-(C₁₋₄)alkoxy(C₁₋₄)alkyl (e.g methoxyethoxymethyl),benzyloxy(C₁₋₄)alkyl (e.g. benzyloxymethyl), C₂₋₆ alkenyloxy (e.g.allyloxy), —S(O)_(x)(C₁₋₆)alkyl wherein x is 0, 1 or 2 and the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.2,2,2-trifluoroethylthio), mono- or di-(C₁₋₆)alkylamino (e.g.N-methylamino, N,N-dimethylamino) or tri(C₁₋₄)alkylsilyl (e.g.trimethylsilyl), orR⁴ is C₂₋₆ alkenyl (e.g. ethenyl, allyl) optionally substituted withone, two or three substituents independently selected from halo (e.g.chloro), cyano, hydroxy, C₁₋₆ alkoxy (e.g. methoxy), C₁₋₆ alkylcarbonyl(e.g. acetyl), C₁₋₆ alkoxycarbonyl (e.g. methoxycarbonyl), phenyloptionally substituted with C₁₋₄ alkoxy, orR⁴ is C₃₋₆ cycloalkyl (e.g. cyclopropyl, cyclopentyl, cyclohexyl), C₅₋₆cycloalkenyl (e.g. cyclopentenyl, cyclohexenyl), aryl (e.g. phenyl,naphthyl), heteroaryl (5 membered heteroaryl e.g. pyrrolyl, furyl,thienyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl,isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl;6-membered heteroaryl e.g. pyridyl, pyridazinyl, pyrimidyl, pyrazinyl,triazinyl), or a partially or fully saturated cyclyl optionallycontaining one or two heteroatoms independently selected from N, O or S(e.g. pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl, piperidyl,dioxolanyl, morpholino, thiadiazinyl, 1,2,3,4-tetrahydronaphthyl,2,3-dihydrobenzo-furanyl),the aryl, heteroaryl or partially or fully saturated cyclyl beingoptionally substituted with one, two or three substituents independentlyselected from halo (e.g. fluoro, chloro, bromo, iodo), cyano, nitro,azido, C₁₋₆ alkyl (e.g. methyl, n-pentyl), halo(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.difluoromethoxy, trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)-alkynyloxy, —SF₅, —S(O)_(x)(C₁₋₆)alkyl wherein x is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethylsulphonyloxy), —CONR^(x)R^(y), —CON(OR^(x))R^(y),—COR^(x), —CO₂R^(x), —CR^(x)═NR^(y), —NR^(x)R^(y), —NR^(x)COR^(y),—NR^(x)CO₂R^(y), —SO₂NR^(x)R^(y) or —NR^(x)SO₂R^(z) where R^(z) is C₁₋₈alkyl optionally substituted with halogen and R^(x) and R^(y) areindependently H or C₁₋₆ alkyl optionally substituted with halogen (e.g.—NHCOCF₃ or —N(CH₃)₂), orR² and R³ may join to form a saturated or unsaturated 5- or 6-memberedring optionally containing an O or S atom (e.g. tetrahydropyrrolyl,thiazolidinyl, piperidino, morpholino, thiomorpholino, 2,5dihydropyrrolyl) and optionally substituted with one, two or three halo(e.g. chloro), C₁₋₄ alkyl (e.g. methyl, ethyl) or mono- ordi-(C₁₋₄)alkylamino-carbonyl, or optionally containing an N atom (e.g.piperazinyl) which is optionally substituted on the N atom with C₁₋₄alkyl optionally substituted with halo, C₁₋₆ alkoxy or cyano, or phenyloptionally substituted with nitro, C₁₋₄ alkyl, halo(C₁₋₄)alkyl (e.g.trifluoromethyl), C₁₋₄ alkylcarbonyl (e.g. acetyl) or heteroaryl (e.g.pyridyl), or R² and R³ may join to form a 6,6-membered saturated bicycle(e.g. decahydro-isoquinoline); wherein any of the foregoing alkyl,cycloalkyl, alkenyl, alkynyl, aryl or heteroaryl groups or moieties areoptionally substituted;

L is O or S; and

n is 0, 1 or 2.

Of particular interest are compounds (1) where Ar is phenyl optionallysubstituted with one, two, three, four or five substitutentsindependently selected from halo (e.g. fluoro, chloro, bromo, iodo),cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl), halo(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo-(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g. phenoxy),aryl(C₁₋₆)alkyl (e.g. benzyl), aryl(C₁₋₆)alkoxy (e.g. benzyloxy),heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl-(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy(e.g. pyridylmethoxy), —SF₅, —S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethylsulphonyloxy), —CONR^(u)R^(v), —COR^(u), —CO₂R^(u),—CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NR^(u)CO₂R^(v),—SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted.

Of more particular interest are compounds (1) where Ar is phenyloptionally substituted with one, two or three substituents independentlyselected from halo, in particular chloro or bromo, cyano, and C₁₋₆alkyl, in particular methyl. Of especial interest are compounds where Aris 3,5-dichlorophenyl, 3,4,5-trimethylphenyl, 4-bromo-3,5-dimethylphenylor 4-cyano-3,5-dimethylphenyl.

Of further interest are compounds (1) where Ar is pyridyl optionallysubstituted with one, two, three, four or five substitutentsindependently selected from halo (e.g. fluoro, chloro, bromo, iodo),cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl), halo(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo-(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g. phenoxy),aryl(C₁₋₆)alkyl (e.g. benzyl), aryl(C₁₋₆)alkoxy (e.g. benzyloxy),heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl-(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy(e.g. pyridylmethoxy), —SF₅, —S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethylsulphonyloxy), —CONR^(u)R^(v), —COR^(u), —CO₂R^(u),—CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NR^(u)CO₂R^(v),—SO₂NR^(u)R^(w) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted.

Of yet further interest are compounds (1) where Ar is pyridyl optionallysubstituted with halo, in particular chloro. Of special interest arecompounds in which the pyridyl is attached via the 3-position, such as5-chloropyrid-3-yl.

Of further interest are compounds (1) where Ar is benzothiazolyloptionally substituted with one, two, three, four or five substitutentsindependently selected from halo (e.g. fluoro, chloro, bromo, iodo),cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl), halo-(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g. phenoxy),aryl(C₁₋₆)alkyl (e.g. benzyl), aryl(C₁₋₆)alkoxy (e.g. benzyloxy),heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl-(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy(e.g. pyridylmethoxy), —SF₅, —S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethylsulphonyloxy), —CONR^(u)R^(v), —COR^(u), —CO₂R^(u),—CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NR^(u)CO₂R^(v),—SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted.

Of yet further interest are compounds (1) where Ar is benzothiazolyloptionally substituted with halo, in particular chloro. Of specialinterest are compounds in which the benzothiazolyl is attached via the6-position, such as benzothiazol-6-yl.

Of particular interest are compounds (1) where Ar is dibenzofuranyloptionally substituted with one, two, three, four or five substitutentsindependently selected from halo (e.g. fluoro, chloro, bromo, iodo),cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl), halo-(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g. phenoxy),aryl(C₁₋₆)alkyl (e.g. benzyl), aryl(C₁₋₆)alkoxy (e.g. benzyloxy),heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl-(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy(e.g. pyridylmethoxy), —SF₅, —S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethyl-sulphonyloxy), —CONR^(u)R^(v), —COR^(u), —CO₂R^(u),—CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NR^(u)CO₂R^(v),—SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted.

Of more particular interest are compounds (1) where Ar is dibenzofuranyloptionally substituted with one, two or three substituents independentlyselected from halo, in particular chloro or bromo, and C₁₋₆ alkyl, inparticular methyl. Of special interest are compounds in which thedibenzofuranyl is attached via the 2-position, such asdibenzofuran-2-yl.

Of special interest are compounds (1) where Ar is quinolinyl optionallysubstituted with one, two, three, four or five substitutentsindependently selected from halo (e.g. fluoro, chloro, bromo, iodo),cyano, nitro, azido, C₁₋₆ alkyl (e.g. methyl), halo-(C₁₋₆)alkyl (e.g.trifluoromethyl), C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl (e.g. allyl), halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl (e.g. propargyl),halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy (e.g. methoxy), halo(C₁₋₆)alkoxy (e.g.trifluoromethoxy), C₂₋₆ alkenyloxy (e.g. allyloxy),halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy (e.g. propargyloxy),halo(C₂₋₆)alkynyloxy, aryl (e.g. phenyl), aryloxy (e.g. phenoxy),aryl(C₁₋₆)alkyl (e.g. benzyl), aryl(C₁₋₆)alkoxy (e.g. benzyloxy),heteroaryl (e.g. pyridyl), heteroaryloxy (e.g. pyridyloxy),heteroaryl-(C₁₋₆)alkyl (e.g. pyridylmethyl), heteroaryl(C₁₋₆)alkoxy(e.g. pyridylmethoxy), —SF₅, —S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2and the alkyl group is optionally substituted with halo (particularlyfluoro, e.g. trifluoromethylsulphonyl), —OSO₂(C₁₋₄)alkyl where the alkylgroup is optionally substituted with halo (particularly fluoro, e.g.trifluoromethyl-sulphonyloxy), —CONR^(u)R^(v), —COR^(u), —CO₂R^(u),—CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NR^(u)CO₂R^(v),—SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen (e.g. —NHCOCF₃ or —N(CH₃)₂),or, in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a5- or 6-membered ring containing a single nitrogen atom, a singlesulphur atom, saturated carbon atoms and optionally a single oxygenatom; wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl,aryl or heteroaryl groups or moieties are optionally substituted.

Of special interest are compounds (1) where Ar is quinolinyl optionallysubstituted with one, two or three substituents independently selectedfrom halo, in particular fluoro, chloro or bromo, C₁₋₄ alkyl, inparticular methyl, halo(C₁₋₄)alkyl, in particular trifluoromethyl, aryl,in particular phenyl, and heteroaryl, in particular pyridyl. Preferredare compounds (1) where the quinolinyl is attached via the 6 position,e.g. 3-bromoquinolin-6-yl, 3-chloroquinolin-6-yl, 3-fluoroquinolin-6-yl,3,8-dibromoquinolin-6-yl, 3-bromo-8-chloroquinolin-6-yl,3-bromo-8-methylquinolin-6-yl, 3-phenylquinolin-6-yl or3-pyrid-4-ylquinolin-6-yl. Most preferred are compounds (1) where Ar is3-bromoquinolin-6-yl, 3,8-dibromoquinolin-6-yl,3-bromo-8-chloroquinolin-6-yl or 3-bromo-8-methylquinolin-6-yl.

Another group of preferred compounds (1) are those wherein Ar is3,8-difluoroquinolin-6-yl, 3-fluoro-8-chloroquinolin-6-yl,3-fluoro-8-bromoquinolin-6-yl, 3-fluoro-8-iodoquinolin-6-yl,3-fluoro-8-methylquinolin-6-yl, 3,8-dichloroquinolin-6-yl,3-chloro-8-fluoroquinolin-6-yl, 3-chloro-8-bromoquinolin-6-yl,3-chloro-8-iodoquinolin-6-yl, 3-chloro-8-methylquinolin-6-yl,3,8-bromoquinolin-6-yl, 3-bromo-8-chloroquinolin-6-yl,3-bromo-8-fluoroquinolin-6-yl, 3-bromo-8-iodoquinolin-6-yl,3-bromo-8-methylquinolin-6-yl, 3,8-iodoquinolin-6-yl,3-iodo-8-chloroquinolin-6-yl, 3-iodo-8-bromoquinolin-6-yl,3-iodo-8-fluoroquinolin-6-yl or 3-iodo-8-methylquinolin-6-yl.

Another group of particularly preferred compounds (1) are those whereinAr is 8-haloquinolin-6-yl or 8-methylquinolin-6-yl.

R¹ is typically methyl.

R² is typically H or methyl, most preferably H.

Preferred values of R² also includes C₁₋₈ alkyl, C₃₋₄ cycloalkyl, C₂₋₈alkenyl and cyano(C₁₋₄)alkyl.

R² also includes C₁₋₄ alkoxy(C₁₋₄)alkyl, especially C₁₋₄ alkoxymethyl,and benzyloxymethyl in which the phenyl ring of the benzyl groupoptionally carries an alkoxy substituent, e.g. a methoxy substituent.

Of particular interest are compounds (1) where in the definition of R³ pis 1, q, r and s are 0, and R^(a) and R^(b) are both methyl or R^(a) ismethyl and R^(b) is cyano. Of more particular interest are compounds (1)where R³ is tert-butyl, 1,1,1-trifluoro-2-methyl-prop-2-yl,2-cyanoprop-2-yl, 1-methoxy-2-methylprop-2-yl,1-methylthio-2-methylprop-2-yl, 1-methoxy-3-methylbut-3-yl,2-cyano-1-methoxyprop-2-yl, 2-methoxycarbonyl-prop-2-yl or2-methylaminocarbonylprop-2-yl. The most preferred are compounds (1)where R³ is tert-butyl, 1-methoxy-2-methylprop-2-yl or2-cyano-1-methoxyprop-2-yl.

Of further interest are compounds (1) where R³ is2-hydroxymethyl-1-methoxy-prop-2-yl or1-methoxy-2-methoxymethylprop-2-yl.

L is typically 0; n is typically 0.

Compounds that form part of the invention are illustrated in Tables 1 to366 below.

Melting points (mp) and/or diagnostic molecular ion (eg M⁺, [M+1]⁺)values are provided in part for compounds in the following tables.Additional spectroscopic (1H NMR) data are provided in Examples 1-13Ewhile biological activities are provided in Example 14.

TABLE 1 The compounds in Table 1 are of the general formula (1) where Aris 3,5-dichlorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in the table. Compound No. R² R³ 1 H CH₃ 2 CH₃ CH₃ 3 HC₂H₅ 4 C₂H₅ C₂H₅ 5 H prop-2-yl 6 CH₃ prop-2-yl 7 prop-2-yl prop-2-yl 8CH₃ n-butyl 9 H but-2-yl 10 H 2-methyl-prop-1-yl 11 2-methyl-prop-1-yl2-methyl-prop-1-yl 12 H tert-C₄H₉ 13 CH₃ tert-C₄H₉ 14 H pent-2-yl 15 Hpent-3-yl 16 H 2-methyl-but-2-yl 17 H 3-methyl-but-1-yl 18 H3-methyl-pent-2-yl 19 H 4-methyl-pent-2-yl 20 H 3,3-dimethyl-but-2-yl 21H 2-methyl-hex-2-yl 22 H 2,4-dimethyl-pent-2-yl 23 H2,4,4-trimethyl-but-2-yl 24 H 2,4,4-trimethyl-pent-2-yl 25 H Cl-n-C₃H₆—26 H Cl—CH₂(CH₃)₂C— 27 H F₃C(CH₃)₂C— 28 H NC—CH₂— 29 CH₃ NC—CH₂— 30NC—CH₂— NC—CH₂— 31 H (NC)₂CH— 32 H NC—C₂H₄— 33 CH₃ NC—C₂H₄— 34 NC—C₂H₄—NC—C₂H₄— 35 H (CH₃)₂C(CN)— 36 H C₂H₅(CH₃)C(CN)— 37 H (C₂H₅)₂C(CN)— 38 H(CH₃)₂CH(CH₃)C(CN)— 39 H HO—CH₂(CH₃)₂C— 40 H HO—C₂H₄(CH₃)₂C— 41 H1-hydroxy-2-(hydroxymethyl)- prop-2-yl 42 H 1-hydroxy-2-(methoxy-methyl)prop-2-yl 43 H 1-methoxy-2-(methoxy- methyl)prop-2-yl 44 H1-hydroxy-2-(hydroxymethyl)- but-2-yl 45 C₂H₅OC₂H₄— C₂H₅OC₂H₄— 46 CH₃(CH₃O)₂CHCH₂— 47 H CH₃O—CH₂(CH₃)₂C— 48 H CH₃O—C₂H₄(CH₃)₂C— 49 HC₂H₅O—C₂H₄(CH₃)₂C— 50 H CH₃S—CH₂(CH₃)₂C— 51 H NC—(CH₃O)CH— 52 HCH₃OCH₂(CH₃)C(CN)— M⁺ 363 53 H CH₃SCH₂(CH₃)C(CN)— M⁺ 379 54 HCH₃(CO)(CH₃)₂C— 55 H CH₃CHBr(CO)(CH₃)₂C— 56 H CH₃(CO)(OH)CH(CH₃)₂C— 57 HCH₃OC₂H₄(CO)(CH₃)₂C— 58 H CH₃(CO)CH₂(CH₃)₂C— 59 H CH₃O(CO)(CH₃)CH— 60 HCH₃O(CO)(CH₃)₂C— 61 H C₂H₅O(CO)C₂H₄— 62 H CH₃NH(CO)(CH₃)₂C— 63 H(CH₃)₂N(CO)(CH₃)₂C— 64 H (CH₃)₃SiCH₂— 65 H tert-C₄H₉(CH₃)₂SiO—CH₂(CH₃)₂C— 66 H tert-C₄H₉(CH₃)₂SiO— C₂H₄(CH₃)₂C— 67 H4-FPhCH₂OCH₂(CH₃)₂C— 68 H C₂H₅OCH₂(CH₃)₂C— 69 H CH₃OCH₂CH₂O(CH₃)₂C— 70 HCH₂═CHCH₂— 71 CH₂═CHCH₂— CH₂═CHCH₂— 72 H CH₂═C(CH₃)CH₂— 73 HCH₂═CH(CH₃)CH— 74 H CH₂═CH(CH₃)₂C— 75 H CH₃(CO)CH═CH— 76 CH₃CH₃(CO)CH═CH— 77 H pent-3-en-2-yl 78 H 2-methyl-hex-3-en-2-yl (E) 79 H2-methyl-hex-3-en-2-yl (Z) 80 H 2-methyl-pent-4-en-3-on-2-yl 81 HCH₃O(CO)CH═(Cl)C(CH₃)₂C— 82 H C₆H₅—C(CH₃)═CH(CH₃)₂C— 83 CH₂═CHCH₂—CH₂═CHCH₂OC₂H₄— 84 H CH≡CCH₂— 85 CH₃ CH≡CCH₂— 86 H cycloprop-1-yl 87NC—C₂H₄— cycloprop-1-yl 88 cycloprop-1-yl cycloprop-1-yl 89 H1-cyano-cycloprop-1-yl 90 H 2-cyano-cycloprop-1-yl 91 H1-methoxycarbonyl-cycloprop- 1-yl 92 H 1-[N,N-dimethylamino-carbonyl]-cycloprop-1-yl 93 H 1-[N-methyl-N-methoxy-aminocarbonyl]-cycloprop-1-yl 94 H 1-cyano-1-cyclopropyl-eth-1-yl 95 Hcyclopent-1-yl 96 H 1-cyano-cyclopent-1-yl 97 H cyclohex-1-yl 98CH₂═CHCH₂— cyclohex-1-yl 99 H 4-cyano-cyclohex-1-yl 100 H1-cyano-4-methyl-cyclohex-1- yl 101 H 4-tert-butyl-1-cyano-cyclohex-1-yl 102 H 2-methyl-3-cyanotetrahydro- furan-3-yl 103 H5-methyl-1,3-dioxolan-5-yl 104 H 5-ethyl-1,3-dioxolan-5-yl 105 H3,5-dimethyl-1,3-dioxolan-5-yl 106 H N-ethoxycarbonyl-piperid-4-yl 107 Hmorpholino 108 H cyclohex-1-yl-methyl 109 H 4-cyano-cyclopenten-3-yl 110H 5-tert-butyl-2H-1,3,4- thiadiazin-2-yl 111 H2-(cyclohexen-1-yl)-eth-1-yl 112 H fur-2-yl 113 H5-methoxycarbonyl-fur-2-yl 114 H thien-2-yl 115 H2-methoxycarbonyl-thien-3-yl 116 H 4-methoxycarbonyl-thien-3-yl 117 Hoxazol-2-yl 118 H 5-methyl-isoxazol-3-yl 119 H4-cyano-3-methyl-isoxazol-5- yl 120 H thiazol-2-yl 121 H5-ethylthio-1,3,4-thiadiazol-2- 122 H fur-2-ylmethyl 123 Hcyanofur-1-ylmethyl 124 H thien-2-ylmethyl 125 H C₆H₅— 126 H 2-Cl—C₆H₄—127 H 2-I—C₆H₄— 128 H 2-NC—C₆H₄— 129 H 3-CF₃—C₆H₄— 130 H 3-CH₃S—C₆H₄—131 H 3-CH₃O(CO)—C₆H₄— 132 H 4-Cl—C₆H₄— 133 H 4-F—C₆H₄— 134 H4-CF₃O—C₆H₄— 135 H 4-(C₂H₅)₂N—C₆H₄— 136 H 4-(N-methyl-N-acetyl-amino)-phenyl 137 H 2,4-dichlorophenyl 138 H 4-methoxy-2-methylphenyl 139 H3,4-dichlorophenyl 140 H 3-chloro-4-fluorophenyl 141 H2,5-difluorophenyl 142 H 5-fluoro-2-methylphenyl 143 H5,6,7,8-tetrahydronaphth-2-yl 144 H 2,3-dihydrobenzofuran-5-yl- methyl145 H 5-cyano-4,6-dimethoxy-pyrid- 2-yl 146 H 2,6-dimethoxy-pyrid-3-yl147 H 6-chloro-pyridazin-3-yl 148 H 4,6-dimethoxy-pyrimid-2-yl 149 H2-chloro-5-fluoro-pyrimid-6-yl 150 H C₆H₅CH₂— 151 CH₃ C₆H₅CH₂— 152 H2-F—C₆H₄CH₂— 153 H 2-Cl—C₆H₄CH₂— 154 CH₃ 2-Cl—C₆H₄CH₂— 155 H2-NO₂—C₆H₄CH₂— 156 H 2-CH₃—C₆H₄CH₂— 157 H 2-CH₃O—C₆H₄CH₂— 158 H2-CHF₂O—C₆H₄CH₂— 159 H 2-CH₃S—C₆H₄CH₂— 160 H 2-CF₃S—C₆H₄CH₂— 161 H3-Cl—C₆H₄CH₂— 162 H 3-I—C₆H₄CH₂— 163 H 3-CH₃—C₆H₄CH₂— 164 H3-CH₃O—C₆H₄CH₂— 165 H 4-F—C₆H₄CH₂— 166 H 4-Cl—C₆H₄CH₂— 167 H4-CH₃—C₆H₄CH₂— 168 H 4-CF₃—C₆H₄CH₂— 169 H 4-CH₃O—C₆H₄CH₂— 170 H4-CF₃O—C₆H₄CH₂— 171 H 2,6-di-F—C₆H₃CH₂— 172 3-methyl-but-2-2,5-di-F—C₆H₃CH₂— en-1-yl 173 H 2-F-4-Cl—C₆H₃CH₂— 174 H2-F-6-Cl—C₆H₃CH₂— 175 H 2,6-di-Cl—C₆H₃CH₂— 176 4-methyl-pent-3,4-di-Cl—C₆H₃CH₂— 2-en-1-yl 177 H 2-F-6-CH₃O—C₆H₃CH₂— 178 H2,4,5-tri-F—C₆H₂CH₂— 179 H 2,4-di-Cl-6-CH₃—C₆H₂CH₂— 180 H3,4,5-tri-CH₃O—C₆H₂CH₂— 181 H C₆H₅—CH(CH₃)— 182 H 4-F—C₆H₄—CH(CH₃)— 183H 4-NO₂—C₆H₄—CH(CH₃)— 184 H 4-n-pentyl-C₆H₄—CH(CH₃)— 185 H4-CH₃SO₂—C₆H₄—CH(CH₃)— 186 H C₆H₅(CO)CH₂— 187 H C₆H₅—CH(CN)— 188 HC₆H₅—(CH₃O)CH— 189 H C₆H₅—(CH₃)₂C— 190 H m-Cl—C₆H₅—(CH₃)₂C— 191 H3,5-di-Cl—C₆H₃—(CH₃)₂C— 192 H C₆H₅—(C₂H₅O(CO))CH— 193 H phenethyl 194 H3-methoxy-4-propargyloxy- phenethyl 195 H 3-methoxy-4-(pent-2-yn-1-yloxy)-phenethyl 196 H 2-methyl-3-phenyl-prop-2-yl 197 H C₆H₅O—C₂H₄— 198H 4-F—C₆H₄—CH₂OCH₂(CH₃)₂C— 199 H C₆H₅—CH₂O(CO)C₂H₄— 200 Hnaphth-2-yl-(CH₃)CH— 201 NC—C₂H₄— pyrid-3-ylmethyl 202 CH₃2-pyrid-2-yleth-1-yl 203 H 2-(3-chloro-5-trifluoromethyl-pyrid-2-yl)oxyeth-1-yl 204 H 2-methyl-4-pyrazin-2-yl-but-3- on-2-yl 205—(CH₂)₄— 206 —(CH₂)₅— 207 —(CH₂)₄CH(C₂H₅)— 208 —C₃H₆CH[(CO)N(C₂H₅)₂]CH₂—209 —CH(CH₃)CH═CHCH(CH₃)— 210

211 —C₂H₄OC₂H₄— 212 —CH₂CH(CH₃)OCH(CH₃)CH₂— 213 —C₂H₄SCH₂— 214—C₂H₄SC₂H₄— 215 —(CH₂)₂NH(CH₂)₂— 216 —(CH₂)₂N(p-NO₂—C₆H₄)(CH₂)₂— 217—(CH₂)₂N(m-CF₃—C₆H₄)(CH₂)₂— 218 —(CH₂)₂N(p-CH₃CO—C₆H₄)(CH₂)₂— 219—(CH₂)₂N(pyrid-2-yl)(CH₂)₂— 220 H (H₂C═CHCH₂OCH₂)(CH₃)₂C— 221 H(HCCHCH₂OCH₂)(CH₃)₂C— 222 H (CH₃CH₂OCH₂)(CH₃)₂C— 223 H((CH₃)₂CHOCH₂)(CH₃)₂C— 224 H C₆H₅CH₂OCH₂(CH₃)₂C— 225 H(CH₃CH₂OCH₂)(CH₃)₂C— 226 H 4-F—C₆H₄—CH₂(CH₃)C(CN)— M⁺ 427 227 H4-Cl—C₆H₄—CH₂(CH₃)C(CN)— [M + 2]⁺ 445 228 H 4-CH₃O—C₆H₄— M⁺ 453CH₂CH₂(CH₃)C(CN)— 229 H 2-Cl—C₆H₄—CH₂(CH₃)C(CN)— [M + 2]⁺ 445 230 H(CH₃)₂CH—CH₂(CH₃)C(CN)— M⁺ 375 231 H 1-methoxymethyl-cycloprop-1-yl 232H 1-benzyloxymethyl-cycloprop-1-yl M⁺ 426 233 H1-methoxymethoxy-2-methyl- prop-2-yl 234 H1-(2-methoxy-ethoxymethoxy)-2- methyl-prop-2-yl 235 H1-cyclopropyl-eth-1-yl 236 H 2-fluoro-eth-1-yl 237 H2,2,2-trifluoro-1-methyl-eth-1-yl

Table 2

The compounds in Table 2 are of the general formula (1) where Ar is3,5-dibromophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 2 is the same ascompound 1 of Table 1 except that in compound 1 of Table 2 Ar is3,5-dibromophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 2 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 2 Ar is3,5-dibromophenyl instead of 3,5-dichlorophenyl.

Table 3

The compounds in Table 3 are of the general formula (1) where Ar is3,5-difluorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 3 is the same ascompound 1 of Table 1 except that in compound 1 of Table 3 Ar is3,5-difluorophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 3 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 3 Ar is3,5-difluorophenyl instead of 3,5-dichlorophenyl.

Table 4

The compounds in Table 4 are of the general formula (1) where Ar is3,5-dimethylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 4 is the same ascompound 1 of Table 1 except that in compound 1 of Table 4 Ar is3,5-dimethylphenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 4 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 4 Ar is3,5-dimethylphenyl instead of 3,5-dichlorophenyl.

Table 5

The compounds in Table 5 are of the general formula (1) where Ar is3-chloro-5-methylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 5 is thesame as compound 1 of Table 1 except that in compound 1 of Table 5 Ar is3-chloro-5-methylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 5 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 5 Ar is3-chloro-5-methylphenyl instead of 3,5-dichlorophenyl.

Table 6

The compounds in Table 6 are of the general formula (1) where Ar is3,5-bis(trifluoromethyl)phenyl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 6 is thesame as compound 1 of Table 1 except that in compound 1 of Table 6 Ar is3,5-bis(trifluoromethyl)phenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 6 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 6 Ar is3,5-bis(trifluoromethyl)phenyl instead of 3,5-dichlorophenyl.

Table 7

The compounds in Table 7 are of the general formula (1) where Ar is3-ethyl-5-methylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 7 is the same ascompound 1 of Table 1 except that in compound 1 of Table 7 Ar is3-ethyl-5-methylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 7 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 7 Ar is3-ethyl-5-methylphenyl instead of 3,5-dichlorophenyl.

Table 8

The compounds in Table 8 are of the general formula (1), where Ar is3,5-dimethoxy-phenyl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 8 is the same ascompound 1 of Table 1 except that in compound 1 of Table 8 Ar is3,5-dimethoxyphenyl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 8 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 8 Ar is3,5-dimethoxyphenyl instead of 3,5-dichlorophenyl.

Table 9

The compounds in Table 9 are of the general formula (1) where Ar is3-chloro-5-methoxyphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 9 is thesame as compound 1 of Table 1 except that in compound 1 of Table 9 Ar is3-chloro-5-methoxyphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 9 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 9 Ar is3-chloro-5-methoxyphenyl instead of 3,5-dichlorophenyl.

Table 10

The compounds in Table 10 are of the general formula (1) where Ar is3-cyano-5-methoxyphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 10 is thesame as compound 1 of Table 1 except that in compound 1 of Table 10 Aris 3-cyano-5-methoxyphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 10 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 10 Ar is3-cyano-5-methoxyphenyl instead of 3,5-dichlorophenyl.

Table 11

The compounds in Table 11 are of the general formula (1) where Ar is3,4,5-trichlorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 11 is the same ascompound 1 of Table 1 Ar is 3,4,5-trichlorophenyl instead of3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 11 are thesame as compounds 2 to 237 of Table 1, respectively, except that in thecompounds of Table 11 Ar is 3,4,5-trichlorophenyl instead of3,5-dichlorophenyl.

Table 12

The compounds in Table 12 are of the general formula (1) where Ar is3,5-dibromo-4-methylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 12 is thesame as compound 1 of Table 1 except that in compound 1 of Table 12 Aris 3,5-dibromo-4-methylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 12 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 12 Ar is3,5-dibromo-4-methylphenyl instead of 3,5-dichlorophenyl.

Table 13

The compounds in Table 13 are of the general formula (1) where Ar is3,4,5-trimethylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 13 is the same ascompound 1 of Table 1 except that in compound 1 of Table 13 Ar is3,4,5-trimethylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 13 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 13 Ar is3,4,5-trimethylphenyl instead of 3,5-dichlorophenyl.

The preparation of2-(3,4,5-trimethylphenoxy)-2-methylthio-N-(2-methyl-prop-2-yl)acetamide(Compound No. 12 of Table 13), is described in Example 2, page 73.

¹H NMR characterisation of compound No.s 12, 52, 70, 120, 124 and 150 ofTable 13 is provided on page 76.

Table 14

The compounds in Table 14 are of the general formula (1) where Ar is3,5-dimethyl-4-chlorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 14 is thesame as compound 1 of Table 1 except that in compound 1 of Table 14 Aris 3,5-dimethyl-4-chlorophenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 14 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 14 Ar is3,5-dimethyl-4-chlorophenyl instead of 3,5-dichlorophenyl.

Table 15

The compounds in Table 15 are of the general formula (1) where Ar3,5-dimethyl-4-bromophenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 15 is thesame as compound 1 of Table 1 except that in compound 1 of Table 15 Aris 3,5-dimethyl-4-bromophenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 15 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 15 Ar is3,5-dimethyl-4-bromophenyl instead of 3,5-dichlorophenyl.

Compound No. R² R³ 52 H CH₃OCH₂(CH₃)C(CN)— [M + 2]⁺ 403

Table 16

The compounds in Table 16 are of the general formula (1) where Ar is3,5-dimethyl-4-methylthiophenyl, n is 0, L is O, R¹ is methyl, and R²and R³ have the values listed in Table 1. Thus compound 1 of Table 16 isthe same as compound 1 of Table 1 except that in compound 1 of Table 16Ar is 3,5-dimethyl-4-methylthiophenyl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 16 are the same as compounds 2 to237 of Table 1, respectively, except that in the compounds of Table 16Ar is 3,5-dimethyl-4-methylthiophenyl instead of 3,5-dichlorophenyl.

Table 17

The compounds in Table 17 are of the general formula (1) where Ar is4-cyano-3,5-dimethylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 17 is thesame as compound 1 of Table 1 except that in compound 1 of Table 17 Aris 4-cyano-3,5-dimethylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 17 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 17 Ar is4-cyano-3,5-dimethylphenyl instead of 3,5-dichlorophenyl.

Table 18

The compounds in Table 18 are of the general formula (1) where Ar is3,4-dichlorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 18 is the same ascompound 1 of Table 1 except that in compound 1 of Table 18 Ar is3,4-dichlorophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 18 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 18 Ar is3,4-dichlorophenyl instead of 3,5-dichlorophenyl.

Table 19

The compounds in Table 19 are of the general formula (1) where Ar is3-chloro-4-methylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 19 is thesame as compound 1 of Table 1 except that in compound 1 of Table 19 Aris 3-chloro-4-methylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 19 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 19 Ar is3-chloro-4-methylphenyl instead of 3,5-dichlorophenyl.

Table 20

The compounds in Table 20 are of the general formula (1) where Ar3-methyl-4-chlorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 20 is thesame as compound 1 of Table 1 except that in compound 1 of Table 20 Aris 3-methyl-4-chlorophenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 20 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 20 Ar is3-methyl-4-chlorophenyl instead of 3,5-dichlorophenyl.

Table 21

The compounds in Table 21 are of the general formula (1) where Ar is3-chloro-4-cyanophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 21 is the same ascompound 1 of Table 1 except that in compound 1 of Table 21 Ar is3-chloro-4-cyanophenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 21 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 21 Ar is3-chloro-4-cyanophenyl instead of 3,5-dichlorophenyl.

Table 22

The compounds in Table 22 are of the general formula (1) where Ar is3-methyl-4-methylthiophenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 22 is thesame as compound 1 of Table 1 except that in compound 1 of Table 22 Aris 3-methyl-4-methylthiophenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 22 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 22 Ar is3-methyl-4-methylthiophenyl instead of 3,5-dichlorophenyl.

Table 23

The compounds in Table 23 are of the general formula (1) where Ar is3-chlorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 23 is the same ascompound 1 of Table 1 except that in compound 1 of Table 23 Ar is3-chlorophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 23 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 23 3-chlorophenylinstead of 3,5-dichlorophenyl.

Table 24

The compounds in Table 24 are of the general formula (1) where Ar is3-trifluoromethylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 24 is thesame as compound 1 of Table 1 except that in compound 1 of Table 24 Aris 3-trifluoromethylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 24 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 24 Ar is3-trifluoromethylphenyl instead of 3,5-dichlorophenyl.

Table 25

The compounds in Table 25 are of the general formula (1) where Ar is3-trifluoromethoxyphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 25 is thesame as compound 1 of Table 1 except that in compound 1 of Table 25 Aris 3-trifluoromethoxyphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 25 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 25 Ar is3-trifluoromethoxyphenyl instead of 3,5-dichlorophenyl.

Table 26

The compounds in Table 26 are of the general formula (1) where Ar is3-nitrophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 26 is the same ascompound 1 of Table 1 except that in compound 1 of Table 26 Ar is3-nitrophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 26 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 26 Ar is3-nitrophenyl instead of 3,5-dichlorophenyl.

Table 27

The compounds in Table 27 are of the general formula (1) where Ar is3-acetylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 27 is the same ascompound 1 of Table 1 except that in compound 1 of Table 27 Ar is3-acetylphenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 27 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 27 Ar is3-acetylphenyl instead of 3,5-dichlorophenyl.

Table 28

The compounds in Table 28 are of the general formula (1) where Ar is4-chlorophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 28 is the same ascompound 1 of Table 1 except that in compound 1 of Table 28 Ar is4-chlorophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 28 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 28 Ar is4-chlorophenyl instead of 3,5-dichlorophenyl.

Table 29

The compounds in Table 29 are of the general formula (1) where Ar is4-bromophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 29 is the same ascompound 1 of Table 1 except that in compound 1 of Table 29 Ar is4-bromophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 29 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 29 Ar is4-bromophenyl instead of 3,5-dichlorophenyl.

Table 30

The compounds in Table 30 are of the general formula (1) where Ar isp-tolyl, n is 0, L is O, R¹ is methyl, and R² and R³ have the valueslisted in Table 1. Thus compound 1 of Table 30 is the same as compound 1of Table 1 except that in compound 1 of Table 30 Ar is p-tolyl insteadof 3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 30 are thesame as compounds 2 to 237 of Table 1, respectively, except that in thecompounds of Table 30 Ar is p-tolyl instead of 3,5-dichlorophenyl.

Table 31

The compounds in Table 31 are of the general formula (1) where Ar is4-trifluoromethylphenyl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 31 is thesame as compound 1 of Table 1 except that in compound 1 of Table 31 Aris 4-trifluoromethylphenyl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 31 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 31 Ar is4-trifluoromethylphenyl instead of 3,5-dichlorophenyl.

Table 32

The compounds in Table 32 are of the general formula (1) where Ar is4-tert-butyl-phenyl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 32 is the same ascompound 1 of Table 1 except that in compound 1 of Table 32 Ar is4-tert-butylphenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 32 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 32 Ar is4-tert-butylphenyl instead of 3,5-dichlorophenyl.

Table 33

The compounds in Table 33 are of the general formula (1) where Ar is4-cyanophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 33 is the same ascompound 1 of Table 1 except that in compound 1 of Table 33 Ar is4-cyanophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 33 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 33 Ar is4-cyanophenyl instead of 3,5-dichlorophenyl.

Table 34

The compounds in Table 34 are of the general formula (1) where Ar is4-pentafluorosulphanylphenyl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 34 is thesame as compound 1 of Table 1 except that in compound 1 of Table 34 Aris 4-pentafluorosulphanylphenyl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 34 are the same as compounds 2 to237 of Table 1, respectively, except that in the compounds of Table 34Ar is 4-pentafluorosulphanylphenyl instead of 3,5-dichlorophenyl.

Table 35

The compounds in Table 35 are of the general formula (1) where Ar is4-nitrophenyl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 35 is the same ascompound 1 of Table 1 except that in compound 1 of Table 35 Ar is4-nitrophenyl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 35 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 35 Ar is4-nitrophenyl instead of 3,5-dichlorophenyl.

Table 36

The compounds in Table 36 are of the general formula (1) where Ar isindan-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have the valuesgiven in Table 1. Thus compound 1 of Table 36 is the same as compound 1of Table 1 except that in compound 1 of Table 36 Ar is indan-5-ylinstead of 3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 36are the same as compounds 2 to 237 of Table 1, respectively, except thatin the compounds of Table 36 Ar is indan-5-yl instead of3,5-dichlorophenyl.

Compound No. R² R³ 12 H tert-C₄H₉ oil

Table 37

The compounds in Table 37 are of the general formula (1) where Ar is1,3-benzodioxol-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 37 is the same ascompound 1 of Table 1 except that in compound 1 of Table 37 Ar is1,3-benzodioxol-5-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 37 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 37 Ar is1,3-benzodioxol-5-yl instead of 3,5-dichlorophenyl.

Table 38

The compounds in Table 38 are of the general formula (1) where Ar is2-oxo-1,3-benzodioxol-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 38 is thesame as compound 1 of Table 1 except that in compound 1 of Table 38 Aris 2-oxo-1,3-benzodioxol-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 38 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 38 Ar is2-oxo-1,3-benzodioxol-5-yl instead of 3,5-dichlorophenyl.

Table 39

The compounds in Table 39 are of the general formula (1) where Ar is2-thioxo-1,3-benzodioxol-5-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values given in Table 1. Thus compound 1 of Table 39 is thesame as compound 1 of Table 1 except that in compound 1 of Table 39 Aris 2-thioxo-1,3-benzodioxol-5-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 39 are the same as compounds 2 to237 of Table 1, respectively, except that in the compounds of Table 39Ar is 2-thioxo-1,3-benzodioxol-5-yl instead of 3,5-dichlorophenyl.

Table 40

The compounds in Table 40 are of the general formula (1) where Ar is1,3-benzoxathiol-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 40 is the same ascompound 1 of Table 1 except that in compound 1 of Table 40 Ar is1,3-benzoxathiol-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 40 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 40 Ar is1,3-benzoxathiol-5-yl instead of 3,5-dichlorophenyl.

Table 41

The compounds in Table 41 are of the general formula (1) where Ar is2-oxo-1,3-benzoxathiol-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 41 is thesame as compound 1 of Table 1 except that in compound 1 of Table 41 Aris 2-oxo-1,3-benzoxathiol-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 41 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 41 Ar is2-oxo-1,3-benzoxathiol-5-yl instead of 3,5-dichlorophenyl.

Table 42

The compounds in Table 42 are of the general formula (1) where Ar is1,3-benzodithiol-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 42 is the same ascompound 1 of Table 1 except that in compound 1 of Table 42 Ar is1,3-benzodithiol-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 42 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 42 Ar is1,3-benzodithiol-5-yl instead of 3,5-dichlorophenyl.

Table 43

The compounds in Table 43 are of the general formula (1) where Ar isinden-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have the valuesgiven in Table 1. Thus compound 1 of Table 43 is the same as compound 1of Table 1 except that in compound 1 of Table 43 Ar is inden-5-ylinstead of 3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 43are the same as compounds 2 to 237 of Table 1, respectively, except thatin the compounds of Table 43 Ar is inden-5-yl instead of3,5-dichlorophenyl.

Table 44

The compounds in Table 44 are of the general formula (1) where Ar isbenzofuran-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 44 is the same ascompound 1 of Table 1 except that in compound 1 of Table 44 Ar isbenzofuran-5-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 44 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 44 Ar isbenzofuran-5-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ 12 H tert-C₄H₉ oil 189 H C₆H₅—(CH₃)₂C— 111-113° C.

Table 45

The compounds in Table 45 are of the general formula (1) where Ar is2-phenylbenzofuran-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 45 is thesame as compound 1 of Table 1 except that in compound 1 of Table 45 Aris 2-phenylbenzofuran-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 45 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 45 Ar is2-phenylbenzofuran-5-yl instead of 3,5-dichlorophenyl.

Table 46

The compounds in Table 46 are of the general formula (1) where Ar is3-methylbenzo-furan-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 46 is thesame as compound 1 of Table 1 except that in compound 1 of Table 46 Aris 3-methylbenzofuran-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 46 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 46 Ar is3-methylbenzofuran-5-yl instead of 3,5-dichlorophenyl.

Table 47

The compounds in Table 47 are of the general formula (1) where Ar isbenzothien-5-yl of the formula (A), n is 0, L is O, R¹ is methyl, and R²and R³ have the values given in Table 1. Thus compound 1 of Table 47 isthe same as compound 1 of Table 1 except that in compound 1 of Table 47Ar is benzothien-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 47 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 47 Ar isbenzothien-5-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ 12 H tert-C₄H₉ oil

Table 48

The compounds in Table 48 are of the general formula (1) where Ar is9H-fluoren-3-yl of the formula (A), n is 0, L is O, R¹ is methyl, and R²and R³ have the values given in Table 1. Thus compound 1 of Table 48 isthe same as compound 1 of Table 1 except that in compound 1 of Table 48Ar is 9H-fluoren-3-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 48 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 48 Ar is9H-fluoren-3-yl instead of 3,5-dichlorophenyl.

Table 49

The compounds in Table 49 are of the general formula (1) where Ar is9-oxo-9H-fluoren-3-yl of the formula (A), n is 0, L is O, R¹ is methyl,and R² and R³ have the values given in Table 1. Thus compound 1 of Table49 is the same as compound 1 of Table 1 except that in compound 1 ofTable 49 Ar is 9-oxo-9H-fluoren-3-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 49 are the same as compounds 2 to237 of Table 1, respectively, except that in the compounds of Table 49Ar is 9-oxo-H-fluoren-3-yl instead of 3,5-dichlorophenyl.

Table 50

The compounds in Table 50 are of the general formula (1) where Ar isdibenzofuran-2-yl of the formula (A), n is 0, L is O, R¹ is methyl, andR² and R³ have the values given in Table 1. Thus compound 1 of Table 50is the same as compound 1 of Table 1 except that in compound 1 of Table50 Ar is dibenzofuran-2-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 50 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 50 Ar isdibenzofuran-2-yl instead of 3,5-dichlorophenyl.

Compound no. R² R³ 232 H 1-benzyloxymethyl- [M + 1]⁺ 449 cycloprop-1-yl230 H (CH₃)₂CH—CH₂(CH₃)C(CN)— [M + 1]⁺ 398 228 H4-CH₃O—C₆H₄—CH₂CH₂(CH₃)C(CN)— [M + 2]⁺ 477 227 H4-Cl—C₆H₄—CH₂(CH₃)C(CN)— [M + 1]⁺ 466

The preparation of2-(dibenzofuranyl-2-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 50) is described in Example 12, page 93. ¹HNMR characterisation of compound No.s 12, 35, 38, 52, 70, 84, 120, 122,128, 133 and 189 of Table 50 is provided on pages 94 and 95.

Table 51

The compounds in Table 51 are of the general formula (1) where Ar is7-methyldibenzofuran-2-yl of the formula (A), n is 0, L is O, R¹ ismethyl, and R² and R³ have the values given in Table 1. Thus compound 1of Table 51 is the same as compound 1 of Table 1 except that in compound1 of Table 51 Ar is 7-methyldibenzofuran-2-yl instead of3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 51 are thesame as compounds 2 to 237 of Table 1, respectively, except that in thecompounds of Table 51 Ar is 7-methyl-dibenzofuran-2-yl instead of3,5-dichlorophenyl.

Table 52

The compounds in Table 52 are of the general formula (1) where Ar is8-chlorodibenzofuran-2-yl of the formula (A), n is 0, L is O, R¹ ismethyl, and R² and R³ have the values given in Table 1. Thus compound 1of Table 52 is the same as compound 1 of Table 1 except that in compound1 of Table 52 Ar is 8-chlorodibenzofuran-2-yl instead of3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 52 are thesame as compounds 2 to 237 of Table 1, respectively, except that in thecompounds of Table 52 Ar is 8-chloro-dibenzofuran-2-yl instead of3,5-dichlorophenyl.

Table 53

The compounds in Table 53 are of the general formula (1) where Ar is9-chlorodibenzofuran-2-yl of the formula (A), n is 0, L is O, R¹ ismethyl, and R² and R³ have the values given in Table 1. Thus compound 1of Table 53 is the same as compound 1 of Table 1 except that in compound1 of Table 53 Ar is 9-chlorodibenzofuran-2-yl instead of3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 53 are thesame as compounds 2 to 237 of Table 1, respectively, except that in thecompounds of Table 53 Ar is 9-chlorodibenzofuran-2-yl instead of3,5-dichlorophenyl.

Table 54

The compounds in Table 54 are of the general formula (1) where Ar isdibenzothien-2-yl of the formula (A), n is 0, L is O, R¹ is methyl, andR² and R³ have the values given in Table 1. Thus compound 1 of Table 54is the same as compound 1 of Table 1 except that in compound 1 of Table54 Ar is dibenzothien-2-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 54 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 54 Ar isdibenzothien-2-yl instead of 3,5-dichlorophenyl.

Table 55

The compounds in Table 55 are of the general formula (1) where Ar is5,6,7,8-tetrahydronaphth-2-yl of the formula (A), n is 0, L is O, R¹ ismethyl, and R² and R³ have the values given in Table 1. Thus compound 1of Table 55 is the same as compound 1 of Table 1 except that in compound1 of Table 55 Ar is 5,6,7,8-tetrahydronaphth-2-yl instead of3,5-dichlorophenyl. Similarly, compounds 2 to 237 of Table 55 are thesame as compounds 2 to 237 of Table 1, respectively, except that in thecompounds of Table 55 Ar is 5,6,7,8-tetrahydronaphth-2-yl instead of3,5-dichlorophenyl.

Compound No. R² R³ 12 H tert-C₄H₉ oil

Table 56

The compounds in Table 56 are of the general formula (1) where Ar isquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 56 is the same ascompound 1 of Table 1 except that in compound 1 of Table 56 Ar isquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 56 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 56 Ar isquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 57

The compounds in Table 57 are of the general formula (1) where Ar is3-bromoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 57 is the same ascompound 1 of Table 1 except that in compound 1 of Table 57 Ar is3-bromoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 57 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 57 Ar is3-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound no. R² R³ Mp/° C. 68 H C₂H₅OCH₂(CH₃)₂C— [M + 2]⁺ 429   75-76.5220 H (H₂C═CHCH₂OCH₂)(CH₃)₂C— [M + 2]⁺ 441 80-82 224 HC₆H₅CH₂OCH₂(CH₃)₂C— [M + 2]⁺ 491 90-91 16 H 2-methyl-but-2-yl [M + 2]⁺399 103-104 229 H 2-Cl—C₆H₄—CH₂(CH₃)C(CN)— / 138-140 227 H4-Cl—C₆H₄—CH₂(CH₃)C(CN)— / 77-79 226 H 4-F—C₆H₄—CH₂(CH₃)C(CN)— [M+] 488/ 230 H (CH₃)₂CH—CH₂(CH₃)C(CN)— [M + 2]⁺ 438 / 235 H1-cyclopropyl-eth-1-yl / 106-108 236 H 2-fluoro-eth-1-yl / 104-106 237 H2,2,2-trifluoro-1-methyl-eth-1-yl / 163-166

The preparation of Compound No. 48 of Table 57,2-(3-bromoquinolinyl-6-oxy)-2-methylthio-N-(1-methoxy-3-methylbut-3-yl)acetamideis described in Example 7, page 85. ¹H NMR characterisation of compoundNo.s 4, 12, 24, 27, 35, 38, 40, 47, 48, 49, 50, 52, 60, 64, 65, 70, 84,88, 89, 111, 120, 122, 124, 133, 150, 189 and 198 of Table 57 isprovided on pages 86 to 89.

The preparation of compound Compound No. 82 of Table 57,2-(methylthio)-2-(3-bromoquinolinyl-6-oxy)-N-E-(4-phenyl-2-methylpent-3-ene-2-yl)acetamide,is described in Example 9, page 91.

The preparation of compound No. 39 of Table 57,2-(3-bromoquinolinyl-6-oxy)-2-(methylthio)-N-(1-hydroxy-2-methylprop-2-yl)acetamide, is described in Example 11, page 93 along with ¹H NMRcharacterisation.

Table 58

The compounds in Table 58 are of the general formula (1) where Ar is3-chloroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 58 is the same ascompound 1 of Table 1 except that in compound 1 of Table 58 Ar is3-chloroquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 58 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 58 Ar is3-chloroquinolin-6-yl instead of 3,5-dichlorophenyl.

The preparation of Compound No. 12 of Table 58,2-(3-chloroquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamideis described in Example 5, page 80. ¹H NMR characterisation of compoundNo.s 12, 35, 38, 52, 64, 70, 84, 120, 122, 124, 128, 133, 150, 189, andof Table 58 is provided on pages 82 to 83.

Table 58A

The compounds in Table 58A are of the general formula (1) where Ar is3-iodoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 58A is the sameas compound 1 of Table 1 except that in compound 1 of Table 58A Ar is3-iodoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 58A are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 58A Ar is3-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ Mp/° C. 12 H tert-C₄H₉ [M + 1]⁺ 431 151-153 52 HCH₃OCH₂(CH₃)C(CN)— [M + 1]⁺ 472 /

Table 59

The compounds in Table 59 are of the general formula (1) where Ar is3-fluoroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 59 is the same ascompound 1 of Table 1 except that in compound 1 of Table 59 Ar is3-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 59 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 59 Ar is3-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.

The preparation of2-(3-fluoroquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 59) is described in Example 8, page 89-91along with ¹H NMR characterisation for compounds 12 and 52.

Table 60

The compounds in Table 60 are of the general formula (1) where Ar is8-bromoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 60 is the same ascompound 1 of Table 1 except that in compound 1 of Table 60 Ar is8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 60 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 60 Ar is8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ Mp/° C. 12 H tert-C₄H₉ 122-125 52 HCH₃OCH₂(CH₃)C(CN)— 139-141

Table 60A

The compounds in Table 60A are of the general formula (1) where Ar is8-chloroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 60A is the sameas compound 1 of Table 1 except that in compound 1 of Table 60A Ar is8-chloroquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 60A are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 60A Ar is8-chloroquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 60B

The compounds in Table 60B are of the general formula (1) where Ar is8-fluoroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 60B is the sameas compound 1 of Table 1 except that in compound 1 of Table 60B Ar is8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 60B are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 60B Ar is8-flroroquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 60C

The compounds in Table 60C are of the general formula (1) where Ar is8-iodoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 60C is the sameas compound 1 of Table 1 except that in compound 1 of Table 60C Ar is8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 60C are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 60C Ar is8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 61

The compounds in Table 61 are of the general formula (1) where Ar is3,8-dibromoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 61 is thesame as compound 1 of Table 1 except that in compound 1 of Table 61 Aris 3,8-dibromoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 61 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 61 Ar is3,8-dibromoquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ Mp/° C. 16 H 2-methyl-but-2-yl 132-133 52 HCH₃OCH₂(CH₃)C(CN)— 139-142 50 H CH₃S—CH₂(CH₃)₂C— 141-143 68 HC₂H₅OCH₂(CH₃)₂C— 128.5-131.5 220 H (H₂C═CHCH₂OCH₂)(CH₃)₂C— 97.5-101  224H C₆H₅CH₂OCH₂(CH₃)₂C— 126-127

The preparation of2-(3,8-dibromoquinolinyl-6-oxy)-2-methylthio-N-(2-thienylmethyl)acetamide(Compound No. 124 of Table 61) is described in Example 6, page 83. ¹HNMR characterisation of compound No.s 12, 38, 52, 150 and 211 of Table61 is provided on pages 85 and 85.

Table 62

The compounds in Table 62 are of the general formula (1) where Ar is3-bromo-8-chloroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62 is thesame as compound 1 of Table 1 except that in compound 1 of Table 62 Aris 3-bromo-8-chloroquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62 are the same as compounds 2 to237 of Table 1, respectively, except that in the compounds of Table 62Ar is 3-bromo-8-chloroquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ Mp/° C. 47 H CH₃O—CH₂(CH₃)₂C— [M + 1]⁺ 449125.5-127   12 H tert-C₄H₉ [M + 1]⁺ 419 160-161 16 H 2-methyl-but-2-yl[M + 1]⁺ 433 / 50 H CH₃S—CH₂(CH₃)₂C— [M + 1]⁺ 465 148-149 68 HC₂H₅OCH₂(CH₃)₂C— [M + 1]⁺ 463 143-146 220 H (H₂C═CHCH₂OCH₂)(CH₃)₂C— [M +1]⁺ 475 104-106 224 H C₆H₅CH₂OCH₂(CH₃)₂C— [M + 1]⁺ 525 118-121

Table 62A

The compounds in Table 62A are of the general formula (1) where Ar is3-bromo-8-iodoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 62A is thesame as compound 1 of Table 1 except that in compound 1 of Table 62A Aris 3-bromo-8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 62A are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 62A Ar is3-bromo-8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound no. R² R³ Mp/° C. 12 H tert-C₄H₉ 171-172

Table 62B

The compounds in Table 62B are of the general formula (1) where Ar is3-bromo-8-fluoroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62B isthe same as compound 1 of Table 1 except that in compound 1 of Table 62BAr is 3-bromo-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62B are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62B Ar is 3-bromo-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ Mp/° C. 12 H tert-C₄H₉ 158.5-159.5° C. 52 HCH₃OCH₂(CH₃)C(CN)— gum 230 H (CH₃)₂CH—CH₂(CH₃)C(CN)— gum

Table 62C

The compounds in Table 62C are of the general formula (1) where Ar is3-chloro-8-bromoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62C isthe same as compound 1 of Table 1 except that in compound 1 of Table 62CAr is 3-chloro-8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62C are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62C Ar is 3-chloro-8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62D

The compounds in Table 62D are of the general formula (1) where Ar is3,8-dichloroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 62D is thesame as compound 1 of Table 1 except that in compound 1 of Table 62D Aris 3,8-dichloro-quinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 62D are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 62D Ar is3,8-dichloro-quinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62E

The compounds in Table 62E are of the general formula (1) where Ar is3-chloro-8-iodoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62E isthe same as compound 1 of Table 1 except that in compound 1 of Table 62EAr is 3-chloro-8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62E are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62E Ar is 3-chloro-8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62F

The compounds in Table 62F are of the general formula (1) where Ar is3-chloro-8-fluoroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62F isthe same as compound 1 of Table 1 except that in compound 1 of Table 62FAr is 3-chloro-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62F are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62F Ar is 3-chloro-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62G

The compounds in Table 62G are of the general formula (1) where Ar is3-fluoro-8-bromoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62G isthe same as compound 1 of Table 1 except that in compound 1 of Table 62GAr is 3-fluoro-8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62G are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62G Ar is 3-fluoro-8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62H

The compounds in Table 62H are of the general formula (1) where Ar is3-fluoro-8-chloro-quinolin-6-yl, n is 0, L is O, R¹ is methyl, and R²and R³ have the values listed in Table 1. Thus compound 1 of Table 62His the same as compound 1 of Table 1 except that in compound 1 of Table62H Ar is 3-fluoro-8-chloro-quinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62H are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62H Ar is 3-fluoro-8-chloro-quinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62I

The compounds in Table 62I are of the general formula (1) where Ar is3-fluoro-8-iodoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62I isthe same as compound 1 of Table 1 except that in compound 1 of Table 62IAr is 3-fluoro-8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62I are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62I Ar is 3-fluoro-8-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62J

The compounds in Table 62J are of the general formula (1) where Ar is3,8-difluoroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 62J is thesame as compound 1 of Table 1 except that in compound 1 of Table 62J Aris 3-chloro-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62J are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62J Ar is 3-chloro-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62K

The compounds in Table 62K are of the general formula (1) where Ar is3-iodo-8-bromo-quinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62K isthe same as compound 1 of Table 1 except that in compound 1 of Table 62KAr is 3-iodo-8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62K are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62K Ar is 3-iodo-8-bromoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62L

The compounds in Table 62L are of the general formula (1) where Ar is3-iodo-8-chloro-quinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62L isthe same as compound 1 of Table 1 except that in compound 1 of Table 62LAr is 3-iodo-8-chloro-quinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62L are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62L Ar is 3-iodo-8-chloro-quinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62M

The compounds in Table 62M are of the general formula (1) where Ar is3,8-di-iodoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values listed in Table 1. Thus compound 1 of Table 62M is thesame as compound 1 of Table 1 except that in compound 1 of Table 62M Aris 3,8-di-iodoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 62M are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 62M Ar is3,8-di-iodoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62N

The compounds in Table 62N are of the general formula (1) where Ar is3-iodo-8-fluoroquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 62N isthe same as compound 1 of Table 1 except that in compound 1 of Table 62NAr is 3-chloro-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 62N are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table62N Ar is 3-chloro-8-fluoroquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 62P

The compounds in Table 62P are of the general formula (1) where Ar is8-methylquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 62P is the sameas compound 1 of Table 1 except that in compound 1 of Table 62P Ar is8-methylquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 62P are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 62P Ar is8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 63

The compounds in Table 63 are of the general formula (1) where Ar isquinazolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 63 is the same ascompound 1 of Table 1 except that in compound 1 of Table 63 Ar isquinazolin-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 63 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 63 Ar isquinazolin-6-yl instead of 3,5-dichlorophenyl.

Table 64

The compounds in Table 64 are of the general formula (1) where Ar isisoquinolin-7-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 64 is the same ascompound 1 of Table 1 except that in compound 1 of Table 64 Ar isisoquinolin-7-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 64 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 64 Ar isisoquinolin-7-yl instead of 3,5-dichlorophenyl.

Table 65

The compounds in Table 65 are of the general formula (1) where Ar is3-phenylquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 65 is the same ascompound 1 of Table 1 except that in compound 1 of Table 65 Ar is3-phenylquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 65 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 65 Ar is3-phenylquinolin-6-yl instead of 3,5-dichlorophenyl.

Mp and ¹H NMR characterisation of compound No. 12 of Table 65 isprovided on page 93.

Table 66

The compounds in Table 66 are of the general formula (1) where Ar is3-benzylquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 66 is the same ascompound 1 of Table 1 except that in compound 1 of Table 66 Ar is3-benzylquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 66 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 66 Ar is3-benzylquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 67

The compounds in Table 67 are of the general formula (1) where Ar is7-bromo-naphth-2-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 67 is the same ascompound 1 of Table 1 except that in compound 1 of Table 67 Ar is7-bromo-naphth-2-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 67 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 67 Ar is7-bromo-naphth-2-yl instead of 3,5-dichlorophenyl.

Table 68

The compounds in Table 68 are of the general formula (1) where Ar is3-pyrid-4-yl-quinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 68 is thesame as compound 1 of Table 1 except that in compound 1 of Table 68 Aris 3-pyrid-4-ylquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 68 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 68 Ar is3-pyrid-4-ylquinolin-6-yl instead of 3,5-dichlorophenyl.

The preparation of compound No. 12 of Table 68, 2-(methylthio)-2-(3-[4pyridyl]-quinolinyl-6-oxy)-N-(2-methylprop-2-yl) acetamide, is describedin Example 10, page 92.

Table 69

The compounds in Table 69 are of the general formula (1) where Ar isisoquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 69 is the same ascompound 1 of Table 1 except that in compound 1 of Table 69 Ar isisoquinolin-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 69 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 69 Ar isisoquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 70

The compounds in Table 70 are of the general formula (1) where Ar is5-chloropyrid-3-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 70 is the same ascompound 1 of Table 1 except that in compound 1 of Table 70 Ar is5-chloropyrid-3-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 70 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 70 Ar is5-chloropyrid-3-yl instead of 3,5-dichlorophenyl.

The preparation of compound No. 12 of Table 70,2-(5-chloropyridyl-3-oxy)-2-(methylthio)-N-(2-methylprop-2-yl)acetamide, is described in Example 3, page 77. ¹H NMR characterisationof compound numbers 12, 50 and 72 of Table 70 is provided on page 78.

Table 71

The compounds in Table 71 are of the general formula (1) where Ar is5-bromopyrid-3-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 71 is the same ascompound 1 of Table 1 except that in compound 1 of Table 71 Ar is5-bromopyrid-3-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 71 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 71 Ar is5-bromopyrid-3-yl instead of 3,5-dichlorophenyl.

Table 72

The compounds in Table 72 are of the general formula (1) where Ar is3-bromo-8-methylquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 72 is thesame as compound 1 of Table 1 except that in compound 1 of Table 72 Aris 3-bromo-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 72 are the same as compounds 2 to237 of Table 1, respectively, except that in the compounds of Table 72Ar is 3-bromo-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ Mp/° C. 12 H tert-C₄H₉ [M + 2]⁺ 399 146-147 16 H2-methyl-but-2-yl [M + 2]⁺ 413 129-132 47 H CH₃O—CH₂(CH₃)₂C— [M + 2]⁺429   127-128.5 50 H CH₃S—CH₂(CH₃)₂C— [M + 2]⁺ 445 130-131 52 HCH₃OCH₂(CH₃)C(CN)— [M + 2]⁺ 440 116-118 68 H C₂H₅OCH₂(CH₃)₂C— [M + 2]⁺443 / 220 H (H₂C═CHCH₂OCH₂)(CH₃)₂C— [M + 2]⁺ 455 / 224 HC₆H₅CH₂OCH₂(CH₃)₂C— [M + 2]⁺ 505 112-113

Table 72A

The compounds in Table 72A are of the general formula (1) where Ar is3-iodo-8-methylquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 72A isthe same as compound 1 of Table 1 except that in compound 1 of Table 72AAr is 3-iodo-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 72A are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table72A Ar is 3-iodo-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ Mp/° C. 12 H tert-C₄H₉ 148-150 52 HCH₃OCH₂(CH₃)C(CN)— 57-59

Table 72B

The compounds in Table 72B are of the general formula (1) where Ar is3-chloro-8-methylquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 72B isthe same as compound 1 of Table 1 except that in compound 1 of Table 72AAr is 3-chloro-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 72B are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table72B Ar is 3-chloro-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 72C

The compounds in Table 72C are of the general formula (1) where Ar is3-fluoro-8-methylquinolin-6-yl, n is 0, L is O, R¹ is methyl, and R² andR³ have the values listed in Table 1. Thus compound 1 of Table 72C isthe same as compound 1 of Table 1 except that in compound 1 of Table 72CAr is 3-fluoro-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 72C are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table72C Ar is 3-fluoro-8-methylquinolin-6-yl instead of 3,5-dichlorophenyl.

Table 73

The compounds in Table 73 are of the general formula (1) where Ar is5,6-dichloropyrid-3-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 73 is the same ascompound 1 of Table 1 except that in compound 1 of Table 73 Ar is5,6-dichloropyrid-3-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 73 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 73 Ar is5,6-dichloropyrid-3-yl instead of 3,5-dichlorophenyl.

Table 74

The compounds in Table 74 are of the general formula (1) where Ar is5-cyanopyrid-3-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 74 is the same ascompound 1 of Table 1 except that in compound 1 of Table 74 Ar is5-cyanopyrid-3-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 74 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 74 Ar is5-cyanopyrid-3-yl instead of 3,5-dichlorophenyl.

Table 75

The compounds in Table 75 are of the general formula (1) where Ar is5-ethynylpyrid-3-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 75 is the same ascompound 1 of Table 1 except that in compound 1 of Table 75 Ar is5-ethynylpyrid-3-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 75 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 75 Ar is5-ethynylpyrid-3-yl instead of 3,5-dichlorophenyl.

Table 76

The compounds in Table 76 are of the general formula (1) where Ar is5-ethenylpyrid-3-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values listed in Table 1. Thus compound 1 of Table 76 is the same ascompound 1 of Table 1 except that in compound 1 of Table 76 Ar is5-ethynylpyrid-3-yl instead of 3,5-dichlorophenyl. Similarly, compounds2 to 237 of Table 76 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 76 Ar is5-ethynylpyrid-3-yl instead of 3,5-dichlorophenyl.

Table 77

The compounds in Table 77 are of the general formula (1) where Ar is a2,6-dichloro-pyrid-4-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 77 is thesame as compound 1 of Table 1 except that in compound 1 of Table 77 Aris 2,6-dichloro-pyrid-4-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 77 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 77 Ar is2,6-dichloro-pyrid-4-yl instead of 3,5-dichlorophenyl.

Table 78

The compounds in Table 78 are of the general formula (1) where Ar isbenzothiazol-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 78 is the same ascompound 1 of Table 1 except that in compound 1 of Table 78 Ar isbenzothiazol-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 78 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 78 Ar isbenzothiazol-6-yl instead of 3,5-dichlorophenyl.

The preparation of2-(benzothiazolyl-6-oxy)-2-(methylthio)-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 78), is described in Example 4, page 78 alongwith ¹H NMR characterisation for compounds 12, 35, 52, 70, 133, 189 onpages 79 to 80.

Table 79

The compounds in Table 79 are of the general formula (1) where Ar isbenzothiazol-6-yl, n is 0, L is O, R¹ is ethyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 79 is the same ascompound 1 of Table 78 except that in compound 1 of Table 79 R¹ is ethylinstead of methyl. Similarly, compounds 2 to 237 of Table 79 are thesame as compounds 2 to 237 of Table 78, respectively, except that in thecompounds of Table 79 R¹ is ethyl instead of methyl.

Table 80

The compounds in Table 80 are of the general formula (1) where Ar is2-bromo-benzothiazol-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 80 is thesame as compound 1 of Table 1 except that in compound 1 of Table 80 Aris 2-bromobenzothiazol-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 80 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 80 Ar is2-bromo-benzothiazol-6-yl instead of 3,5-dichlorophenyl.

Table 81

The compounds in Table 81 are of the general formula (1) where Ar is2-chloro-benzothiazol-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³have the values given in Table 1. Thus compound 1 of Table 81 is thesame as compound 1 of Table 1 except that in compound 1 of Table 81 Aris 2-chlorobenzothiazol-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 81 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 81 Ar is2-chloro-benzothiazol-6-yl instead of 3,5-dichlorophenyl.

Table 82

The compounds in Table 82 are of the general formula (1) where Ar is2-methylamino-benzothiazol-6-yl, n is 0, L is O, R¹ is methyl, and R²and R³ have the values given in Table 1. Thus compound 1 of Table 82 isthe same as compound 1 of Table 1 except that in compound 1 of Table 82Ar is 2-methylaminobenzothiazol-6-yl instead of 3,5-dichlorophenyl.Similarly, compounds 2 to 237 of Table 82 are the same as compounds 2 to237 of Table 1, respectively, except that in the compounds of Table 82Ar is 2-methylaminobenzothiazol-6-yl instead of 3,5-dichlorophenyl.

Table 83

The compounds in Table 83 are of the general formula (1) where Ar isbenzoxazol-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 83 is the same ascompound 1 of Table 1 except that in compound 1 of Table 83 Ar isbenzoxazol-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 83 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 83 Ar isbenzoxazol-6-yl instead of 3,5-dichlorophenyl.

Table 83A

The compounds in Table 83A are of the general formula (1) where Ar isbenzo[b]thiophene-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 83A is the same ascompound 1 of Table 1 except that in compound 1 of Table 83A Ar isbenzo[b]thiophene-6-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 83A are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 83A Ar isbenzo[b]thiophene-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ 12 H tert-C₄H₉ oil

Table 83B

The compounds in Table 83B are of the general formula (1) where Ar isbenzofuran-6-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 83B is the same ascompound 1 of Table 1 except that in compound 1 of Table 83B Ar isbenzofuran-6-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2 to237 of Table 83B are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 83B Ar isbenzofuran-6-yl instead of 3,5-dichlorophenyl.

Compound No. R² R³ 12 H tert-C₄H₉ oil

Table 84

The compounds in Table 84 are of the general formula (1) where Ar isbenzoxazol-6-yl, n is 0, L is O, R¹ is ethyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 84 is the same ascompound 1 of Table 84 except that in compound 1 of Table 84 R¹ is ethylinstead of methyl. Similarly, compounds 2 to 237 of Table 84 are thesame as compounds 2 to 237 of Table 83, respectively, except that in thecompounds of Table 84 R¹ is ethyl instead of methyl.

Table 85

The compounds in Table 85 are of the general formula (1) where Ar is2,1-benzoisoxazol-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ havethe values given in Table 1. Thus compound 1 of Table 85 is the same ascompound 1 of Table 1 except that in compound 1 of Table 85 Ar is2,1-benzoisoxazol-5-yl instead of 3,5-dichlorophenyl. Similarly,compounds 2 to 237 of Table 85 are the same as compounds 2 to 237 ofTable 1, respectively, except that in the compounds of Table 85 Ar is2,1-benzoisoxazol-5-yl instead of 3,5-dichlorophenyl.

Table 86

The compounds in Table 86 are of the general formula (1) where Ar isbenzothiazol-5-yl, n is 0, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 86 is the same ascompound 1 of Table 1 except that in compound 1 of Table 86 Ar isbenzothiazol-5-yl instead of 3,5-dichlorophenyl. Similarly, compounds 2to 237 of Table 86 are the same as compounds 2 to 237 of Table 1,respectively, except that in the compounds of Table 86 Ar isbenzothiazol-5-yl instead of 3,5-dichlorophenyl.

Table 87

The compounds in Table 87 are of the general formula (1) where Ar isbenzothiazol-5-yl, n is 0, L is O, R¹ is ethyl, and R² and R³ have thevalues listed in Table 1. Thus compound 1 of Table 87 is the same ascompound 1 of Table 87 except that in compound 1 of Table 87 R¹ is ethylinstead of methyl. Similarly, compounds 2 to 237 of Table 87 are thesame as compounds 2 to 237 of Table 87, respectively, except that in thecompounds of Table 87 R¹ is ethyl instead of methyl.

Tables 88 to 122

Tables 88 to 122 correspond exactly to Tables 1 to 35 (i.e. Table 88corresponds exactly to Table 1, Table 89 corresponds exactly to Table 2,and so on) the only difference being that in each of Tables 88 to 122 Lis S instead of O.

Tables 123 to 268

Tables 123 to 268 correspond exactly to Tables 1 to 122 (i.e. Table 123corresponds exactly to Table 1, Table 124 corresponds exactly to Table2, Table and so on) the only difference being that in each of Tables 123to 268 n is 1 instead of 0.

Table 166

The compounds in Table 166 are of the general formula (1) where Ar isbenzofuran-5-yl, n is 1, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 166 is the same ascompound 1 of Table 1 except that in compound 1 of Table 166 Ar isbenzofuran-5-yl instead of 3,5-dichlorophenyl and n is 1 instead of 0.Similarly, compounds 2 to 237 of Table 166 are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table166 Ar is benzofuran-5-yl instead of 3,5-dichlorophenyl and n is 1instead of 0.

Compound No. R² R³ 12 H tert-C₄H₉ oil 189 H C₆H₅—(CH₃)₂C— oil

Tables 269 to 414

Tables 269 to 414 correspond exactly to Tables 1 to 122 (i.e. Table 245corresponds exactly to Table 1, Table 246 corresponds exactly to Table2, and so on) the only difference being that in each of Tables 269 to414, n is 2 instead of 0.

Table 312

The compounds in Table 312 are of the general formula (1) where Ar isbenzofuran-5-yl, n is 2, L is O, R¹ is methyl, and R² and R³ have thevalues given in Table 1. Thus compound 1 of Table 312 is the same ascompound 1 of Table 1 except that in compound 1 of Table 312 Ar isbenzofuran-5-yl instead of 3,5-dichlorophenyl and n is 2 instead of 0.Similarly, compounds 2 to 237 of Table 312 are the same as compounds 2to 237 of Table 1, respectively, except that in the compounds of Table312 Ar is benzofuran-5-yl instead of 3,5-dichlorophenyl and n is 2instead of 0.

Compound No. R² R³ 12 H tert-C₄H₉ 140-143° C. 189 H C₆H₅—(CH₃)₂C—140-142° C.

The compounds of general formula (1) may be prepared as outlined inSchemes 1 to 4 below, in which Ar, R¹, R² and R³ have the meanings givenabove, R⁵ is H or C₁₋₄ alkyl, as indicated, R¹⁰ is C₁₋₆ alkyl,optionally substituted benzyl or optionally substituted thienylmethyl,R⁶, R⁷, R¹, R⁹, R¹² and R¹³ are independently H or C₁₋₃ alkyl, providedthat when R¹² and R¹³ are both alkyl their total number of carbon atomsdoes not exceed 3, m is 0, 1 or 2, DMF is N,N-dimethylformamide, NBS isN-bromosuccinimide, NCS is N-chlorosuccinimide and MCPBA ism-chloroperbenzoic acid. Other abbreviations are defined in the text.

Compounds of formula (1), where n is 0 and L is O, may be prepared asshown in Scheme 1. Esters of formula (2), where R⁵ is C₁₋₄ alkyl, may behalogenated to give haloesters of formula (3), where Hal is a halogenatom such as bromine, chlorine or iodine, by reaction with ahalogenating agent such as N-bromosuccinimide, in a suitable solventsuch as carbon tetrachloride or acetonitrile, in the presence of aradical initiator such as AIBN (azo-isobutyronitrile), and a lightsource, at between ambient temperature and the reflux temperature of thesolvent. Compounds of general formula (3) are then reacted withalkanethiols of general formula R¹SH, in the presence of a base such assodium hydride, in a suitable solvent such as DMF, to give compounds ofgeneral formula (6), or are reacted with alkanethiol salts R¹S⁻M⁺, whereM is a metal such as sodium or lithium, in a suitable solvent such asDMF, to give compounds of general formula (6).

Alternatively esters of general formula (4) are halogenated to givehaloesters of formula (5), where Hal is a halogen atom such as bromine,chlorine or iodine, by reaction with a halogenating agent such asN-chlorosuccinimide or N-bromosuccinimide or sulphuryl chloride, in asuitable solvent such as carbon tetrachloride or acetonitrile ordichloromethane, at between 0° C. and the reflux temperature of thesolvent. Haloesters of formula (5) are reacted with hydroxy(hetero)arylsArOH, where Ar is as defined above, in the presence of a base such aspotassium t-butoxide, potassium carbonate, or sodium hydride in asuitable solvent such as t-butanol, 1,4-dioxane or DMF, at betweenambient temperature and the reflux temperature of the solvent, to givecompounds of formula (6). Compounds of formula (6) are hydrolysed toacids of formula (7) by reaction with an alkali metal hydroxide M⁺OH⁻,in a suitable solvent such as aqueous methanol, ethanol, or THF(tetrahydrofuran) at between ambient temperature and the refluxtemperature of the solvent followed by acidification. Acids of formula(7) can be condensed with amines of formula (8), using suitableactivating agents such as HOBT (1-hydroxybenzotriazole) and EDC(1-ethyl-3-N,N-dimethylaminopropylcarbodiimide hydrochloride), atbetween 0° C. and ambient temperature in a suitable solvent such as DMF,to give compounds of general formula (1) where n is 0 and L is O.

Compounds of general formula (1), where n is 1 or 2, are prepared byoxidation of compounds (1) where n=0 to the sulphoxide (n is 1) orsulphone (n is 2) oxidation state, as shown in Scheme 2. For example,esters of the general formula (6) where R⁵ is C₁₋₄ alkyl can be oxidisedto sulphoxides of formula (9) with an oxidising agent such as sodiumperiodate in a suitable solvent such ethanol, between 0° C. and ambienttemperature. Sulphones of formula (10) can be made either directly fromcompounds of formula (6) with two or more equivalents of an oxidisingagent such as m-chloroperbenzoic acid (MCPBA), in a suitable solventsuch as dichloromethane between 0° C. and the reflux temperature of thesolvent, or from sulphoxides of formula (9) with one or more equivalentsof m-chloroperbenzoic acid. Sulphides of formula (6), sulphoxides offormula (9) or sulphones of formula (10) can be hydrolysed to thecorresponding acids (7), (11) or (12) by reaction with an alkali metalhydroxide in a suitable solvent such as ethanol at between 0° C. and thereflux temperature of the solvent followed by acidification. The acidsof formula (7), (11) or (12) can be condensed with amines of formula(8), using suitable activating agents such as HOBT and EDC, at between0° C. and ambient temperature, to give compounds of general formula (1)where n is 0, 1 or 2.

Similarly, sulphoxides of formula (11) and of formula (1) where n is 1can be prepared from sulphides of formula (7) and of formula (1) where nis 0 respectively, using oxidising agents such as sodium metaperiodateor m-chloroperbenzoic acid as described above. Sulphones of formula (12)and of formula (1) where n is 2, can be prepared either from sulphidesof formula (7) and of formula (1) where n is 0, by using at least twoequivalents of oxidising agents such as m-chloroperbenzoic acid, or fromsulphoxides of formula (11) and of formula (1) where n is 1, using oneor more equivalents of oxidising agents such as m-chloroperbenzoic acid,as described above.

Compounds of formula (1) can also be prepared as shown in Scheme 3.Acids of formula (13) can be condensed with amines of formula (8), usingsuitable activating agents such as HOBT and EDC, at between 0° C. andambient temperature, to give compounds of formula (14). Compounds offormula (14) can be halogenated to compounds of formula (16) using ahalogenating agent such as N-chlorosuccinimide, in a suitable solventsuch as carbon tetrachloride or acetonitrile, at between 0° C. andambient temperature. Amides of formula (16) can also be prepared fromacid halides of formula (15) by reaction with amines of formula (8) inthe presence of a base such as triethyl-amine in a suitable solvent suchas dichloromethane, at between 0° C. and ambient temperature.

Halosulphides of formula (16) can be reacted with hydroxy(hetero)arylsArOH, in the presence of a base such as potassium carbonate or sodiumhydride, in a suitable solvent such as DMF, at between 0° C. and 80° C.,to give compounds of formula (1) where n is 0.

As shown in Scheme 4, amines of the general formula (18) or (20), whichare examples of amines of the general formula (8) wherein R² is H, maybe prepared by alkylation of an aminoalcohol of the general formula (17)or (19) using a suitable base, such as n-butyl lithium or sodiumhydride, followed by reaction with a suitable alkylating reagent R¹⁰LG,such as an alkyl iodide, for example, methyl iodide, to form analkylated compound of the general formula (18) or (20), respectively. Acarbonyl derivative R¹²COR¹³ (21), for example formaldehyde, can bereacted with ammonia, usually in form of ammonium chloride, and cyanide,conveniently in form of an aqueous solution sodium cyanide, to providean α-aminoalkyne (22) (Strecker synthesis).

Other amines of the general formula (8) are either commerciallyavailable or may be prepared by standard literature methods or standardmodifications.

Thioamides (Compounds of the general formula (1) where L=S (such as2-(3-bromo-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-thioacetamide{13C NMR (CDCl₃) δ (C═S) 193.3 ppm} derived from compound number 12 ofTable 72) may be prepared from the corresponding amides using thionatingagents such as phosphorus pentasulphide, Lawesson's or Davy's reagentsor prepared from the corresponding thionoacids or thionoesters usingstandard literature methods or standard modifications.

Hydroxy (hetero)aryls ArOH are either commercially available or may beprepared by standard literature methods (see, for example, Ann. Chem.,Justus Liebigs (1966), 98-106 for the synthesis of3-bromo-6-hydroxy-quinoline used for the preparation of compounds inTable 57; Journal of the Chemical Society, Perkin Transactions 1:Organic and Bio-Organic Chemistry (1972-1999) (1982), (3), 815-21 forthe synthesis of benzo[b]thiophen-6-ol used for the preparation ofcompounds in Table 83A: Journal of Medicinal Chemistry 2004, 47(20),4829-4837 for the synthesis of benzofuran-6-ol used for the preparationof compounds in Table 83B and European Journal of Organic Chemistry(2000), (3), 491-497 for the synthesis of 7-bromo-naphthalen-2-ol usedfor the preparation of compounds in Table 67).

The compounds of formula (1) are active fungicides and may be used tocontrol one or more of the following pathogens: Pyricularia oryzae(Magnaporthe grisea) on rice and wheat and other Pyricularia spp. onother hosts; Puccinia triticina (or recondita), Puccinia striiformis andother rusts on wheat, Puccinia hordei, Puccinia striiformis and otherrusts on barley, and rusts on other hosts (for example turf, rye,coffee, pears, apples, peanuts, sugar beet, vegetables and ornamentalplants); Erysiphe cichoracearum on cucurbits (for example melon);Blumeria (or Erysiphe) graminis (powdery mildew) on barley, wheat, ryeand turf and other powdery mildews on various hosts, such asSphaerotheca macularis on hops, Sphaerotheca fusca (Sphaerothecafuliginea) on cucurbits (for example cucumber), Leveilluia taurica ontomatoes, aubergine and green pepper, Podosphaera leucotricha on applesand Uncinula necator on vines; Cochliobolus spp., Helminthosporium spp.,Drechslera spp. (Pyrenophora spp.), Rhynchosporium spp., Mycosphaerellagraminicola (Septoria tritici) and Phaeosphaeria nodorum (Stagonosporanodorum or Septoria nodorum), Pseudocercosporella herpotrichoides andGaeumannomyces graminis on cereals (for example wheat, barley, rye),turf and other hosts; Cercospora arachidicola and Cercosporidiumpersonatum on peanuts and other Cercospora spp. on other hosts, forexample sugar beet, bananas, soya beans and rice; Botrytis cinerea (greymould) on tomatoes, strawberries, vegetables, vines and other hosts andother Botrytis spp. on other hosts; Altentaria spp. on vegetables (forexample carrots), oil-seed rape, apples, tomatoes, potatoes, cereals(for example wheat) and other hosts; Venturia spp. (including Venturiainaequalis (scab)) on apples, pears, stone fruit, tree nuts and otherhosts; Cladosporium spp. on a range of hosts including cereals (forexample wheat) and tomatoes; Monilinia spp. on stone fruit, tree nutsand other hosts; Didymella spp. on tomatoes, turf, wheat, cucurbits andother hosts; Phoina spp. on oil-seed rape, turf, rice, potatoes, wheatand other hosts; Aspergillus spp. and Aureobasidium spp. on wheat,lumber and other hosts; Ascochyta spp. on peas, wheat, barley and otherhosts; Stemphyliuni spp. (Pleospora spp.) on apples, pears, onions andother hosts; summer diseases (for example bitter rot (Glomerellacingulata), black rot or frogeye leaf spot (Botryosphaeria obtusa),Brooks fruit spot (Mycosphaerella pomi), Cedar apple rust(Gymnosporangium juniperi-virginianae), sooty blotch (Gloeodespomigena), flyspeck (Schizothytium pomi) and white rot (Botryosphaeriadothidea)) on apples and pears; Plasmopara viticola on vines; otherdowny mildews, such as Bremia lactucae on lettuce, Peronospora spp. onsoybeans, tobacco, onions and other hosts, Pseudoperonospora humuli onhops and Pseudoperonospora cubensis on cucurbits; Pythium spp.(including Pythium ultinium) on turf and other hosts; Phytophthorainfestans on potatoes and tomatoes and other Phytophthora spp. onvegetables, strawberries, avocado, pepper, ornamentals, tobacco, cocoaand other hosts; Thanatephorus cucumeris on rice and turf and otherRhizoctonia spp. on various hosts such as wheat and barley, peanuts,vegetables, cotton and turf; Sclerotinia spp. on turf, peanuts,potatoes, oil-seed rape and other hosts; Sclerotium spp. on turf,peanuts and other hosts; Gibberella fujikuroi on rice; Colletotrichumspp. on a range of hosts including turf, coffee and vegetables;Laetisaria fuciformis on turf; Mycosphaerella spp. on bananas, peanuts,citrus, pecans, papaya and other hosts; Diaporthe spp. on citrus,soybean, melon, pears, lupin and other hosts; Elsinoe spp. on citrus,vines, olives, pecans, roses and other hosts; Verticillium spp. on arange of hosts including hops, potatoes and tomatoes; Pyrenopeziza spp.on oil-seed rape and other hosts; Oncobasidium theobromae on cocoacausing vascular streak dieback; Fusarium spp., Typhula spp.,Microdochium nivale, Ustilago spp., Urocystis spp., Tilletia spp. andClaviceps purpurea on a variety of hosts but particularly wheat, barley,turf and maize; Ramularia spp. on sugar beet, barley and other hosts;post-harvest diseases particularly of fruit (for example Penicilliumdigitatum, Penicillium italicum and Trichoderma viride on oranges,Colletotrichum musae and Gloeosporium musarum on bananas and Botrytiscinerea on grapes); other pathogens on vines, notably Eutypa lata,Guignardia bidwellii, Phellinus igniarus, Phomopsis viticola,Pseudopeziza tracheiphila and Stereum hirsutum; other pathogens on trees(for example Lophodernium seditiosum) or lumber, notably Cephaloascusfragrans, Ceratocystis spp., Ophiostoma piceae, Penicillium spp.,Trichodenna pseudokoningii, Trichoderma viride, Trichoderma harzianum,Aspergillus niger, Leptographium lindbergi and Aureobasidium pullulans;and fungal vectors of viral diseases (for example Polymyxa graminis oncereals as the vector of barley yellow mosaic virus (BYMV) and Polymyxabetae on sugar beet as the vector of rhizomania).

A compound of formula (1) may move acropetally, basipetally or locallyin plant tissue to be active against one or more fungi. Moreover, acompound of formula (1) may be volatile enough to be active in thevapour phase against one or more fungi on the plant.

The invention therefore provides a method of combating or controllingphytopathogenic fungi which comprises applying a fungicidally effectiveamount of a compound of formula (1), or a composition containing acompound of formula (1), to a plant, to a seed of a plant, to the locusof the plant or seed or to soil or any other plant growth medium, e.g.nutrient solution.

The term “plant” as used herein includes seedlings, bushes and trees.Furthermore, the fungicidal method of the invention includes protectant,curative, systemic, eradicant and antisporulant treatments.

The compounds of formula (1) are preferably used for agricultural,horticultural and turfgrass purposes in the form of a composition.

In order to apply a compound of formula (1) to a plant, to a seed of aplant, to the locus of the plant or seed or to soil or any other growthmedium, a compound of formula (1) is usually formulated into acomposition which includes, in addition to the compound of formula (1),a suitable inert diluent or carrier and, optionally, a surface activeagent (SFA). SFAs are chemicals that are able to modify the propertiesof an interface (for example, liquid/solid, liquid/air or liquid/liquidinterfaces) by lowering the interfacial tension and thereby leading tochanges in other properties (for example dispersion, emulsification andwetting). It is preferred that all compositions (both solid and liquidformulations) comprise, by weight, 0.0001 to 95%, more preferably 1 to85%, for example 5 to 60%, of a compound of formula (1). The compositionis generally used for the control of fungi such that a compound offormula (1) is applied at a rate of from 0.1 g to 10 kg per hectare,preferably from 1 g to 6 kg per hectare, more preferably from 1 g to 1kg per hectare.

When used in a seed dressing, a compound of formula (1) is used at arate of 0.0001 g to 10 g (for example 0.001 g or 0.05 g), preferably0.005 g to 10 g, more preferably 0.005 g to 4 g, per kilogram of seed.

In another aspect the present invention provides a fungicidalcomposition comprising a fungicidally effective amount of a compound offormula (1) and a suitable carrier or diluent therefor.

In a still further aspect the invention provides a method of combatingand controlling fungi at a locus, which comprises treating the fungi, orthe locus of the fungi with a fungicidally effective amount of acomposition comprising a compound of formula (1).

The compositions can be chosen from a number of formulation types,including dustable powders (DP), soluble powders (SP), water solublegranules (SG), water dispersible granules (WG), wettable powders (WP),granules (GR) (slow or fast release), soluble concentrates (SL), oilmiscible liquids (OL), ultra low volume liquids (UL), emulsifiableconcentrates (EC), dispersible concentrates (DC), emulsions (both oil inwater (EW) and water in oil (EO)), micro-emulsions (ME), suspensionconcentrates (SC), aerosols, fogging/smoke formulations, capsulesuspensions (CS) and seed treatment formulations. The formulation typechosen in any instance will depend upon the particular purpose envisagedand the physical, chemical and biological properties of the compound offormula (1).

Dustable powders (DP) may be prepared by mixing a compound of formula(1) with one or more solid diluents (for example natural clays, kaolin,pyrophyllite, bentonite, alumina, montmorillonite, kieselguhr, chalk,diatomaceous earths, calcium phosphates, calcium and magnesiumcarbonates, sulphur, lime, flours, talc and other organic and inorganicsolid carriers) and mechanically grinding the mixture to a fine powder.

Soluble powders (SP) may be prepared by mixing a compound of formula (1)with one or more water-soluble inorganic salts (such as sodiumbicarbonate, sodium carbonate or magnesium sulphate) or one or morewater-soluble organic solids (such as a polysaccharide) and, optionally,one or more wetting agents, one or more dispersing agents or a mixtureof said agents to improve water dispersibility/solubility. The mixtureis then ground to a fine powder. Similar compositions may also begranulated to form water soluble granules (SG).

Wettable powders (WP) may be prepared by mixing a compound of formula(1) with one or more solid diluents or carriers, one or more wettingagents and, preferably, one or more dispersing agents and, optionally,one or more suspending agents to facilitate the dispersion in liquids.The mixture is then ground to a fine powder. Similar compositions mayalso be granulated to form water dispersible granules (WG).

Granules (GR) may be formed either by granulating a mixture of acompound of formula (1) and one or more powdered solid diluents orcarriers, or from pre-formed blank granules by absorbing a compound offormula (1) (or a solution thereof, in a suitable agent) in a porousgranular material (such as pumice, attapulgite clays, fuller's earth,kieselguhr, diatomaceous earths or ground corn cobs) or by adsorbing acompound of formula (1) (or a solution thereof, in a suitable agent) onto a hard core material (such as sands, silicates, mineral carbonates,sulphates or phosphates) and drying if necessary. Agents which arecommonly used to aid absorption or adsorption include solvents (such asaliphatic and aromatic petroleum solvents, alcohols, ethers, ketones andesters) and sticking agents (such as polyvinyl acetates, polyvinylalcohols, dextrins, sugars and vegetable oils). One or more otheradditives may also be included in granules (for example an emulsifyingagent, wetting agent or dispersing agent).

Dispersible Concentrates (DC) may be prepared by dissolving a compoundof formula (1) in water or an organic solvent, such as a ketone, alcoholor glycol ether. These solutions may contain a surface active agent (forexample to improve water dilution or prevent crystallisation in a spraytank).

Emulsifiable concentrates (EC) or oil-in-water emulsions (EW) may beprepared by dissolving a compound of formula (1) in an organic solvent(optionally containing one or more wetting agents, one or moreemulsifying agents or a mixture of said agents). Suitable organicsolvents for use in ECs include aromatic hydrocarbons (such asalkylbenzenes or alkylnaphthalenes, exemplified by SOLVESSO 100,SOLVESSO 150 and SOLVESSO 200; SOLVESSO is a Registered Trade Mark),ketones (such as cyclohexanone or methylcyclohexanone), alcohols (suchas benzyl alcohol, furfuryl alcohol or butanol), N-alkylpyrrolidones(such as N-methylpyrrolidone or N-octyl-pyrrolidone), dimethyl amides offatty acids (such as C₈-C₁₀ fatty acid dimethylamide) and chlorinatedhydrocarbons. An EC product may spontaneously emulsify on addition towater, to produce an emulsion with sufficient stability to allow sprayapplication through appropriate equipment. Preparation of an EW involvesobtaining a compound of formula (1) either as a liquid (if it is not aliquid at ambient temperature, it may be melted at a reasonabletemperature, typically below 70° C.) or in solution (by dissolving it inan appropriate solvent) and then emulsifying the resultant liquid orsolution into water containing one or more SFAs, under high shear, toproduce an emulsion. Suitable solvents for use in EWs include vegetableoils, chlorinated hydrocarbons (such as chlorobenzenes), aromaticsolvents (such as alkylbenzenes or alkylnaphthalenes) and otherappropriate organic solvents that have a low solubility in water.

Microemulsions (ME) may be prepared by mixing water with a blend of oneor more solvents with one or more SFAs, to produce spontaneously athermodynamically stable isotropic liquid formulation. A compound offormula (1) is present initially in either the water or the solvent/SFAblend. Suitable solvents for use in MEs include those hereinbeforedescribed for use in ECs or in EWs. An ME may be either an oil-in-wateror a water-in-oil system (which system is present may be determined byconductivity measurements) and may be suitable for mixing water-solubleand oil-soluble pesticides in the same formulation. An ME is suitablefor dilution into water, either remaining as a microemulsion or forminga conventional oil-in-water emulsion.

Suspension concentrates (SC) may comprise aqueous or non-aqueoussuspensions of finely divided insoluble solid particles of a compound offormula (1). SCs may be prepared by ball or bead milling the solidcompound of formula (1) in a suitable medium, optionally with one ormore dispersing agents, to produce a fine particle suspension of thecompound. One or more wetting agents may be included in the compositionand a suspending agent may be included to reduce the rate at which theparticles settle. Alternatively, a compound of formula (1) may be drymilled and added to water, containing agents hereinbefore described, toproduce the desired end product.

Aerosol formulations comprise a compound of formula (1) and a suitablepropellant (for example n-butane). A compound of formula (1) may also bedissolved or dispersed in a suitable medium (for example water or awater miscible liquid, such as n-propanol) to provide compositions foruse in non-pressurised, hand-actuated spray pumps.

A compound of formula (1) may be mixed in the dry state with apyrotechnic mixture to form a composition suitable for generating, in anenclosed space, a smoke containing the compound.

Capsule suspensions (CS) may be prepared in a manner similar to thepreparation of EW formulations but with an additional polymerisationstage such that an aqueous dispersion of oil droplets is obtained, inwhich each oil droplet is encapsulated by a polymeric shell and containsa compound of formula (1) and, optionally, a carrier or diluenttherefor. The polymeric shell may be produced by either an interfacialpolycondensation reaction or by a coacervation procedure. Thecompositions may provide for controlled release of the compound offormula (1) and they may be used for seed treatment. A compound offormula (1) may also be formulated in a biodegradable polymeric matrixto provide a slow, controlled release of the compound.

A composition may include one or more additives to improve thebiological performance of the composition (for example by improvingwetting, retention or distribution on surfaces; resistance to rain ontreated surfaces; or uptake or mobility of a compound of formula (1)).Such additives include surface active agents, spray additives based onoils, for example certain mineral oils or natural plant oils (such assoy bean and rape seed oil), and blends of these with otherbio-enhancing adjuvants (ingredients which may aid or modify the actionof a compound of formula (1)).

A compound of formula (1) may also be formulated for use as a seedtreatment, for example as a powder composition, including a powder fordry seed treatment (DS), a water soluble powder (SS) or a waterdispersible powder for slurry treatment (WS), or as a liquidcomposition, including a flowable concentrate (FS), a solution (LS) or acapsule suspension (CS). The preparations of DS, SS, WS, FS and LScompositions are very similar to those of, respectively, DP, SP, WP, SCand DC compositions described above. Compositions for treating seed mayinclude an agent for assisting the adhesion of the composition to theseed (for example a mineral oil or a film-forming barrier).

Wetting agents, dispersing agents and emulsifying agents may be SFAs ofthe cationic, anionic, amphoteric or non-ionic type.

Suitable SFAs of the cationic type include quaternary ammonium compounds(for example cetyltrimethyl ammonium bromide), imidazolines and aminesalts.

Suitable anionic SFAs include alkali metals salts of fatty acids, saltsof aliphatic monoesters of sulphuric acid (for example sodium laurylsulphate), salts of sulphonated aromatic compounds (for example sodiumdodecylbenzenesulphonate, calcium dodecylbenzenesulphonate,butylnaphthalene sulphonate and mixtures of sodium di-isopropyl- andtri-isopropyl-naphthalene sulphonates), ether sulphates, alcohol ethersulphates (for example sodium laureth-3-sulphate), ether carboxylates(for example sodium laureth-3-carboxylate), phosphate esters (productsfrom the reaction between one or more fatty alcohols and phosphoric acid(predominately mono-esters) or phosphorus pentoxide (predominatelydi-esters), for example the reaction between lauryl alcohol andtetraphosphoric acid; additionally these products may be ethoxylated),sulphosuccinamates, paraffin or olefin sulphonates, taurates andlignosulphonates.

Suitable SFAs of the amphoteric type include betaines, propionates andglycinates.

Suitable SFAs of the non-ionic type include condensation products ofalkylene oxides, such as ethylene oxide, propylene oxide, butylene oxideor mixtures thereof, with fatty alcohols (such as oleyl alcohol or cetylalcohol) or with alkylphenols (such as octylphenol, nonylphenol oroctylcresol); partial esters derived from long chain fatty acids orhexitol anhydrides; condensation products of said partial esters withethylene oxide; block polymers (comprising ethylene oxide and propyleneoxide); alkanolamides; simple esters (for example fatty acidpolyethylene glycol esters); amine oxides (for example lauryl dimethylamine oxide); and lecithins.

Suitable suspending agents include hydrophilic colloids (such aspolysaccharides, polyvinylpyrrolidone or sodium carboxymethylcellulose)and swelling clays (such as bentonite or attapulgite).

A compound of formula (1) may be applied by any of the known means ofapplying fungicidal compounds. For example, it may be applied,formulated or unformulated, to any part of the plant, including thefoliage, stems, branches or roots, to the seed before it is planted orto other media in which plants are growing or are to be planted (such assoil surrounding the roots, the soil generally, paddy water orhydroponic culture systems), directly or it may be sprayed on, dustedon, applied by dipping, applied as a cream or paste formulation, appliedas a vapour or applied through distribution or incorporation of acomposition (such as a granular composition or a composition packed in awater-soluble bag) in soil or an aqueous environment.

A compound of formula (1) may also be injected into plants or sprayedonto vegetation using electrodynamic spraying techniques or other lowvolume methods, or applied by land or aerial irrigation systems.

Compositions for use as aqueous preparations (aqueous solutions ordispersions) are generally supplied in the form of a concentratecontaining a high proportion of the active ingredient, the concentratebeing added to water before use. These concentrates, which may includeDCs, SCs, ECs, EWs, MEs, SGs, SPs, WPs, WGs and CSs, are often requiredto withstand storage for prolonged periods and, after such storage, tobe capable of addition to water to form aqueous preparations whichremain homogeneous for a sufficient time to enable them to be applied byconventional spray equipment. Such aqueous preparations may containvarying amounts of a compound of formula (1) (for example 0.0001 to 10%,by weight) depending upon the purpose for which they are to be used.

A compound of formula (1) may be used in mixtures with fertilisers (forexample nitrogen-, potassium- or phosphorus-containing fertilisers).Suitable formulation types include granules of fertiliser. The mixturessuitably contain up to 25% by weight of the compound of formula (1).

The invention therefore also provides a fertiliser compositioncomprising a fertiliser and a compound of formula (1).

The compositions of this invention may contain other compounds havingbiological activity, for example micronutrients or compounds havingsimilar or complementary fungicidal activity or which possess plantgrowth regulating, herbicidal, insecticidal, nematicidal or acaricidalactivity.

By including another fungicide, the resulting composition may have abroader spectrum of activity or a greater level of intrinsic activitythan the compound of formula (1) alone. Further the other fungicide mayhave a synergistic effect on the fungicidal activity of the compound offormula (1).

The compound of formula (1) may be the sole active ingredient of thecomposition or it may be admixed with one or more additional activeingredients such as a pesticide, fungicide, synergist, herbicide orplant growth regulator where appropriate. An additional activeingredient may: provide a composition having a broader spectrum ofactivity or increased persistence at a locus; synergise the activity orcomplement the activity (for example by increasing the speed of effector overcoming repellency) of the compound of formula (1); or help toovercome or prevent the development of resistance to individualcomponents. The particular additional active ingredient will depend uponthe intended utility of the composition.

Examples of fungicidal compounds which may be included in thecomposition of the invention are AC 382042(N-(1-cyano-1,2-dimethylpropyl)-2-(2,4-dichlorophenoxy) propionamide),acibenzolar-5-methyl, alanycarb, aldimorph, anilazine, azaconazole,azafenidin, azoxystrobin, benalaxyl, benomyl, benthiavalicarb,biloxazol, bitertanol, blasticidin S, boscalid (new name for nicobifen),bromuconazole, bupirimate, captafol, captan, carbendazim, carbendazimchlorhydrate, carboxin, carpropamid, carvone, CGA 41396, CGA 41397,chinomethionate, chlorbenzthiazone, chlorothalonil, chlorozolinate,clozylacon, copper containing compounds such as copper oxychloride,copper oxyquinolate, copper sulphate, copper tallate, and Bordeauxmixture, cyamidazosulfamid, cyazofamid (IKF-916), cyflufenamid,cymoxanil, cyproconazole, cyprodinil, debacarb, di-2-pyridyl disulphide1,1′-dioxide, dichlofluanid, diclocymet, diclomezine, dicloran,diethofencarb, difenoconazole, difenzoquat, diflumetorim,O,O-di-iso-propyl-5-benzyl thiophosphate, dimefluazole, dimetconazole,dimethirimol, dimethomorph, dimoxystrobin, diniconazole, dinocap,dithianon, dodecyl dimethyl ammonium chloride, dodemorph, dodine,doguadine, edifenphos, epoxiconazole, ethaboxam, ethirimol, ethyl(Z)-N-benzyl-N([methyl(methyl-thioethylideneaminooxycarbonyl)amino]thio)-β-alaninate,etridiazole, famoxadone, fenamidone, fenarimol, fenbuconazole, fenfuram,fenhexamid, fenoxanil (AC 382042), fenpiclonil, fenpropidin,fenpropimorph, fentin acetate, fentin hydroxide, ferbam, ferimzone,fluazinam, fludioxonil, flumetover, flumorph, fluoroimide,fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutolanil,flutriafol, folpet, fosetyl-aluminium, fuberidazole, furalaxyl,furametpyr, guazatine, hexaconazole, hydroxyisoxazole, hymexazole,imazalil, imibenconazole, iminoctadine, iminoctadine triacetate,ipconazole, iprobenfos, iprodione, iprovalicarb, isopropanyl butylcarbamate, isoprothiolane, kasugamycin, kresoxim-methyl, LY186054,LY211795, LY 248908, mancozeb, maneb, mefenoxam, mepanipyrim, mepronil,metalaxyl, metalaxyl M, metconazole, metiram, metiram-zinc,metominostrobin, metrafenone, MON65500(N-allyl-4,5-dimethyl-2-trimethylsilylthiophene-3-carboxamide),myclobutanil, NTN0301, neoasozin, nickel dimethyldithiocarbamate,nitrothale-isopropyl, nuarimol, ofurace, organomercury compounds,orysastrobin, oxadixyl, oxasulfuron, oxolinic acid, oxpoconazole,oxycarboxin, pefurazoate, penconazole, pencycuron, phenazin oxide,phosphorus acids, phthalide, picoxystrobin, polyoxin D, polyram,probenazole, prochloraz, procymidone, propamocarb, propamocarbhydrochloride, propiconazole, propineb, propionic acid, proquinazid,prothioconazole, pyraclostrobin, pyrazophos, pyrifenox, pyrimethanil,pyroquilon, pyroxyfur, pyrrolnitrin, quaternary ammonium compounds,quinomethionate, quinoxyfen, quintozene, silthiofam (MON 65500),S-imazalil, simeconazole, sipconazole, sodium pentachlorophenate,spiroxamine, streptomycin, sulphur, tebuconazole, tecloftalam,tecnazene, tetraconazole, thiabendazole, thifluzamide,2-(thiocyanomethylthio)benzothiazole, thiophanate-methyl, thiram,tiadinil, timibenconazole, tolclofos-methyl, tolylfluanid, triadimefon,triadimenol, triazbutil, triazoxide, tricyclazole, tridemorph,trifloxystrobin, triflumizole, triforine, triticonazole, validamycin A,vapam, vinclozolin, XRD-563, zineb, ziram, zoxamide and compounds of theformulae:

The compounds of formula (1) may be mixed with soil, peat or otherrooting media for the protection of plants against seed-borne,soil-borne or foliar fungal diseases.

Some mixtures may comprise active ingredients, which have significantlydifferent physical, chemical or biological properties such that they donot easily lend themselves to the same conventional formulation type. Inthese circumstances other formulation types may be prepared. Forexample, where one active ingredient is a water insoluble solid and theother a water insoluble liquid, it may nevertheless be possible todisperse each active ingredient in the same continuous aqueous phase bydispersing the solid active ingredient as a suspension (using apreparation analogous to that of an SC) but dispersing the liquid activeingredient as an emulsion (using a preparation analogous to that of anEW). The resultant composition is a suspoemulsion (SE) formulation.

The invention is illustrated by the following Examples in which thefollowing abbreviations are used:

-   ml=millilitres m.p.=melting point (uncorrected)-   g=grammes b.p.=boiling point-   THF=tetrahydrofuran DMSO=dimethylsulphoxide-   M⁺=mass ion DMF=N,N-dimethylformamide-   s=singlet d=doublet-   HOBT=1-hydroxybenzotriazole HOAT=7-aza-1-hydroxybenzotriazole-   bs=broad singlet NMR=nuclear magnetic resonance-   t=triplet HPLC=high performance liquid chromatography-   q=quartet TLC=thin layer chromatography-   m=multiplet glc=gas-liquid chromatography-   ppm=parts per million EDC=1-ethyl-3-N,N-dimethylamino-   M=molar propylcarbodiimide hydrochloride

EXAMPLE 1

This Example illustrates the preparation of2-(3,5-dichlorophenoxy)-2-methylthio-N-2-methylprop-2-yl acetamide(Compound No. 12 of Table 1)

Stage 1: Preparation of 2-methylthio-2-(3,5-dichlorophenoxy)acetic acidStep 1

t-Butyl 2-bromo-2-(3,5-dichlorophenoxy)acetate (1.0 g) was dissolved in1,4-dioxane (3 ml), and sodium thiomethoxide (0.218 g) was added to themixture. The resulting pale yellow suspension was stirred at ambienttemperature for 5 hours and then stored for 18 hours. The solvent wasevaporated, water was added and the aqueous layer was extracted twicewith ethyl acetate (100 ml). The organic layers were combined, washedwith brine, dried over magnesium sulphate, filtered and evaporated togive t-butyl 2-methylthio-2-(3,5-dichlorophenoxy)acetate as a paleyellow solid (0.80 g) which was used in the next step without furtherpurification.

¹H NMR (CDCl₃) δ ppm: 1.52 (9H, s); 2.19 (3H, s), 5.39 (1H, s); 6.92(2H, d); 7.04 (1H, t).

Step 2

To the product of Step 1 (0.2 g) in methanol (3 ml) at ambienttemperature was added a solution of sodium hydroxide (0.050 g) in water(1 ml). The reaction was stirred for 2 hours, the solvent evaporatedthen water and ethyl acetate were added. The aqueous phase wasseparated, acidified with dilute aqueous hydrochloric acid thenextracted with ethyl acetate. The organic phases were combined, driedover magnesium sulphate, filtered and evaporated to give2-methylthio-2-(3,5-dichlorophenoxy)acetic acid as a pale yellow gum(0.153 g).

¹H NMR (CDCl₃) δ ppm: 2.21 (3H, s); 5.59 (1H, s); 6.95 (2H, s); 7.08(1H, s).

Stage 2

2-Methylthio-2-(3,5-dichlorophenoxy)acetic acid (0.27 g), in dryN,N-dimethylformamide (6 ml) was treated with t-butylamine (0.077 g),N-(3-dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride (0.211 g),HOAt (0.15 g) and triethylamine (0.28 ml) at ambient temperature withstirring for 10 hours. The mixture was poured into water, extracted withethyl acetate (three times) and the extracts combined, washed withsaturated aqueous sodium carbonate solution, water (three times) thendried over magnesium sulfate, filtered and evaporated under reducedpressure to give an oil. The oil was fractionated by chromatography(silica; hexane/ethyl acetate, 95:5 by volume) to give the requiredproduct, 0.03 g, as a pale yellow solid, m.p. 125-126° C.

¹H NMR (CDCl₃) δ ppm: 1.36 (9H, s); 2.08 (3H, s); 5.34 (1H, s); 6.24(1H, bs); 6.86 (2H, d); 9.02 (1H, t).

The following amides were prepared using a similar procedure.

Compound No. 122 of Table 1: using 2-aminomethylfuran, ¹H NMR (CDCl₃) δppm: 2.10 (3H, s); 4.48-4.66 (2H, 2×dd); 5.56 (1H, s); 6.29 (1H, d);6.33 (1H, m); 6.88 (1H, bs); 6.92 (2H, d); 7.09 (1H, t); 7.38 (1H, m).

Compound No. 150 of Table 1: using benzylamine, ¹H NMR (CDCl₃) δ ppm:2.13 (3H, s); 4.48-4.64 (2H, 4×d); 5.57 (1H, s); 6.86 (1H, s); 6.92 (1H,s); 7.08 (1H, t); 7.30-7.38 (5H, m).

EXAMPLE 2

This Example illustrates the preparation of2-(3,4,5-trimethylphenoxy)-2-methylthio-N-(2-methyl-prop-2-yl)acetamide(Compound No. 12 of Table 13) and2-(4-bromo-3,5-dimethylphenoxy)-2-methylthio-N-(2-methyl-prop-2-yl)acetamide(Compound No. 12 of Table 15)

Stage 1: Preparation of 2-methylthio-2-(3,4,5-trimethylphenoxy)aceticacid Step 1: Preparation of ethyl 2-chloro-2-methylthioacetate

To a stirred solution of ethyl 2-methylthioacetate (10.0 g) in dryacetonitrile (50 ml) at 0° C. was added in portions N-chlorosuccinimide(NCS, 9.8 g), maintaining the reaction temperature below 5° C. duringthe addition. The mixture was stirred for 0.5 hours then further NCS(0.5 g) was added to complete the reaction and the suspension stirredfor a further 0.5 hours. The mixture was treated with saturated aqueoussodium hydrogen carbonate, the organic phase separated and the aqueousphase extracted with diethyl ether (twice). The organic fractions werecombined, washed with aqueous sodium hydrogen carbonate (twice), brine(twice) then dried over magnesium sulfate, filtered and the solventevaporated under reduced pressure to give ethyl2-chloro-2-methylthioacetate, (9.2 g), as a colourless liquid. Theproduct was used in the next Stage without further purification.

¹H NMR (CDCl₃) δ ppm: 1.32-1.36 (3H, t); 2.32 (3H, s); 4.26-4.32 (2H,q); 5.36 (1H, s).

Step 2: Preparation of ethyl2-methylthio-2-(3,4,5-trimethylphenoxy)acetate

To a stirred suspension of sodium hydride (0.33 g, 60% in mineral oils)in dry N,N-dimethylformamide (2 ml) under an atmosphere of nitrogen wasadded 3,4,5-trimethylphenol (11.0 g) in N,N-dimethylformamide (20 ml)over 5 minutes at ambient temperature. The mixture was stirred for 1hour and diluted with further N,N-dimethylformamide (40 ml) then addeddropwise simultaneously with a solution of ethyl 2-chloro-2-thioacetate(1.87 g) in N,N-dimethylformamide (10 ml) to a stirred suspension ofanhydrous potassium carbonate (1.5 g) in dry DMF (10 ml) heated to 50°C. with stirring for 0.75 hours. The mixture was cooled to ambienttemperature, poured into water then extracted with ethyl acetate (threetimes). The extracts were combined, washed with water (three times),dried over magnesium sulphate then evaporated to give a yellow oil, 2.15g, containing ethyl 2-methylthio-2-(3,4,5-trimethylphenoxy)acetate andsome unreacted trimethylphenol. A portion of the oil was fractionated bychromatography (silica; hexane:ethyl acetate) to give a pure sample ofethyl 2-methylthio-2-(3,4,5-trimethylphenoxy)acetate as a pale yellowoil. The remainder of the oil was used in Step 3 without furtherpurification.

¹H NMR (CDCl₃) 8 ppm: 1.30-1.34 (3H, t); 2.10 (3H, s); 2.20 (3H, s);2.26 (6H, s); 4.28-4.36 (2H, m); 5.56 (1H, s); 6.70 (2H, s).

Step 3

The product from Step 2 (2.0 g) in THF (10 ml) and water (3 ml)containing sodium hydroxide (0.4 g) were stirred at 60° C. for 2 hoursthen cooled to ambient temperature, evaporated under reduced pressure,diluted with water and washed with diethyl ether. The aqueous fractionwas acidified with dilute hydrochloric acid and extracted with ethylacetate (three times). The extracts were combined, washed with brine,dried over magnesium sulphate, then evaporated to give2-methylthio-2-(3,4,5-trimethylphenoxy)acetic acid, 1.05 g, as a yellowgum. A portion of the gum was fractionated by chromatography (silica;ethyl acetate then methanol) to provided an analytical sample and theremainder used in the next stage without further purification.

¹H NMR (CDCl₃) δ ppm: 2.12 (3H, s); 2.24 (3H, s); 2.26 (6H, s); 5.64(1H, s); 6.72 (2H, s).

Stage 2

In a similar procedure to Stage 2 of Example 1,2-methylthio-2-(3,4,5-trimethyl-phenoxy)acetic was condensed withtert-butylamine to give2-methylthio-2-(3,4,5-trimethylphenoxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide.

¹H NMR (CDCl₃) δ ppm: 1.34 (9H, s); 2.04 (3H, s); 2.08 (3H, s); 2.20(6H, s); 5.34 (1H, s); 6.44 (1H, s); 6.60 (2H, s).

In a similar procedure to Stage 1, Step 1 of Example 2,4-bromo-3,5-dimethylphenol was reacted with ethyl2-bromo-2-methylthioacetate to give ethyl2-methylthio-2-(4-bromo-3,5-dimethylphenoxy)acetate as a pale yellowliquid.

¹H NMR (CDCl₃) δ ppm: 1.33 (3H, t); 2.20 (3H, s); 2.39 (6H, s); 4.31(2H, m); 5.53 (1H, s); 6.77 (2H, s).

In a similar procedure to Stage 1, Step 1 of Example 2,4-cyano-3,5-dimethylphenol was reacted with ethyl2-chloro-2-methylthioacetate to give ethyl2-methylthio-2-(4-cyano-3,5-dimethylphenoxy)acetate as a pale yellowliquid.

¹H NMR (CDCl₃) δ ppm: 1.34 (3H, t); 2.20 (3H, s); 2.51 (6H, s); 4.32(2H, q); 5.49 (1H, s); 6.75 (2H, s).

In a similar procedure to Stage 1, Step 2 of Example 1, ethyl2-methylthio-2-(4-bromo-3,5-dimethylphenoxy)acetate was hydrolysed togive 2-methylthio-2-(4-bromo-3,5-dimethylphenoxy)acetic acid as anoff-white solid.

¹H NMR (CDCl₃) δ ppm: 2.23 (3H, s); 2.40 (6H, s); 5.61 (1H, s); 6.79(2H, s).

In a similar procedure to Stage 1, Step 2 of Example 1, ethyl2-methylthio-2-(4-cyano-3,5-dimethylphenoxy)acetate was hydrolysed togive 2-methylthio-2-(4-cyano-3,5-dimethylphenoxy)acetic acid as acolourless solid.

¹H NMR (CDCl₃) δ ppm: 2.24 (3H, s); 2.52 (6H, s); 5.67 (1H, s); 6.78(2H, s).

In a similar procedure to Stage 2 of Example 1,2-methylthio-2(4-bromo-3,5-dimethylphenoxy)acetic acid was condensedwith tert-butylamine to give2-(4-bromo-3,5-dimethylphenoxy)-2-methylthio-N-(2-methyl-prop-2-yl)acetamideas a colourless solid, m.p. 123-125° C.

¹H NMR (CDCl₃) δ ppm: 1.41 (9H, s); 2.14 (3H, s); 2.39 (6H, s); 5.39(1H, s); 6.41 (1H, s); 6.74 (2H, s).

The following amides were prepared using a similar procedure.

Compound No. 52 of Table 13: using 2-cyano-1-methoxy-prop-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 3.40 (3H, 2×s); 3.66 (2H, m); 5.58 (1H, 2×s); 6.68(2H, s); 7.25 (1H, 2×s).

Compound No. 120 of Table 13: using thiazol-2-ylamine, ¹H NMR (CH₃CN) δppm: 5.85 (1H, s); 6.76 (2H, s); 7.10 (1H, d); 7.45 (1H, d).

Compound No. 70 of Table 13: using allylamine, ¹H NMR (CH₃CN) δ ppm:3.83 (2H, t); 5.10 (2H, m); 5.55 (1H, s); 5.82 (1H, m); 6.68 (2H, s);7.23 (1H, s).

Compound No. 150 of Table 13: using benzylamine, ¹H NMR (CH₃CN) δ ppm:5.57 (1H, s); 6.67 (2H, s); 7.26 (5H, m); 7.58 (1H, s).

Compound No. 124 of Table 13: using thienylmethylamine, ¹H NMR (CH₃CN) δppm: 4.56 (2H, t); 5.54 (1H, s); 6.66 (2H, s); 6.92 (2H, m); 7.24 (1H,d); 7.64 (1H, s).

Compound No. 47 of Table 17: using 1-methoxy-2-methylprop-2-ylamine and2-methylthio-2-(4-cyano-3,5-dimethylphenoxy)acetic acid, ¹H NMR (CDCl₃)δ ppm: 1.36 (3H, s); 1.40 (3H, s); 2.15 (3H, s); 2.51 (6H, s); 3.38 (3H,s); 3.39 (2H, q); 5.49 (1H, s); 6.63 (1H, s); 6.73 (2H, s), colourlesssolid m.p. 123-125° C.

EXAMPLE 3

This Example illustrates the preparation of2-(5-chloropyridyl-3-oxy)-2-(methylthio)-N-(2-methylprop-2-yl) acetamide(Compound No. 12 of Table 70)

Stage 1: Preparation of ethyl 2-bromo-2-methylthioacetate

To a stirred solution of ethyl 2-methylthioacetate (40.2 g) in carbontetrachloride (250 ml) at 15° C. was added in portionsN-bromosuccinimide (NBS, 54 g) maintaining the reaction temperaturebelow 20° C. during the addition. The mixture was stirred for 5 hoursthen further NBS (10 g) was added in portions and the reaction stirredfor a further 18 hours. The mixture was washed with aqueous sodiumcarbonate then brine, dried over magnesium sulfate, filtered and thesolvent evaporated under reduced pressure to give (56 g) as an orangeliquid containing 10% of unreacted ethyl 2-methylthioacetate. Theproduct was used in the next Stage without further purification. Ananalytical sample of ethyl 2-bromo-2-methylthioacetate was obtained byvacuum distillation, b.p. 54-56° C. at 0.1 mmHg.

¹H NMR (CDCl₃) δ ppm: 1.30 (3H, s); 2.34 (3H, s); 4.26 (2H, q); 5.39(1H, s).

Stage 2: Preparation of2-(5-chloropyridyl-3-oxy)-2-(methylthio)-N-(2-methylprop-2-yl)acetamideStep 1

5-Chloro-3-hydroxypyridine (1.30 g), ethyl 2-bromo-2-methylthioacetate(2.43 g, 70% pure) and anhydrous potassium carbonate (1.38 g) werestirred in dry DMF (15 ml) and heated to 80° C. with stirring for 1hour. The mixture was cooled to ambient temperature, poured into waterthen extracted with diethyl ether (three times). The extracts werecombined, washed with water, dried over magnesium sulphate thenevaporated to give an oil, which was purified by flash chromatography onsilica gel (40-60 mesh) eluting with hexane/ethyl acetate (1:1 byvolume), to give ethyl 2-(5-chloropyridyl-3-oxy)-2-(methylthio)acetateas an orange oil (0.65 g).

¹H NMR (CDCl₃) 8 ppm: 1.34-1.38 (3H, t); 2.20 (3H, s); 4.30-4.38 (2H,m); 5.58 (1H, s); 7.38 (1H, m); 8.30-8.32 (2H, d).

Step 2

The product from Step 1 (0.62 g) in THF (10 ml) and water (3 ml)containing sodium hydroxide (0.19 g) were stirred at 60° C. for 1.5hours then cooled to ambient temperature and stored for 18 hours. Themixture was evaporated and the residue was diluted with water thenwashed with diethyl ether. The aqueous fraction was acidified withdilute hydrochloric acid and extracted with ethyl acetate. The extractswere combined, washed with water, dried over magnesium sulphate, thenevaporated to give 2-(5-chloropyridyl-3-oxy)-2-(methylthio)acetic acid,0.48 g, as a dark yellow gum.

¹H NMR (CDCl₃) δ ppm: 2.24 (3H, s); 5.72 (1H, s); 7.54 (1H, m); 8.34(1H, s); 8.40 (1H, s); 9.52 (1H, bs).

Step 3

In a similar procedure to Stage 2 of Example1,2-(5-chloropyridyl-3-oxy)-2-(methylthio)acetic acid was condensed withtert-butylamine to give the required product as a colourless oil.

¹H NMR (CDCl₃) 8 ppm: 1.41 (9H, s); 2.14 (3H, s); 5.47 (1H, s); 6.35(1H, bs); 7.36 (1H, t); 8.28 (1H, d); 8.30 (1H, d).

The following amides were made in a similar procedure:

Compound No. 50 of Table 70: using 1-methylthio-2-methylprop-2-ylamine,pale yellow oil, ¹H NMR (CDCl₃) δ ppm: 1.48 (6H, s); 2.17 (3H, s); 2.19(3H, s); 2.97 (2H, dd); 5.47 (1H, s); 6.63 (1H, s); 7.39 (1H, t); 8.30(1H, d); 8.32 (1H, d).

Compound No. 52 of Table 70: using 2-cyano-1-methoxyprop-2-ylamine, gum,¹H NMR (CDCl₃) δ ppm: 1.81 (3H, 2×s); 2.18 (3H, 2×s); 3.52 (3H, 2×s);2.64-3.80 (2H, 4×d); 5.59 &5.60 (1H, 2×s); 7.02 & 7.07 (1H, 2×s); 7.39(1H, m); 8.31 (1H, m); 8.35 (1H, m), data consistent with a 1:1 mixtureof diastereoisomers.

EXAMPLE 4

This Example illustrates the preparation of2-(benzothiazolyl-6-oxy)-2-(methylthio)-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 78)

Stage 1: Preparation of 6-hydroxybenzothiazole Step 1: Preparation of6-methoxybenzothiazole

2-Amino-6-methoxybenzothiazole (9.0 g) in dry DMF (10 ml) was addeddropwise over 35 minutes to a stirred solution of t-butyl nitrite (9.9ml) in DMF (40 ml) at 65° C. The temperature of the mixture was kept<73° C. during the addition. On complete addition of the solution ofbenzothiazole, the dark red solution was stirred for an additional 15minutes, cooled to ambient temperature then poured into dilutehydrochloric acid (200 ml) and diluted with brine. The dark redsuspension was extracted with diethyl ether and the solid filtered thenwashed with further water and diethyl ether. The diethyl ether extractswere combined and the aqueous fraction re-extracted with ethyl acetate.The organic fractions were combined, washed with water and dried overmagnesium sulphate then evaporated to give a brown solid. The solid waspurified by flash column chromatography on silica gel (40-60 mesh)eluting with hexane/ethyl acetate (4:1 by volume) to give6-methoxybenzothiazole as a colourless solid (2.1 g).

¹H NMR (CDCl₃) δ ppm: 3.89 (3H, s); 7.12 (1H, dd); 7.40 (1H, d); 8.01(1H, d); 8.82 (1H, s).

Step 2

The product of Step 1 (1.2 g) in hydrobromic acid (10 ml, 48%) washeated at 120° C. with stirring for 6 hours then stored at ambienttemperature for 2 days. The hot, pale yellow solution produced asuspension on cooling. The suspension was dissolved by the addition ofwater then the solution was adjusted to pH 6 by addition of sodiumhydrogen carbonate and the solid that precipitated was filtered fromsolution, washed with water and sucked to dryness. The solid wasdissolved in ethyl acetate, the solution dried over magnesium sulphateand evaporated to give 6-hydroxybenzothiazole as a colourless solid(1.05 g).

¹H NMR (CDCl₃) δ ppm: 7.07 (1H, dd); 7.91 (1H, d); 8.76 (1H, d); 9.18(1H, s).

Stage 2: Preparation of 2-(benzothiazolyl-6-oxy)-2-methylthioacetic acidStep 1: Preparation of 2-(benzothiazolyl-6-oxy)-2-(methylthio acetate

6-Hydroxybenzothiazole (1.10 g), ethyl 2-bromo-2-methylthioacetate (2.22g, 73% pure) and anhydrous potassium carbonate (2.0 g) were stirred indry DMF (5 ml) at 80° C. for 0.5 hours then cooled to ambienttemperature. The mixture was poured into saturated aqueous ammoniumchloride, made acidic with dilute hydrochloric acid then extracted withdiethyl ether. The extract was washed with water, dried over magnesiumsulphate and evaporated to give a brown gum. The gum was purified byflash column chromatography on silica gel (40-60 mesh) eluting withhexane/ethyl acetate (1:1 by volume) to give ethyl2-(benzothiazolyl-6-oxy)-2-(methylthio)acetate as a yellow solid (0.50g).

¹H NMR (CDCl₃) δ ppm: 1.37 (3H, t); 2.27 (3H, s); 4.30-4.42 (2H, m);5.65 (1H, s); 7.28 (1H, m); 7.59 (1H, m); 8.08 (1H, d); 8.90 (1H, s).

Step 2: Preparation of 2-(benzothiazolyl-6-oxy)-2-(methylthio)aceticacid

To a stirred solution of ethyl2-(benzothiazolyl-6-oxy)-2-(methylthio)acetate (0.50 g) in THF (4 ml)was added a solution of lithium hydroxide monohydrate (0.076 g) in water(1 ml) at ambient temperature. After 1 hour, the mixture was made acidicwith dilute sulphuric acid, extracted with diethyl ether and the extractwas dried over magnesium sulphate then evaporated to give2-(benzothiazolyl-6-oxy)-2-(methylthio)-acetic acid as a pale yellowsolid (0.45 g).

¹H NMR (CDCl₃) δ ppm: 2.28 (3H, s); 5.72 (1H, s); 7.28 (1H, dd); 7.60(1H, m); 8.11 (1H, d); 8.99 (1H, s).

Step 3

In a similar procedure to Stage 2 of Example1,2-(benzothiazolyl-6-oxy)-2-(methylthio)acetic acid was condensed withtert-butylamine to give2-(benzothiazolyl-6-oxy)-2-(methylthio)-N-2-methylprop-2-yl acetamide.

¹H NMR (CH₃CN) δ ppm: 1.34 (9H, s); 5.56 (1H, s); 6.69 (1H, s); 7.25(1H, d); 7.66 (1H, s); 7.98 (1H, d); 8.96 (1H, s).

The following amides were prepared using a similar procedure.

Compound No. 70 of Table 78: using allylamine, ¹H NMR (CH₃CN) δ ppm:3.86 (2H, m); 5.56 (1H, s); 5.84 (1H, m); 7.26 (1H, d); 7.36 (1H, m);7.36 (2H, d); 7.68 (1H, s); 7.99 (1H, d); 8.97 (1H, s).

Compound No. 189 of Table 78: using 2-phenyl-prop-2-ylamine, ¹H NMR(CH₃CN) δ ppm: 1.60 (6H, s); 5.61 (1H, s); 7.17 (1H, t); 7.25 (5H, m);7.36 (2H, d); 7.66 (1H, s); 8.00 (1H, d); 8.98 (1H, s).

Compound No. 35 of Table 78: using 2-cyano-prop-2-ylamine, ¹H NMR(CH₃CN) δ ppm: 1.68 (6H, d); 5.71 (1H, s); 7.30 (1H, m); 7.34 (1H, s);7.69 (1H, s); 7.99 (1H, d); 8.98 (1H, s).

Compound No. 133 of Table 78: using 4-fluoroaniline, ¹H NMR (CDCl₃) δppm: 2.24 (3H, s); 5.74 (1H, s); 7.08 (2H, t); 7.28 (1H, m); 7.61 (3H,m); 8.10 (1H, d); 8.40 (1H, s); 8.94 (1H, s).

Compound No. 52 of Table 78: using 2-cyano-1-methoxy-prop-2-ylamine, ¹HNMR (CDCl₃) δ ppm: 1.81 (3H, 2×s); 2.20 (3H, s); 3.52 (3H, 2×s); 3.68(1H, m); 3.78 (1H, m); 5.63 (1H, 2×s); 7.15 (1H, 2×s); 7.24 (1H, m);7.60 (1H, m); 8.10 (1H, d); 8.94 (1H, s).

EXAMPLE 5

This Example illustrates the preparation of2-(3-chloroquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 58)

Stage 1: Preparation of 3-chloro-6-hydroxyquinoline

To a stirred solution of 3-bromo-6-hydroxyquinoline (1.0 g) inN-methylpyrrolidin-2-one (12 ml, deoxygenated by bubbling nitrogenthrough the solution) was added copper (1) chloride (1.10 g) andpotassium chloride (1.66 g). The mixture was heated to 120° C. for 2hours under an atmosphere of nitrogen then for 2 hours at 170° C. Thereaction was diluted with saturated aqueous ammonium chloride solution,ethyl acetate was added and the mixture was stirred to dissolve therequired product. The mixture was filtered to remove the insolublematerial and the organic phase separated. The aqueous phase wasextracted with ethyl acetate (three times) and the insoluble materialwashed with warm ethyl acetate. The ethyl acetate fractions werecombined, washed with water, dried over magnesium sulphate thenevaporated under reduced pressure to give a solid. The solid wasfractionated by chromatography (silica; ethyl acetate/hexane 9:1 byvolume) to give 3-chloro-6-hydroxyquinoline, 0.7 g, as a colourlesssolid.

¹H NMR (CDCl₃) δ ppm: 7.06 (1H, d); 7.35 (1H, dd); 7.91 (1H, d); 7.96(1H, d); 8.59 (1H, d); 9.55 (1H, s).

Stage 2 Step 1

To a stirred solution of 3-chloro-6-hydroxyquinoline (8.98 g) in dry DMF(200 ml) containing anhydrous potassium carbonate (20.7 g) at ambienttemperature was added dropwise a solution of ethyl2-bromo-2-methylthioacetate (13.0 g) in N,N-dimethylformamide (50 ml)over 5 minutes. The mixture was heated for 2.5 hours at 70-75° C. thencooled to ambient temperature, diluted with water and extracted withethyl acetate (four times). The extracts were combined, washed withbrine, dried over magnesium sulfate, filtered and evaporated underreduced pressure to give a brown oil (21 g) containing the requiredproduct that was used in the next stage without further purification. Aportion of the oil (0.5 g) was fractionated by chromatography (silica;hexane:ethyl acetate) to give ethyl2(3-chloro-6-oxyquinoline)-2-methylthioacetate as a yellow oil, 0.18 g.

¹H NMR (CDCl₃) δ ppm: 1.34-1.38 (3H, t); 2.26 (3H, s); 4.30-4.38 (2H,m); 5.72 (1H, s) 7.16 (1H, d); 7.48-7.52 (1H, dd); 8.02-8.06 (2H, m);8.72 (1H, s).

Step 2

To a stirred solution of the product from Stage 2 Step 1 (20.5 g) intetrahydrofuran (150 ml) at ambient temperature was added a solution ofsodium hydroxide (3.3 g) in water (15 ml). The mixture was stirred for 3hours then evaporated under reduced pressure, the residue diluted withwater, and washed with diethyl ether (twice). The aqueous fraction wasacidified with concentrated hydrochloric acid to give a brownprecipitate that was filtered from solution, washed with cold water andsucked to dryness to give 2(3-chloroquinolinyl-6-oxy)-2-methylthioaceticacid (8.5 g), m.p. 173-174° C.

¹H NMR (DMSO-d₆) δ ppm: 2.16 (3H, s); 6.10 (1H, s) 7.50 (1H, m);7.54-7.58 (1H, dd); 7.98-8.02 (1H, d); 8.44 (1H, s); 8.76 (1H, s); 13.6(1H, bs).

Step 3

In a similar procedure to Stage 2 of Example1,2-(3-chloroquinolinyl-6-oxy)-2-methylthioacetic acid was condensedwith t-butylamine to give the required product.

¹H NMR (CH₃CN) δ ppm: 5.64 (1H, s); 6.71 (1H, s); 7.30 (1H, s); 7.51(1H, d); 7.98 (1H, d); 8.16 (1H, s); 8.68 (1H, s).

The following amides were prepared using a similar procedure.

Compound No. 35 of Table 58: using 2-cyano-prop-2-ylamine, ¹H NMR(CH₃CN)δ ppm: 5.80 (1H, s); 7.32 (1H, s); 7.36 (1H, s); 7.52 (1H, d); 7.99 (1H,d); 8.18 (1H, s); 8.68 (1H, s).

Compound No. 128 of Table 58: using 2-cyanoaniline, ¹H NMR (CH₃CN) δppm: 6.03 (1H, s); 7.35 (1H, t); 7.46 (1H, s); 7.59 (1H, d); 7.68 (1H,t); 7.74 (1H, d); 7.88 (1H, d); 8.04 (1H, d); 8.23 (1H, s); 8.71 (1H,s); 9.18 (1H, s).

Compound No. 150 of Table 58: using benzylamine, ¹H NMR (CH₃CN) δ ppm:4.42 (2H, m); 5.81 (1H, s); 7.26 (6H, m); 7.50 (1H, d); 7.71 (1H, s);7.98 (1H, d); 8.16 (1H, s); 8.68 (1H, s).

Compound No. 70 of Table 58: using allylamine, ¹H NMR (CH₃CN) δ ppm:3.86 (2H, m); 5.06 (1H, d); 5.14 (1H, d); 5.80 (1H, s); 5.86 (1H, m);7.32 (1H, s); 7.36 (1H, s); 7.52 (1H, d); 7.99 (1H, d); 8.18 (1H, s);8.68 (1H, s).

Compound No. 120 of Table 58: using thiazol-2-ylamine, ¹H NMR (CH₃CN) δppm: 6.10 (1H, s); 7.14 (1H, d); 7.42 (1H, d); 7.48 (1H, d); 7.62 (1H,d); 8.04 (1H, d); 8.23 (1H, s); 8.72 (1H, s).

Compound No. 122 of Table 58: using furfurylamine, ¹H NMR (CH₃CN) δ ppm:4.40 (2H, m); 5.78 (1H, s); 6.21 (1H, s); 6.31 (1H, s); 7.30 (1H, s);7.36 (1H, s); 7.50 (1H, d); 7.62 (1H, s); 7.98 (1H, d); 8.16 (1H, s);8.68 (1H, s).

Compound No. 124 of Table 58: using thienylmethylamine, ¹H NMR (CH₃CN) δppm: 4.58 (2H, m); 5.78 (1H, s); 6.90 (1H, s); 6.95 (1H, s); 7.12 (1H,d); 7.30 (1H, s); 7.50 (1H, d); 7.78 (1H, s); 7.96 (1H, s); 8.14 (1H,s); 8.66 (1H, s).

Compound No. 189 of Table 58: using 2-phenyl-prop-2-ylamine, ¹H NMR(CH₃CN) δ ppm: 5.69 (1H, s); 7.29 (7H, m); 7.53 (1H, d); 8.00 (1H, d);8.20 (1H, s); 8.70 (1H, s).

Compound No. 52 of Table 58: using 2-cyano-1-methoxy-prop-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 3.40 (3H, d); 3.62 (1H, m); 3.70 (1H, m); 5.82 (1H,s); 7.34 (1H, m); 7.36 (1H, d); 7.52 (1H, m); 8.00 (1H, d); 8.19 (1H,s); 8.69 (1H, s).

Compound No. 133 of Table 58: using 4-fluoroaniline, ¹H NMR (CH₃CN) δppm: 5.91 (1H, s); 7.09 (2H, t); 7.40 (1H, s); 7.62 (3H, m); 8.02 (1H,d); 8.22 (1H, s); 8.70 (1H, s); 8.94 (1H, s).

Compound No. 38 of Table 58: using 2-cyano-3-methyl-but-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 1.00 (6H, 4×d); 1.57 (3H, 2×s); 2.36 (1H, m); 5.80(1H, 2×s); 7.18 (1H, s); 7.32 (1H, m); 7.52 (1H, d); 8.00 (1H, d); 8.20(1H, s); 8.70 (1H, s).

Compound No. 64 of Table 58: using trimethylsilylmethylamine, ¹H NMR(CH₃CN) δ ppm: 2.76 (2H, m); 5.75 (1H, s); 6.98 (1H, s); 7.29 (1H, s);7.50 (1H, d); 7.99 (1H, s); 8.17 (1H, s); 8.68 (1H, s).

Compound No. 84 of Table 58: using propargylamine, ¹H NMR (CH₃CN) δ ppm:2.43 (1H, s); 4.02 (2H, m); 5.80 (1H, s); 7.32 (1H, s); 7.52 (1H, d);7.59 (1H, s); 7.99 (1H, d); 8.18 (1H, s); 8.68 (1H, s).

EXAMPLE 6

This Example illustrates the preparation of2-(3,8-dibromoquinolinyl-6-oxy)-2-methylthio-N-(2-thienylmethyl)acetamide(Compound No. 124 of Table 61)

Stage 1: Preparation of 3,8-dibromo-6-hydroxyquinoline Step 1:Preparation of 6-amino-3,8-dibromoquinoline

3,8-Dibromo-6-nitroquinoline (48.5 g, prepared as described in J Am ChemSoc (1955), 77, 4175-4176) was suspended in concentrated hydrochloricacid (400 ml) at ambient temperature and iron powder (27 g, reduced byhydrogen) was added in portions allowing the reaction temperature torise to 73° C. during the additions. The bright yellow suspension thatwas initially produced became dark brown during the final stages of thereaction. The mixture was cooled to 0° C. and basified with aqueoussodium hydroxide (10M) until the reaction was at pH10. Ethyl acetate wasadded to the suspension and the mixture was thoroughly mixed thenfiltered through a bed of kieselguhr. The organic fraction was separatedand the aqueous fraction re-extracted with further ethyl acetate. Theinsoluble material that was filtered from solution was further extractedwith hot acetone and the organic fractions combined, washed with aqueoussodium hydrogen carbonate, dried over sodium sulphate and evaporatedunder reduced pressure to give 6-amino-3,8-dibromoquinoline as a brownsolid, 34.7 g.

¹H NMR (CDCl₃) δ ppm: 4.09 (2H, s); 6.76 (1H, s); 7.52 (1H, s); 8.03(1H, s); 8.71 (1H, s).

Step 2: Preparation of 3,8-dibromo-6-hydroxy-quinoline

6-Amino-3,8-dibromoquinoline (1.1 g) was suspended in phosphoric acid(10 ml) containing water (10 ml) and heated in a sealed glass tube at180° C. for 4 days. The mixture was cooled to ambient temperature,poured into brine and extracted with ethyl acetate. The organic extractwas dried over magnesium sulphate, evaporated under reduced pressure andthe residual solid fractionated by chromatography (silica; hexane/ethylacetate) to give 3,8-dibromo-6-hydroxy-quinoline, 0.4 g, as a pale brownsolid.

¹H NMR (CDCl₃) δ ppm: 6.97 (1H, s); 7.69 (1H, s); 8.09 (1H, s); 8.72(1H, s).

Stage 2

In a similar procedure to Stage 2, Step 1 of Example 5,3,8-dibromo-6-hydroxyquinoline was reacted with ethyl2-bromo-2-methylthioacetate to give ethyl2-(3,8-dibromo-quinolinyl-6-oxy)-2-methylthioacetate as a pale yellowgum.

¹H NMR (CDCl₃) δ ppm: 1.36 (3H, t); 2.24 (3H, s); 4.29-4.41 (2H, m);5.69 (1H, s); 7.12 (1H, d); 7.88 (1H, d); 8.22 (1H, d); 8.89 (1H, d).

In a similar procedure to Stage 2, Step 2 of Example 5, ethyl2-(3,8-dibromoquinolinyl-6-oxy)-2-methylthioacetate was hydrolysed togive 2-(3,8-dibromoquinolinyl-6-oxy)-2-methylthioacetic acid as a paleyellow solid.

¹H NMR (CDCl₃) δ ppm: 2.26 (3H, s); 5.71 (1H, s); 7.17 (1H, d); 7.89(1H, d); 8.27 (1H, d); 8.88 (1H, d).

In a similar procedure to Stage 2 of Example1,2-(3,8-dibromoquinolinyl-6-oxy)-2-methylthioacetic acid was condensedwith 2-aminomethylthiophene to give2-(3,8-dibromoquinolinyl-6-oxy)-2-methylthio-N-(2-thienylmethyl)acetamide.

¹H NMR (CH₃CN) δ ppm: (some signals at high field obscured by NMRsolvent) 4.41 (2H, m); 5.80 (1H, s); 7.23 (5H, m); 7.30 (1H, s); 7.68(1H, s); 7.90 (1H, s); 8.36 (1H, s); 8.84 (1H, s).

The following amides were prepared using a similar procedure.

Compound No. 38 of Table 61: using 2-cyano-3-methyl-but-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 0.94-1.10 (6H, 4×d); 1.56-1.58 (3H, 2×s); 5.80 (1H,s); 7.15 (1H, s); 7.34 (1H, d); 7.94 (1H, d); 8.42 (1H, s); 8.85 (1H,s).

Compound No. 52 of Table 61: using 2-cyano-1-methoxy-prop-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 3.40 (3H, d); 3.65 (2H, m); 5.81 (1H, s); 7.34 (2H,m); 7.93 (1H, d); 8.39 (1H, s); 8.84 (1H, s).

Compound No. 12 of Table 61: using tert-butylamine, ¹H NMR (CH₃CN) δppm: 5.63 (1H, s); 6.69 (1H, s); 7.30 (1H, s); 7.92 (1H, s); 8.39 (1H,s); 8.84 (1H, s).

Compound No. 150 of Table 61: using benzylamine, ¹H NMR (CH₃CN) δ ppm:4.41 (2H, m); 5.80 (1H, s); 7.23 (5H, m); 7.30 (1H, s); 7.68 (1H, s);7.90 (1H, s); 8.36 (1H, s); 8.84 (1H, s).

Compound No. 211 of Table 61: using N-morpholinohydrazine, ¹H NMR(CH₃CN) δ ppm: 3.59 (8H, m); 5.42 (1H, s); 6.09 (1H, s); 7.20 (1H, s);7.86 (1H, s); 8.40 (1H, s); 8.83 (1H, s).

EXAMPLE 7

This Example illustrates the preparation of2-(3-bromoquinolinyl-6-oxy)-2-methylthio-N-(1-methoxy-3-methylbut-3-yl)acetamide(Compound No. 48 of Table 57)

Stage 1: Preparation of 2-(3-bromoquinolinyl-6-oxy)-2-methylthioaceticacid Step 1

In a similar procedure to Stage 2, Step 1 of Example 5,3-bromo-6-hydroxy-quinoline (preparation described in Liebigs Ann Chem(1966), 98-106) was reacted with ethyl 2-bromo-2-methylthioacetate togive ethyl 2-(3-bromoquinolinyl-6-oxy)-2-methylthioacetate as a paleyellow gum.

¹H NMR (CDCl₃) δ ppm: 1.34 (3H, t); 2.24 (3H, s); 4.30-4.38 (2H, m);5.70 (1H, s); 7.14 (1H, m); 7.48-7.52 (1H, dd); 8.02 (1H, d); 8.22 (1H,s); 8.80 (1H, s).

Step 2

In a similar procedure to Stage 2, Step 2 of Example 5, ethyl2-(3-bromoquinolinyl-6-oxy)-2-methylthioacetate was hydrolysed to2-(3-bromoquinolinyl-6-oxy)-2-methylthioacetic acid, colourless solid,m.p. 166-167° C.

¹H NMR (CDCl₃) δ ppm: 2.26 (3H, s); 5.76 (1H, s); 7.20 (1H, m);7.50-7.54 (1H, dd); 8.01 (1H, d); 8.28 (1H, s); 8.78 (1H, s).

Stage 2: Preparation of 1-methoxy-3-methylbut-3-ylamine hydrochloride

To a stirred suspension of sodium hydride (0.30 g, 80% dispersion inmineral oil) in dry N,N-dimethylformamide (2 ml) under an atmosphere ofnitrogen at ambient temperature was added dropwise a solution of1-hydroxy-3-methylbut-3-ylamine (0.52 g) in N,N-dimethylformamide (5ml). The mixture was stirred for 3 hours, methyl iodide (0.74 g) inN,N-dimethylformamide (5 ml) added over 5 minutes then stirred foranother 2.25 hours and stored for 18 hours at ambient temperature. Thesolution was diluted with water, extracted into ethyl acetate (threetimes) and the extracts combined then extracted with dilute hydrochloricacid. The aqueous acidic extract was evaporated under reduced pressureand co-distilled with toluene to remove residual water to give1-methoxy-3-methylbut-3-ylamine hydrochloride as a yellow gum.

¹H NMR (CDCl₃) δ ppm: 1.54 (6H, s); 1.96-2.00 (2H, t); 3.48 (3H, s);3.62-3.66 (2H, t).

In a similar procedure, 1-hydroxy-3-methylbut-3-ylamine was reacted withethyl iodide to give 1-ethoxy-3-methylbut-3-ylamine hydrochloride.

¹H NMR (CDCl₃) δ ppm: 1.20-1.24 (3H, t); 1.54 (6H, s); 1.96-2.00 (2H,t); 3.50 (2H, q); 3.66-3.70 (2H, t).

In a similar procedure, 1-hydroxy-2-methylprop-2-ylamine was reactedwith methyl iodide to give 1-methoxy-2-methylprop-2-ylaminehydrochloride.

¹H NMR (CDCl₃) δ ppm: 1.47 (6H, s); 3.43 (3H, s); 3.44 (2H, s); 8.24 (3Hbs).

In a similar procedure, 1-hydroxy-2-methylprop-2-ylamine was reactedwith 4-fluorobenzyl bromide to give1-(4-fluorobenzyloxy)-2-methylprop-2-ylamine hydrochloride.

¹H NMR (CDCl₃) δ ppm: 1.41 (6H, s); 3.46 (2H, s); 4.53 (2H, s);7.00-7.04 (2H, m); 7.32-7.36 (2H, m); 8.30 (3H bs).

Stage 3

In a similar procedure to Stage 2 of Example1,2-(3-bromoquinolinyl-6-oxy)-2-methylthioacetic acid was condensed with1-methoxy-3-methylbut-3-ylamine to give2-(3-bromoquinolinyl-6-oxy)-2-methylthio-N-(1-methoxy-3-methylbut-3-yl)acetamideas a pale yellow solid, m.p. 88-90° C.

¹H NMR (CDCl₃) δ ppm: 1.46 (3H, s); 1.52 (3H, s); 1.80-1.84 (2H, q);2.20 (3H, s); 3.30 (3H, s); 3.55-3.58 (2H, t); 5.55 (1H, s); 7.16 (1H,d); 7.43-7.46 (1H, dd); 7.90 (1H, s); 8.02-8.05 (1H, d); 8.24 (1H, s);8.80 (1H, s).

The following amides were prepared using a similar procedure.

Compound No. 12 of Table 57: using t-butylamine, ¹H NMR (CDCl₃) δ ppm:1.43 (9H, s); 2.20 (3H, s); 5.58 (1H, s); 6.43 (1H, s); 7.18 (1H, d);7.44-7.48 (1H, dd); 8.03-8.05 (1H, d); 8.24 (1H, s); 8.82 (1H, s).

Compound No. 65 of Table 57: using 1-tert.butyldimethylsilyloxy-2-methylprop-2-ylamine, pale yellow oil, ¹H NMR(CDCl₃) δ ppm: 0.06 (3H, s); 0.08 (3H, s); 0.88 (9H, s); 1.38 (3H, s);1.42 (3H, s); 2.18 (3H, s); 3.47-3.53 (2H, q); 5.59 (1H, s); 6.98 (1H,s); 7.16 (1H, d); 7.41-7.45 (1H, dd); 8.02-8.04 (1H, d); 8.24 (1H, s);8.81 (1H, s).

Compound No. 50 of Table 57: using 1-methylthio-2-methylprop-2-ylamine,pale yellow oil, ¹H NMR (CDCl₃) δ ppm: 1.46 (3H, s); 1.48 (3H, s); 2.16(3H, s); 2.22 (3H, s); 2.94-3.02 (2H, dd); 5.60 (1H, s); 6.72 (1H, s);7.20 (1H, d); 7.46-7.48 (1H, dd); 8.04-8.06 (1H, d); 8.24 (1H, d); 8.81(1H, d).

Compound No. 47 of Table 57: using 1-methoxy-2-methylprop-2-ylaminecolourless solid, m.p. 90-91° C., ¹H NMR (CDCl₃) δ ppm: 1.40 (3H, s);1.44 (3H, s); 2.20 (3H, s); 3.36-3.48 (2H, dd); 3.49 (3H, s); 5.59 (1H,s); 6.77 (1H, s); 7.18 (1H, d); 7.44-7.48 (1H, dd); 8.03-8.07 (1H, d);8.26 (1H, d); 8.81 (1H, s).

Compound No. 49 of Table 57: using 1-ethoxy-3-methylbut-3-ylamine,colourless solid, m.p. 111-113° C., ¹H NMR (CDCl₃) δ ppm: 1.18-1.22 (3H,t); 1.46 (3H, s); 1.51 (3H, s); 1.78-1.84 (2H, m); 2.21 (3H, s);3.44-3.50 (2H, q); 3.56-3.64 (2H, m); 5.53 (1H, s); 7.17 (1H, d);7.44-7.46 (1H, dd); 7.82 (1H, s); 8.03-8.05 (1H, d); 8.25 (1H, s); 8.81(1H, s).

Compound No. 40 of Table 57: using 1-hydroxy-3-methylbut-3-ylamine,colourless solid m.p. 124-126° C., ¹H NMR (CDCl₃) δ ppm: 1.48 (3H, s);1.51 (3H, s); 1.84-1.92 (2H, m); 2.20 (3H, s); 3.86-3.89 (2H, t); 5.56(1H, s); 7.14 (1H, d); 7.42-7.44 (1H, dd); 7.75 (1H, s); 8.00-8.03 (1H,d); 8.24 (1H, d); 8.80 (1H, d).

Compound No. 198 of Table 57: using1-(4-fluorobenzyloxy)-2-methylprop-2-ylamine, colourless solid m.p.124-126° C., ¹H NMR (CDCl₃) δ ppm: 1.42 (3H, s); 1.44 (3H, s); 2.16 (3H,s); 3.44-3.56 (2H, dd); 4.52 (2H, m); 5.58 (1H, s); 6.82 (1H, bs);6.98-7.02 (2H, m); 7.13 (1H, d); 7.24-7.28 (2H, m); 7.34-7.38 (1H, dd);8.00-8.02 (1H, d); 8.20 (1H, d); 8.80 (1H, d).

Compound No. 89 of Table 57: using 1-cyano-cyclopropylamine (O'Donnellet al, Synthesis (1984), 127), cream coloured solid, mp 178° C., ¹H NMR(CDCl₃) δ ppm: 2.13 (3H, s); 4.48-4.64 (2H, 4×d); 5.57 (1H, s); 6.86(1H, s); 6.92 (1H, s); 7.08 (1H, t); 7.30-7.38 (5H, m).

Compound No. 4 of Table 57: using diethylamine, gum, ¹H NMR (CDCl₃) δppm: 1.15 (3H, t); 1.23 (3H, t); 2.29 (3H, s); 3.34 (1H, m); 3.50 (1H,m); 3.58 (2H, m); 5.83 (1H, s); 7.17 (1H, s); 7.51 (1H, d); 8.00 (1H,d); 8.22 (1H, s); 8.78 (1H, s).

Compound No. 2 of Table 57: using dimethylamine, cream coloured solid,m.p. 158-161° C.

Compound No. 27 of Table 57: using3,3,3-trifluoro-2-methylprop-2-ylamine, pale yellow solid, mp 112° C.

Compound No. 88 of Table 57: using N,N-dicyclopropylamine, colourlesssolid, m.p. 122° C., ¹H NMR (CDCl₃) δ ppm: 0.6-1.15 (8H, m); 2.21 (3H,s); 2.61 (1H, m); 2.80 (1H, m); 6.38 (1H, s); 7.17 (1H, d); 7.52 (1H,dd); 8.00 (1H, d); 8.20 (1H, d); 8.80 (1H, d).

Compound No. 60 of Table 57: using methyl 2-amino-2-methylpropionate,foamy solid, ¹H NMR (CDCl₃) δ ppm: 1.69 (3H, s); 1.70 (3H, s); 2.26 (3H,s); 3.83 (3H, s); 5.70 (1H, s); 7.25 (1H, d); 7.35 (1H, s); 7.54 (1H,dd); 8.10 (1H, d); 8.30 (1H, d); 8.87 (1H, d).

Compound No. 64 of Table 57: using trimethylsilylmethylamine, ¹H NMR(CH₃CN) δ ppm: 0.28 (9H, s); 3.04 (2H, s); 6.05 (1H, s); 7.28 (1H, s);7.57 (1H, s); 7.79 (1H, d); 8.26 (1H, d); 8.64 (1H, s); 9.06 (1H, s).

Compound No. 124 of Table 57: using thienylmethylamine, ¹H NMR (CH₃CN) δppm: 4.58 (2H, m); 5.78 (1H, s); 6.89 (1H, t); 6.96 (1H, s); 7.22 (1H,d); 7.27 (1H, s); 7.50 (1H, d); 7.78 (1H, s); 7.96 (1H, d); 8.32 (1H,s); 8.76 (1H, s).

Compound No. 35 of Table 57: using 2-cyano-prop-2-ylamine, ¹H NMR(CH₃CN) δ ppm: 1.67 (3H, s); 1.69 (3H, s); 5.79 (1H, s); 7.31 (1H, s);7.38 (1H, s); 7.55 (1H, d); 7.98 (1H, d); 8.37 (1H, s); 8.77 (1H, s).

Compound No. 133 of Table 57: using 4-fluoroaniline, ¹H NMR (CDCl₃) δppm: 2.26 (3H, s); 5.82 (1H, s); 7.06 (2H, t); 7.26 (1H, m); 7.52 (1H,m); 7.60 (2H, m); 8.06 (1H, d); 8.26 (1H, d); 8.34 (1H, s); 8.82 (1H,s).

Compound No. 111 of Table 57: using 2-cyclohexenyl-ethylamine, ¹H NMR(CH₃CN) δ ppm: 3.47 (4H, m); 5.58 (1H, s); 5.89 (1H, s); 7.25 (1H, m);7.44 (1H, s); 7.66 (1H, d); 8.13 (1H, d); 8.51 (1H, s); 8.92 (1H, s).

Compound No. 150 of Table 57: using benzylamine, ¹H NMR (CH₃CN) δ ppm:4.42 (2H, m); 5.80 (2H, s); 7.25 (6H, m); 7.52 (1H, d); 7.71 (1H, s);7.96 (1H, d); 8.32 (1H, s); 8.76 (1H, s).

Compound No. 38 of Table 57: using 2-cyano-3-methyl-but-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 1.00 (6H, 4×d); 1.57 (3H, 2×s); 2.38 (1H, m); 5.80(1H, 2×s); 7.29 (1H, s); 7.31 (1H, m); 7.54 (1H, d); 7.99 (1H, d); 8.37(1H, s); 8.77 (1H, s).

Compound No. 120 of Table 57: using thiazol-2-ylamine, ¹H NMR (CH₃CN) δppm: 6.08 (1H, s); 7.12 (1H, s); 7.38 (1H, d); 7.46 (1H, s); 7.62 (1H,d); 8.00 (1H, d); 8.39 (1H, s); 8.78 (1H, s).

Compound No. 122 of Table 57: using furfurylamine, ¹H NMR (CH₃CN) δ ppm:4.42 (2H, m); 5.79 (1H, s); 6.22 (1H, s); 6.31 (1H, s); 7.28 (1H, s);7.36 (1H, s); 7.50 (1H, d); 7.63 (1H, s); 7.95 (1H, d); 8.32 (1H, s);8.75 (1H, s).

Compound No. 52 of Table 57: using 2-cyano-1-methoxy-prop-2-ylamine, ¹HNMR (CDCl₃) δ ppm: 1.82 (3H, 2×s); 2.20 (3H, s); 3.52 (3H, 2×s); 3.66(1H, m); 3.78 (1H, m); 5.72 (1H, 2×s); 7.15 (1H, 2×s); 7.20 (1H, m);7.46 (1H, m); 8.06 (1H, d); 8.26 (1H, s); 8.82 (1H, d).

Compound No. 84 of Table 57: using propargylamine, ¹H NMR (CH₃CN) δ ppm:2.43 (1H, s); 4.00 (2H, m); 5.79 (1H, s); 7.30 (1H, s); 7.52 (1H, d);7.60 (1H, s); 7.98 (1H, d); 8.36 (1H, s); 8.76 (1H, s).

Compound No. 189 of Table 57: using 2-phenyl-prop-2-ylamine, ¹H NMR(CH₃CN) δ ppm: 1.60 (3H, s); 1.66 (3H, s); 5.69 (1H, s); 7.16 (1H, t);7.27 (6H, m); 7.36 (1H, d); 7.54 (1H, d); 7.98 (1H, d); 8.36 (1H, s);8.77 (1H, s).

Compound No. 70 of Table 57: using allylamine, ¹H NMR (CH₃CN) δ ppm:3.86 (2H, t); 5.06 (1H, d); 5.14 (1H, d); 5.79 (1H, s); 5.84 (1H, m);7.32 (1H, s); 7.38 (1H, s); 7.52 (1H, d); 7.98 (1H, d); 8.35 (1H, s);8.76 (1H, s).

EXAMPLE 8

This Example illustrates the preparation of2-(3-fluoroquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 59)

Stage 1: Preparation of 3-fluoro-6-hydroxyquinoline Step 1: Preparationof 3-amino-6-methoxyquinoline

To a stirred mixture of 3-bromo-6-methoxyquinoline [synthesis given inTetrahedron (1986), 42, 1475-1485] (2.38 g), tris(dibenzylideneacetone)dipalladium (0) (0.114 g) and tri t-butylphosphine tetrafluoroborate(0.116 g) in toluene (15 ml) under an atmosphere of nitrogen at ambienttemperature was added a solution of lithium bistrimethylsilylamide (11.0ml, 1.0M solution in hexanes). The mixture was stirred for 2 days andthe brown suspension diluted with diethyl ether and extracted with 2Maqueous hydrochloric acid (twice) and the acidic fractions combined,washed with diethyl ether and made basic with 2M aqueous sodiumhydroxide to give the required product as a brown solid that was used inthe next Step without further purification.

¹H NMR (CDCl₃) δ ppm: 3.90 (3H, s); 6.87 (1H, d); 7.10 (1H, dd); 7.16(1H, d); 7.85 (1H, d); 8.35 (1H, d).

Step 2: Preparation of 3-fluoro-6-methoxyquinoline

To boron trifluoride etherate (1.29 g) at −12° C. under an atmosphere ofnitrogen was added with stirring a solution of3-amino-6-methoxyquinoline (1.05 g) in dry dichloromethane (15 ml). Theyellow suspension was stirred for 15 minutes then a solution oft-butylnitrite (0.74 g) in dichloromethane (5 ml) was added dropwise.The mixture was stirred for 2 hours at 0° C. then 1,2-dichlorobenzenewas added and the mixture gradually heated to 73° C., allowing thedichloromethane to distil out from the reaction vessel and thenincreased to 90° C. to complete the reaction. The mixture was allowed tocool to ambient temperature, diluted with dichloromethane, washed withwater, dried over magnesium sulfate, filtered then evaporated underreduced pressure to give a black oil that was fractionated bychromatography (silica; hexane/ethyl acetate) to give an oil, 0.54 g,containing the required product. MH⁺178

Step 3

The product from Step 2 (0.45 g) and pyridine hydrochloride (4.5 g) werefused at 200° C. for 3 hour under an atmosphere of nitrogen. The mixturewas cooled to ambient temperature, diluted with water and extracted withethyl acetate. The extract was dried over magnesium sulfate, filteredand evaporated under reduced pressure to give the required product as apale brown solid. MH⁺ 164

Stage 2: Preparation of ethyl3-fluoroquinolinyl-6-oxy-2-methylthioacetate

In a similar procedure to Stage 2, Step 1 of Example 5,3-fluoro-6-hydroxy-quinoline was reacted with ethyl2-bromo-2-methylthioacetate to give ethyl2-(3-fluoro-quinolinyl-6-oxy)-2-methylthioacetate as a colourless solid.

¹H NMR (CDCl₃) δ ppm: 1.36 (3H, t); 2.25 (3H, s); 4.29-4.40 (2H, m);5.71 (1H, s); 7.20 (1H, d); 7.47 (1H, dd); 7.71 (1H, dd); 8.11 (1H, d);8.71 (1H, d).

In a similar procedure to Stage 2, Step 2 of Example 5, ethyl2-(3-fluoro-quinolinyl-6-oxy)-2-methylthioacetate was hydrolysed to give2-(3-fluoroquinolinyl-6-oxy)-2-methylthioacetic acid as a colourlesssolid.

¹H NMR (CDCl₃) δ ppm: 2.20 (3H, s); 4.0 (1H, bs); 5.69 (1H, s); 7.19(1H, d); 7.39 (1H, dd); 7.68 (1H, dd); 7.96 (1H, d); 8.62 (d).

In a similar procedure to Stage 2 of Example1,2-(3-fluoroquinolinyl-6-oxy)-2-methylthioacetic acid was condensedwith t-butylamine to give2-(3-fluoroquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamideas a colourless gum.

¹H NMR (CDCl₃) δ ppm: 1.43 (9H, s); 2.20 (3H, s); 5.60 (1H, s); 6.45(1H, s); 7.22 (1H, d); 7.41 (1H, dd); 7.71 (1H, dd); 8.08 (1H, d); 8.72(1H, d).

Compound No. 52 of Table 59: In a similar procedure2-(3-fluoroquinolinyl-6-oxy)-2-methylthioacetic acid was condensed with2-cyano-1-methoxyprop-2-ylamine to give2-(3-fluoroquinolinyl-6-oxy)-2-methylthio-N-(2-cyano-1-methoxyprop-2-yl)acetamideas a colourless gum.

¹H NMR (CDCl₃) δ ppm: 1.79 and 1.81 (3H, s); 2.22 (3H, s); 3.49 and 3.53(3H, s); 3.67 (1H, d); 3.74 and 3.81 (1H, d); 5.71 and 5.74 (1H, s);7.12 and 7.18 (1H, s); 7.26 (1H, d); 7.41 (1H, dd); 7.72 (1H, d); 8.10(1H, d); 8.73 (1H, d) consistent with a 1:1 mixture of diasteroisomers.

EXAMPLE 9

This Example illustrates the preparation of2-(methylthio)-2-(3-bromoquinolinyl-6-oxy)-N-E-(4-phenyl-2-methylpent-3-ene-2-yl)acetamide(Compound No. 82 of Table 57) and2-(methylthio)-2-(3-phenylquinolinyl-6-oxy)-N-E-(4-phenyl-2-methylpent-3-ene-2-ylacetamide (Compound No. 82 of Table 65)

In a similar procedure to Stage 2 of Examplel,2-(3-bromoquinolinyl-6-oxy)-2-methylthioacetic acid was condensed with4-amino-4-methylpent-2-yne to give2-(3-bromoquinolinyl-6-oxy)-2-methylthio-N-(2-methylpent-3-yn-2-yl)acetamideas a colourless solid, m.p. 135-137° C.

¹H NMR (CDCl₃) δ ppm: 1.70 (3H, s); 1.71 (3H, s); 1.83 (3H, s); 2.22(3H, s); 5.62 (1H, s); 6.72 (1H, s); 7.18 (1H, d); 7.47 (1H, dd); 8.05(1H, d); 8.24 (1H, d); 8.82 (1H, m).

A mixture of2-(3-bromoquinolinyl-6-oxy)-2-methylthio-N-(2-methylpent-3-yn-2-yl)acetamide(0.200 g), tris-(dibenzylideneacetone) di-palladium (0) (0.007 g),phenylboronic acid (0.060 g), tri-tert.-butylphosphine tetrafluoroborate(0.006 g), cesium fluoride (0.245 g) in deoxygenated 1,4-dioxane (10 ml)were stirred at ambient temperature for 18 hours under an atmosphere ofnitrogen. The mixture was filtered through kieselguhr then the filtratewas diluted with water, extracted with ethyl acetate and the organicphase separated, washed with brine, dried over magnesium sulfate andevaporated under reduced pressure to give a gum. The gum wasfractionated by chromatography (silica; hexane:ethyl acetate 1:4 to 1:1by volume) to give2-(methylthio)-2-(3-bromoquinolinyl-6-oxy)-N-E-(4-phenyl-2-methylpent-3-ene-2-ylacetamide, 0.034 g as a colourless gum.

¹H NMR (CDCl₃) δ ppm: 1.67 (6H, s); 2.10 (3H, s); 2.24 (3H, s); 5.63(1H, s); 5.91 (1H, s); 6.75 (1H, s); 7.25-7.35 (6H, m); 7.46 (1H, d);8.06 (1H, d); 8.23 (1H, s); 8.81 (1H, s); And2-(methylthio)-2-(3-phenylquinolinyl-6-oxy)-N-E-(4-phenyl-2-methylpent-3-ene-2-yl)acetamide, 0.012 g, as a colourless gum.

¹H NMR (CDCl₃) δ ppm: 1.67 (6H, s); 2.10 (3H, s); 2.26 (3H, s); 5.67(1H, s); 5.92 (1H, s); 6.81 (1H, s); 7.25-7.35 (6H, m); 7.46 (2H, m);7.53 (2H, m); 7.70 (2H, m); 8.10 (1H, d); 8.22 (1H, s); 9.10 (1H, s).

EXAMPLE 10

This Example illustrates the preparation of2-(methylthio)-2-(3-[4-pyridyl]quinolinyl-6-oxy)-N-(2-methylprop-2-yl)acetamide (Compound No. 12 of Table 68)

A mixture of2-(3-bromoquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(0.10 g), tris-(dibenzylideneacetone) di-palladium (0) (0.004 g),pyridine-4-boronic acid (0.032 g), tri-tert.-butylphosphinetetrafluoroborate (0.003 g), cesium fluoride (0.13 g) in deoxygenated1,4-dioxane (10 ml) were stirred at ambient temperature for 18 hoursunder an atmosphere of nitrogen. To the mixture was added (tetrakis)triphenylphosphine palladium (0) (0.005 g) and sodium carbonate (0.100g) and the reaction heated to 100° C. for 6 hours then stored at ambienttemperature for 18 hours. The mixture was filtered through kieselguhrthen the filtrate was diluted with water, extracted with ethyl acetateand the organic phase separated, washed with brine, dried over magnesiumsulfate and evaporated under reduced pressure to give a gum. The gum wasfractionated by chromatography (silica; hexane:ethyl acetate) to givethe required product, 0.010 g, as a colourless solid m.p. 132-134° C.

¹H NMR (CDCl₃) δ ppm: 1.44 (9H, s); 2.22 (3H, s); 5.63 (1H, s); 6.46(1H, s); 7.37 (1H, s); 7.54 (1H, d); 7.70 (2H, m); 8.17 (1H, d); 8.35(1H, s); 8.79 (2H, m); 9.11 (1H, s).

Compound No. 12 of Table 65: In a similar procedure,2-(3-bromoquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamidewas reacted with phenyl boronic acid to give2-(3-phenylquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamideas a cream coloured solid, m.p. 134-137° C.

¹H NMR (CDCl₃) δ ppm: 1.44 (9H, s); 2.22 (3H, s); 5.63 (1H, s); 6.49(1H, s); 7.35-7.40 (2H, m); 7.46 (2H, m); 7.54 (2H, m); 7.72 (1H, d);8.14 (1H, d); 8.26 (1H, s); 9.10 (1H, s).

EXAMPLE 11

This Example illustrates the preparation of2-(3-bromoquinolinyl-6-oxy)-2-(methylthio)-N-(1-hydroxy-2-methylprop-2-yl)acetamide (Compound No. 39 of Table 57)

To a stirred solution of2-(3-bromoquinolinyl-6-oxy)-2-(methylthio)-N-(1-(tert.butyldimethylsilyloxy)-2-methylprop-2-yl)acetamide (0.67 g) in tetrahydrofuran (10 ml) at 0-5° C. was addeddropwise a solution of tetrabutylammonium fluoride (2.38 ml, 1M) intetrahydrofuran. The mixture was stirred for 0.5 hours at 0° C. thenallowed to warm to ambient temperature and stirred for a further 3hours. The solvent was evaporated under reduced pressure and the residuetreated with aqueous ammonium chloride solution, extracted into ethylacetate and the organic phase washed with brine, dried over magnesiumsulfate and evaporated under reduced pressure to give a solid. The solidwas fractionated by chromatography (silica; ethyl acetate) to give therequired product, 0.34 g, as a colourless solid, m.p. 155-157° C.

¹H NMR (CDCl₃) δ ppm: 1.36 (3H, s); 1.40 (3H, s); 2.20 (3H, s);3.66-3.70 (2H, m); 3.89-3.92 (1H, t); 5.64 (1H, s); 6.70 (1H, s); 7.20(1H, d); 7.44-7.48 (1H, dd); 8.02-8.06 (1H, d); 8.24 (1H, s); 8.82 (1H,s).

EXAMPLE 12

This Example illustrates the preparation of2-(dibenzofuranyl-2-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 50)

Step 1: Preparation of ethyl2-(dibenzofuranyl-2-oxy)-2-methylthioacetate

To a stirred suspension of sodium hydride (6.6 g, 80% dispersion inmineral oil) in dry N,N-dimethylformamide (25 ml) under an atmosphere ofnitrogen at ambient temperature was added a solution of2-hydroxydibenzofuran (36.8 g) in N,N-dimethylformamide (150 ml) over 40minutes. The mixture was stirred for 3.25 hours then a solution of ethyl2-bromo-2-methylthioacetate (54.2 g, 90% purity) inN,N-dimethylformamide (50 ml) was added dropwise over 20 minutes duringwhich time the reaction temperature was allowed to rise to 47° C. Oncomplete addition, the mixture was stirred for 21.5 hours, poured intowater and extracted with diethyl ether (three times). The extracts werecombined, washed with dilute aqueous sodium hydroxide (twice), water(three times) then dried over magnesium sulfate and evaporated underreduced pressure. The residue was fractionated by chromatography(silica; diethyl ether: hexane, 1:2 to 1:1 by volume) to give an orangeoil, 33 g, containing the required product that was used in the nextStage without further purification. A sample of the oil was furtherpurified by chromatography to provide an analytical sample.

¹H NMR (CDCl₃) 8 ppm: 1.34-1.38 (3H, t); 2.26 (3H, s); 4.30-4.38 (2H,m); 5.64 (1H, s) 7.16-7.20 (1H, dd); 7.32-7.36 (1H, dd); 7.44-7.60 (4H,m); 7.92-7.94 (1H, d).

Step 2: Preparation of 2-(dibenzofuranyl-2-oxy)-2-methylthioacetic acid

To a stirred solution of ethyl2-(dibenzofuranyl-2-oxy)-2-methylthioacetate (15.8 g) in tetrahydrofuran(250 ml) at ambient temperature was added a solution of sodium hydroxide(2.5 g) in water (25 ml). The mixture was stirred for 2 hours andevaporated under reduced pressure to remove the tetrahydrofuran. Theresidue was diluted with water, washed with diethyl ether (twice) andthe aqueous phase acidified with concentrated hydrochloric acid thenextracted with ethyl acetate (three times). The extracts were combined,washed with brine, dried over magnesium sulfate, filtered and evaporatedunder reduced pressure to give a yellow solid which was washed with asmall volume of dichloromethane and filtered to provide2-(dibenzofuranyl-2-oxy)-2-methylthioacetic acid, 5.90 g as a creamcoloured solid.

¹H NMR (DMSO-d₆) δ ppm: 2.16 (3H, s); 6.02 (1H, s) 7.22-7.26 (1H, dd);7.38-7.42 (1H, dd); 7.50-7.54 (1H, dd); 7.64-7.70 (2H, m); 7.90 (1H, m);8.10-8.14 (1H, d).

Step 3

In a similar procedure to Stage 2 of Example1,2-(dibenzofuranyl-2-oxy)-2-methylthioacetic acid was condensed witht-butylamine to give the required product.

¹H NMR (CH₃CN) δ ppm: (some signals at high field obscured by NMRsolvent) 5.56 (1H, s); 6.74 (1H, s); 7.20 (1H, d); 7.35 (1H, t); 7.48(1H, t); 7.56 (2H, m); 7.70 (1H, s); 7.98 (1H, d).

The following amides were prepared using a similar procedure.

Compound No. 52 of Table 50: using 2-cyano-1-methoxy-prop-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 3.40 (3H, 2×s); 3.64 (1H, m); 3.72 (1H, 2×s); 5.74(1H, 2×s); 7.22 (1H, d); 7.36 (2H, m); 7.48 (1H, t); 7.56 (2H, m); 7.72(1H, s); 8.00 (1H, d).

Compound No. 84 of Table 50: using propargylamine, ¹H NMR (CH₃CN) δ ppm:2.44 (1H, s); 4.03 (2H, m); 5.72 (1H, s); 7.22 (1H, dd); 7.36 (1H, t);7.49 (1H, t); 7.56 (3H, m); 7.71 (1H, s); 8.00 (1H, d).

Compound No. 70 of Table 50: using allylamine, ¹H NMR (CH₃CN) δ ppm:3.88 (2H, t); 5.07 (1H, d); 5.16 (1H, d); 5.16 (1H, d); 5.72 (1H, s);5.88 (1H, m); 7.22 (1H, dd); 7.36 (2H, t s); 7.49 (1H, t); 7.56 (3H, m);7.71 (1H, s); 8.00 (1H, d).

Compound No. 189 of Table 50: using 2-phenyl-prop-2-ylamine, ¹H NMR(CH₃CN) δ ppm: 5.62 (1H, s); 7.16 (1H, t); 7.25 (4H, m); 7.38 (3H, m);7.50 (1H, t); 7.58 (2H, m); 7.71 (1H, s); 8.00 (1H, d).

Compound No. 120 of Table 50: using thiazol-2-ylamine, ¹H NMR(CH₃CN) δppm: 6.00 (1H, s); 7.12 (1H, s); 7.31 (1H, d); 7.37 (1H, t); 7.48 (2H,m); 7.58 (2H, m); 7.80 (1H, s); 8.02 (1H, d).

Compound No. 122 of Table 50: using furfurylamine, ¹H NMR (CH₃CN) δ ppm:4.44 (2H, dq); 5.72 (1H, s); 6.24 (1H, s); 6.32 (1H, s); 7.20 (1H, d);7.36 (2H, m); 7.54 (3H, m); 7.63 (1H, s); 7.70 (1H, s); 7.99 (1H, d).

Compound No. 133 of Table 50: using 4-fluoroaniline, ¹H NMR (CH₃CN) δppm: 5.83 (1H, s); 7.09 (2H, t); 7.30 (1H, d); 7.36 (1H, t); 7.49 (1H,t); 7.58 (2H, m); 7.65 (2H, m); 7.80 (1H, s); 8.02 (1H, d); 8.96 (1H,s).

Compound No. 128 of Table 50: using 2-cyanoaniline, ¹H NMR (CH₃CN) δppm: 5.94 (1H, s); 7.35 (4H, m); 7.50 (1H, t); 7.58 (1H, d); 7.68 (1H,t); 7.74 (1H, d); 7.83 (1H, s); 7.95 (1H, d); 8.02 (1H, s); 9.22 (1H,s).

Compound No. 38 of Table 50: using 2-cyano-3-methyl-but-2-ylamine, ¹HNMR (CH₃CN) δ ppm: 1.04 (6H, 4×d); 2.41 (1H, m); 5.72 (1H, s); 7.22 (2H,d); 7.36 (1H, t); 7.49 (1H, t); 7.56 (2H, m); 7.70 (1H, s); 8.01 (1H,d).

Compound No. 35 of Table 50: using 2-cyano-prop-2-ylamine, ¹H NMR(CH₃CN) δ ppm: 5.72 (1H, s); 7.24 (1H, d); 7.37 (2H, m); 7.49 (1H, t);7.56 (2H, m); 7.72 (1H, s); 8.00 (1H, d).

EXAMPLE 13

This Example illustrates the preparation of2-(3-bromo-8-methylquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 72)

Stage 1: Preparation of 3-bromo-6-hydroxy-8-methylquinoline

6-Amino-3-bromo-8-methylquinoline (12 g) was suspended in a mixture ofwater (5 ml) and phosphoric acid (60 ml) and heated in a sealed glasstube to 180° C. for 3 days. The mixture was cooled to ambienttemperature, diluted with water then taken to pH 3-4 with aqueous (2M)sodium hydroxide. The precipitate formed was filtered from solution,washed with cold water and sucked to dryness to give3-bromo-6-hydroxy-8-methylquinoline, 11.0 g, as a grey solid.

¹H NMR (d6-DMSO) δ ppm: 2.56 (3H, s); 3.50 (1H, bs); 6.91 (1H, d); 7.15(1H, d); 8.38 (1 h, d); 8.61 (1H, d).

Stage 2: Preparation of ethyl2-(3-bromo-8-methylquinolinyl-6-oxy)-2-methylthioacetate

In a similar procedure to Stage 2, Step 1 of Example 5,3-bromo-8-methyl-6-hydroxyquinoline was reacted with ethyl2-chloro-2-methylthioacetate to give ethyl2-(3-bromo-8-methylquinolinyl-6-oxy)-2-methylthioacetate as a paleyellow oil.

¹H NMR (CDCl₃) δ ppm: 1.36 (3H, t); 2.23 (3H, s); 2.76 (3H, s);4.27-4.40 (2H, m); 5.69 (1H, s); 6.97 (1H, d); 7.37 (1H, d); 8.18 (1H,d); 8.80 (1H, d).

In a similar procedure to Stage 2, Step 2 of Example 5, ethyl2-(3-bromo-8-methylquinolinyl-6-oxy)-2-methylthioacetate was hydrolysedto give 2-(3-bromo-8-methylquinolinyl-6-oxy)-2-methylthioacetic acid asan off white solid.

¹H NMR (CDCl₃) δ ppm: 2.22 (3H, s); 2.71 (3H, s); 5.68 (1H, s); 6.97(1H, d); 7.34 (1H, d); 8.17 (1H, d); 8.75 (1H, d).

In a similar procedure to Stage 2 of Example1,2-(3-bromo-8-methylquinolinyl-6-oxy)-2-methylthioacetic acid wascondensed with tert. butylamine to give2-(3-bromo-8-methylquinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide.

¹H NMR (CDCl₃) δ ppm: 1.43 (9H, s); 2.20 (3H, s); 2.78 (3H, s); 5.58(1H, s); 6.42 (1H, s); 7.01 (1H, d); 7.32 (1H, d); 8.21 (1H, d); 8.82(1H, d).

EXAMPLE 13A

This Example illustrates the preparation of2-(3-iodo-quinolinyl-6-oxy)-2-methylthio-N-(2-methylprop-2-yl)acetamide(Compound No. 12 of Table 58A)

Step 1: Preparation of 3-iodo-6-hydroxyquinoline

To a stirred mixture of 3-bromo-6-hydroxyquinoline (preparationdescribed in Liebigs Ann Chem (1966), 98-106) (1.0 g), sodium iodide(1.34 g) and copper iodide (0.09 g) in dioxane (6.5 ml) was addedN,N,N′,N′-tetramethyl-ethane-1,2-diamine (0.1 ml) in a sealed tube. Themixture was stirred at 120° C. for 12 h and upon cooling was treatedwith aqueous ammonia followed by aqueous hydrochloric acid. Extractionwith ethyl acetate, drying of the organic phase over magnesium sulphate,filtration and evaporation under reduced pressure gave the requiredproduct (MH⁺ 272) as a light brown coloured powder that was used as suchin the next step.

Step 2: Preparation ofN-tert-Butyl-2-(3-iodo-quinolin-6-yloxy)-2-methylsulfanyl-acetamide

In a similar procedure to Stage 2, Step 1 of Example 5,3-iodo-6-hydroxy-quinoline was reacted with chloro-methylsulfanyl-aceticacid ethyl ester to give (3-iodo-quinolin-6-yloxy)-methylsulfanyl-aceticacid ethyl ester as a yellow coloured solid.

In a similar procedure to Stage 2, Step 2 of Example 5,(3-iodo-quinolin-6-yloxy)-methylsulfanyl-acetic acid ethyl ester washydrolysed to give (3-iodo-quinolin-6-yloxy)-methylsulfanyl-acetic acidas a yellow coloured solid (MH⁺ 376).

In a similar procedure to Stage 2 of Example 1,(3-iodo-quinolin-6-yloxy)-methylsulfanyl-acetic acid was condensed witht-butylamine to giveN-tert-butyl-2-(3-iodo-quinolin-6-yloxy)-2-methylsulfanyl-acetamide as awhite solid (MH⁺ 431).

¹H NMR (CDCl₃) δ ppm: 1.41 (9H, s); 2.20 (3H, s); 5.58 (1H, s); 6.42(1H, s); 7.12 (1H, d); 7.45 (1H, dd); 8.02 (1H, d), 8.47 (1H, d); 8.92(1H, d).

Compound No. 52 of Table 58A was prepared following a similar procedureusing 2-cyano-1-methoxy-prop-2-ylamine.

EXAMPLE 13B

This Example illustrates the preparation of2-(3-Bromo-8-fluoro-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-acetamide(Compound No. 12 of Table 62B)

Stage 1: Preparation of 3-Bromo-8-fluoro-quinolin-6-ol Step 1:Preparation of 3-Bromo-8-fluoro-6-methoxy-quinoline

A mixture of 3-bromo-6-methoxy-quinolin-8-ylamine (preparation describedin Journal of Pharmaceutical Sciences (1984), 73(12), 1854-6) (5.0 g) in20 ml fluoroboric acid, (50 wt % solution in water) at ˜5° C. wastreated with a solution of sodium nitrite (1.9 g in 3 ml of water) overa period of 40 minutes. The reaction mixture was stirred at roomtemperature for 2 hours after which time the precipitate was filteredand washed with cold diethyl ether. The resulting brown powder was addedportionwise to hot dichlorobenzene over 1.5 hours. Stirring was thencontinued for an additional 30 min at 190° C. On cooling to roomtemperature, the mixture was treated with dilute hydrochloric acid anddiluted with ethyl acetate. The organic phase was washed with dilutesodium hydroxide, dried over sodium sulphate, filtered and evaporatedunder reduced pressure to give a black oil that was fractionated bychromatography (silica; cyclohexane/ethyl acetate) to give the requiredproduct (M+256)

¹H NMR (CDCl₃) δ ppm: 3.88 (3H, s); 6.70 (1H, s); 7.04 (1H, dd); 8.10(1H, s); 8.72 (1H, d).

Step 2

A mixture of the product from Step 1 (1.5 g) and hydrobromic acid (48 wt% solution in water) (6.8 ml) was refluxed for 62 hours. The mixture wascooled to ambient temperature, treated with sodium hydroxide (2M) andextracted with ethyl acetate. The extract was dried over sodium sulfate,filtered and evaporated under reduced pressure to give the requiredproduct, 3-bromo-8-fluoro-quinolin-6-ol, (M+242). ¹H NMR (DMSO) δ ppm:6.93 (1H, d); 7.05 (1H, dd); 8.52 (1H, dd); 8.66 (1H, d); 10.52 (1H, s).

Stage 2: Preparation of2-(3-Bromo-8-fluoro-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-acetamide

In a similar procedure to Stage 2, Step 1 of Example 5,3-bromo-8-fluoro-quinolin-6-ol was reacted withchloro-methylsulfanyl-acetic acid ethyl ester to give(3-Bromo-8-fluoro-quinolin-6-yloxy)-methylsulfanyl-acetic acid ethylester.

1H NMR (CDCl3) δ ppm: 1.35 (3H, t); 2.25 (3H, s); 4.30-4.40 (2H, m);5.69 (1H, s); 6.96 (1H, d); 7.26 (1H, dd); 8.24 (1H, dd); 8.83 (1H, d).

In a similar procedure to Stage 2, Step 2 of Example 5,(3-Bromo-8-fluoro-quinolin-6-yloxy)-methylsulfanyl-acetic acid ethylester was hydrolysed to give3-bromo-8-fluoro-quinolin-6-yloxy)-methylsulfanyl-acetic acid (M+348).

In a similar procedure to Stage 2 of Example 1,3-bromo-8-fluoro-quinolin-6-yloxy)-methylsulfanyl-acetic acid wascondensed with t-butylamine to give2-(3-bromo-8-fluoro-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-acetamide(M+403).

1H NMR (CDCl3) δ ppm: 1.42 (9H, s); 2.20 (3H, s); 5.58 (1H, s); 6.45(1H, s); 6.99 (1H, d); 7.20 (1H, dd); 8.28 (1H, dd); 8.85 (1H, d).

Compound No. 52 of Table 62B was prepared following a similar procedureusing 2-cyano-1-methoxy-prop-2-ylamine.

EXAMPLE 13C

This Example illustrates the preparation ofN-tert-Butyl-2-(3-iodo-8-methyl-quinolin-6-yloxy)-2-methylsulfanyl-acetamide(Compound No. 12 of Table 72A)

Step 1: Preparation of 3-iodo-8-methyl-quinolin-6-ol

In a similar procedure to Step 1 of Example 13A,3-bromo-8-methyl-quinolin-6-ol (preparation described in Example 13Stage 1) was reacted sodium iodide, copper iodide andN,N,N′,N′-tetramethyl-ethane-1,2-diamine to give the required product,3-iodo-8-methyl-quinolin-6-ol, as a brown coloured solid (MH⁺ 286).

¹H NMR (CDCl₃) δ ppm: 2.61 (3H, s); 6.92 (1H, d); 7.20 (1H, d); 8.60(1H, dd); 8.79 (1H, d).

Step 2: Preparation of(3-Iodo-8-methyl-quinolin-6-yloxy)-methylsulfanyl-acetic acid ethylester

In a similar procedure to Stage 2, Step 1 of Example 5,3-iodo-8-methyl-quinolin-6-ol, was reacted withchloro-methylsulfanyl-acetic acid ethyl ester to give (3-iodo-8-methylquinolin-6-yloxy)-methylsulfanyl-acetic acid ethyl ester as a yellowcoloured solid (MH⁺ 418).

In a similar procedure to Stage 2, Step 2 of Example 5,(3-iodo-8-methyl-quinolin-6-yloxy)-methylsulfanyl-acetic acid ethylester was hydrolysed to give(3-iodo-8-methyl-quinolin-6-yloxy)-methylsulfanyl-acetic acid as ayellow coloured solid ([M-1]⁺ 388).

In a similar procedure to Stage 2 of Example 1,(3-iodo-8-methyl-quinolin-6-yloxy)-methylsulfanyl-acetic acid wascondensed with t-butylamine to giveN-tert-Butyl-2-(3-iodo-8-methyl-quinolin-6-yloxy)-2-methylsulfanyl-acetamideas a white solid ([M+1]⁺ 445).

¹H NMR (CDCl₃) δ ppm: 1.41 (9H, s); 2.20 (3H, s); 2.54 (3H, s), 5.56(1H, s); 6.42 (1H, s); 6.98 (1H, d); 7.32 (1H, dd); 8.42 (1H, d), 8.95(1H, d).

Compound No. 52 of Table 72A was prepared following a similar procedureusing 2-cyano-1-methoxy-prop-2-ylamine.

EXAMPLE 13D

This examples illustrates the preparation of2-(3-bromo-8-chloro-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-acetamide(Compound No. 12 of Table 62)

In a similar procedure to Step 2 of Example 6,6-amino-3-bromo-8-chloroquinoline [preparation given in J Am Chem Soc(1955), 77, 4175-4176] was hydrolysed to give3-bromo-8-chloro-6-hydroxyquinoline as a brown solid.

¹H NMR (CDCl₃) δ ppm: 7.00 (1H, d); 7.52 (1H, d); 8.17 (1H, d); 8.77(1H, d); very broad signal at 7 ppm for OH.

In a similar procedure to Stage 2, Step 1 of Example 5,3-bromo-8-chloro-6-hydroxyquinoline was reacted with ethyl2-bromo-2-methylthioacetate to give ethyl2-(3-bromo-8-chloroquinolinyl-6-oxy)-2-methylthioacetate as a yellowgum.

¹H NMR (CDCl₃) δ ppm: 1.37 (3H, t); 2.23 (3H, s); 4.28-4.40 (2H, m);5.69 (1H, s); 7.08 (1H, d); 7.68 (1H, d); 8.25 (1H, d); 8.90 (1H, d).

In a similar procedure to Stage 2, Step 2 of Example 5, ethyl2-(3-bromo-8-chloroquinolinyl-6-oxy)-2-methylthioacetate was hydrolysedto 2-(3-bromo-8-chloroquinolinyl-6-oxy)-2-methylthioacetic acid as acolourless solid.

¹H NMR (d6-DMSO) δ ppm: 2.17 (3H, s); 6.16 (1H, s); 7.52 (1H, d); 7.86(1H, d); 8.68 (1H, d); 8.93 (1H, d).

In a similar procedure to Stage 2 of Example 1,2-(3-bromo-8-chloroquinolinyl-6-oxy)-2-methylthioacetic acid wascondensed with tert-butyl amine to give2-(3-bromo-8-chloro-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-acetamide(Compound No. 12 of Table 62) as a white solid, m.p. 160-161° C.

¹H NMR (CDCl₃) δ ppm: 1.43 (9H, s); 2.20 (3H, s); 5.57 (1H, s); 6.39(1H, bs); 7.11 (1H, d); 7.62 (1H, d); 8.29 (1H, d); 8.92 (1H, d).

EXAMPLE 13E

This examples illustrates the preparation of2-(3-bromo-8-iodo-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-acetamide(Compound No. 12 of Table 62A).

Stage 1. Preparation of 3-bromo-8-iodo-quinolin-6-ol Step 1

2-Iodo-4-nitroaniline (5.3 g) in acetic acid (40 ml) was treated with2,2,3 tribromopropanal (5.9 g) and the mixture was heated at 110° C. for2 h after which it was cooled to room temperature and filtered. Thefiltered solid was washed with diethyl ether, suspended in water andtreated with saturated sodium hydrogen carbonate. Extraction with ethylacetate, drying over sodium sulphate, filtration and evaporation underreduced pressure gave the desired product,3-bromo-8-iodo-6-nitro-quinoline, as a yellow solid after chromatography(silica; hexane/ethyl acetate) (M+379).

¹H NMR (CDCl₃) δ ppm: 8.50 (1H, d); 8.72 (1H, d); 9.08 (1H, d); 8.62(1H, d).

Step 2

In a similar procedure to Stage 1, Step 1 of Example 6,3-bromo-8-iodo-6-nitro-quinoline was treated with concentratedhydrochloric acid and iron powder to give3-bromo-8-iodo-quinolin-6-ylamine as a beige powder ((M+1)⁺ 351).

¹H NMR (CDCl₃) δ ppm: ¹H NMR (CDCl₃) δ ppm: 4.04 (1H, bs); 6.77 (1H,bs); 7.79 (1H, bs); 7.98 (1H, bs); 8.67 (1H, bs).

Step 3

In a procedure described into Step 2 of Example 6,3-bromo-8-iodo-quinolin-6-ylamine from Step 2 was hydrolysed to give3-bromo-8-iodo-quinolin-6-ol as a yellow solid ((M+2)⁺ 352).

¹H NMR (DMSO-d₆) δ ppm: 7.20 (1H, d); 7.98 (1H, d); 8.52 (1H, d); 8.73(1H, d); 40.50 (1H, s).

Stage 2 Step 1

In a similar procedure to Stage 2, Step 1 of Example 5,3-bromo-8-iodo-quinolin-6-ol (from Stage 1, Step 3, Example 13E) wasreacted with chloro-methylsulfanyl-acetic acid methyl ester to give(3-bromo-8-iodo-quinolin-6-yloxy)-methyl-sulfanyl-acetic acid methylester as a yellow solid ((M+2)⁺ 470).

¹H NMR (CDCl₃) δ ppm: 2.22 (3H, s); 3.89 (3H, s); 5.70 (1H, s); 7.15(1H, d); 8.15 (1H, d); 8.20 (1H, d); 8.86 (1H, d).

In a similar procedure to Stage 2, Step 2 of Example 5,(3-bromo-8-iodo-quinolin-6-yloxy)-methyl-sulfanyl-acetic acid methylester was hydrolysed to(3-bromo-8-iodo-quinolin-6-yloxy)-methyl-sulfanyl-acetic acid as ayellow solid ((M+2)⁺ 456).

¹H NMR (d6-DMSO) δ ppm: 2.17 (3H, s); 6.13 (1H, s); 7.59 (1H, d); 8.20(1H, d); 8.59 (1H, d); 8.89 (1H, d).

In a similar procedure to Stage 2 of Example 1,(3-bromo-8-iodo-quinolin-6-yloxy)-methyl-sulfanyl-acetic acid wascondensed with tert-butyl amine to give2-(3-Bromo-8-iodo-quinolin-6-yloxy)-N-tert-butyl-2-methylsulfanyl-acetamide(Compound No. 12 of Table 62A) as a white solid, m.p. 171-172° C.

¹H NMR (CDCl₃) δ ppm: 1.43 (9H, s); 2.19 (3H, s); 5.57 (1H, s); 6.39(1H, bs); 7.19 (1H, d); 8.10 (1H, d); 8.20 (1H, d); 8.89 (1H, d).

EXAMPLE 14

This Example illustrates the fungicidal properties of compounds offormula (1).

The compounds were tested in a leaf disk assay, with methods describedbelow. The test compounds were dissolved in DMSO and diluted into waterto 200 ppm. In the case of the test on Pythium ultimum, they weredissolved in DMSO and diluted into water to 20 ppm.

Erysiphe graminis f.sp. hordei (barley powdery mildew): Barley leafsegments were placed on agar in a 24-well plate and sprayed with asolution of the test compound. After allowing to dry completely, forbetween 12 and 24 hours, the leaf disks were inoculated with a sporesuspension of the fungus. After appropriate incubation the activity of acompound was assessed four days after inoculation as preventivefungicidal activity.

Erysiphe graminis f.sp. tritici (wheat powdery mildew): Wheat leafsegments were placed on agar in a 24-well plate and sprayed with asolution of the test compound. After allowing to dry completely, forbetween 12 and 24 hours, the leaf disks were inoculated with a sporesuspension of the fungus. After appropriate incubation the activity of acompound was assessed four days after inoculation as preventivefungicidal activity.

Puccinia recondita f.sp. tritici (wheat brown rust): Wheat leaf segmentswere placed on agar in a 24-well plate and sprayed with a solution ofthe test compound. After allowing to dry completely, for between 12 and24 hours, the leaf disks were inoculated with a spore suspension of thefungus. After appropriate incubation the activity of a compound wasassessed nine days after inoculation as preventive fungicidal activity.

Septoria nodorum (wheat glume blotch): Wheat leaf segments were placedon agar in a 24-well plate and sprayed with a solution of the testcompound. After allowing to dry completely, for between 12 and 24 hours,the leaf disks were inoculated with a spore suspension of the fungus.After appropriate incubation the activity of a compound was assessedfour days after inoculation as preventive fungicidal activity.

Pyrenophora teres (barley net blotch): Barley leaf segments were placedon agar in a 24-well plate and sprayed with a solution of the testcompound. After allowing to dry completely, for between 12 and 24 hours,the leaf disks were inoculated with a spore suspension of the fungus.After appropriate incubation the activity of a compound was assessedfour days after inoculation as preventive fungicidal activity.

Pyricularia oryzae (rice blast): Rice leaf segments were placed on agarin a 24-well plate and sprayed with a solution of the test compound.After allowing to dry completely, for between 12 and 24 hours, the leafdisks were inoculated with a spore suspension of the fungus. Afterappropriate incubation the activity of a compound was assessed four daysafter inoculation as preventive fungicidal activity.

Botrytis cinerea (grey mould): Bean leaf disks were placed on agar in a24-well plate and sprayed with a solution of the test compound. Afterallowing to dry completely, for between 12 and 24 hours, the leaf diskswere inoculated with a spore suspension of the fungus. After appropriateincubation the activity of a compound was assessed four days afterinoculation as preventive fungicidal activity.

Phytophthora infestans (late blight of potato on tomato): Tomato leafdisks were placed on water agar in a 24-well plate and sprayed with asolution of the test compound. After allowing to dry completely, forbetween 12 and 24 hours, the leaf disks were inoculated with a sporesuspension of the fungus. After appropriate incubation the activity of acompound was assessed four days after inoculation as preventivefungicidal activity.

Plasmopara viticola (downy mildew of grapevine): Grapevine leaf diskswere placed on agar in a 24-well plate and sprayed a solution of thetest compound. After allowing to dry completely, for between 12 and 24hours, the leaf disks were inoculated with a spore suspension of thefungus. After appropriate incubation the activity of a compound wasassessed seven days after inoculation as preventive fungicidal activity.

Septoria tritici (leaf blotch): Conidia of the fungus from cryogenicstorage were directly mixed into nutrient broth (PDB potato dextrosebroth). After placing a (DMSO) solution of the test compounds into amicrotiter plate (96-well format) the nutrient broth containing thefungal spores was added. The test plates were incubated at 24 C and theinhibition of growth was determined photometrically after 72 hrs.

Fusarium culmorum (root rot): Conidia of the fungus from cryogenicstorage were directly mixed into nutrient broth (PDB potato dextrosebroth). After placing a (DMSO) solution of the test compounds into amicrotiter plate (96-well format) the nutrient broth containing thefungal spores was added. The test plates were incubated at 24 C and theinhibition of growth was determined photometrically after 48 hrs.

Pythium ultimum (Damping off): Mycelial fragments of the fungus,prepared from a fresh liquid culture, were mixed into potato dextrosebroth. A solution of the test compound in dimethyl sulphoxide wasdiluted with water to 20 ppm then placed into a 96-well microtiter plateand the nutrient broth containing the fungal spores was added. The testplate was incubated at 24° C. and the inhibition of growth wasdetermined photometrically after 48 hours.

The following compounds (number of compound first, followed by tablenumber in brackets) gave at least 60% control of the following fungalinfection at 200 ppm:

Plasmopara viticola, compounds 8 (57), 12 (1), 12 (13), 12 (15), 12(36),12 (44), 12(47), 12 (55), 12 (57), 12 (58), 12 (58A), 12 (59), 12 (60),12 (62), 12 (62B), 12 (72), 12 (72A), 12 (81), 13 (57), 16 (57), 42(57), 43 (57), 47 (57), 47 (72), 48 (57), 52 (13), 52 (57), 52 (58), 52(58A), 52 (59), 52 (60), 52 (61), 52 (72), 52 (81), 53 (1), 53 (62B), 60(57), 62 (31), 63 (57), 68 (57), 68 (61), 68 (62), 68 (72), 82 (57), 133(81), 144 (57), 152 (57), 153 (57), 155 (57), 164 (57), 171 (57), 180(57), 183 (57), 187 (57), 189 (81), 210 (57), 220 (57), 220 (61), 220(62), 224 (57), 224 (61), 227 (1), 226 (57), 227 (57), 230 (57), 231(50), 235 (57);Phytophthora infestans, compounds 12 (1), 12 (13), 12 (15), 12 (44), 12(57), 12 (58), 12 (58A), 12 (59), 12 (60), 12 (62), 12 (62B), 12 (70),12 (72), 12 (72A), 13 (57), 16 (57), 39 (57), 40 (57), 42 (57), 43 (57),47 (57), 47 (62), 47 (72), 48 (57), 49 (57), 50 (57), 50 (62), 50 (72),52 (13), 52 (57), 52 (58), 52 (58A), 52 (59), 52 (60), 52(72), 52 (72A),52 (81), 53 (62B), 60 (57), 62 (57), 63 (57), 68 (57), 68 (61), 68 (72),70 (58), 82 (57), 82 (65), 84 (58), 89 (57), 102 (57), 198 (57), 220(57), 220 (61), 220 (62), 220 (72), 224 (57), 224 (62), 231 (57); 236(57);Erysiphe graminis f.sp. tritici, compounds 4 (57), 7 (57), 8 (57), 11(57), 12 (1), 12 (13), 12 (44), 12 (50), 12 (57), 12 (58), 12 (58A), 12(61), 12 (62), 12 (62B), 12 (72A), 13 (57), 16 (61), 16 (62), 27 (57),35 (50), 35 (57), 35 (58), 39 (57), 42 (57), 43 (57), 45 (57), 46 (57),47 (57), 47 (62), 47 (72), 48 (57), 49 (57), 50 (57), 50 (61), 50 (62),50 (70), 50 (72), 52 (13), 52 (50), 52 (57), 52 (58), 52 (58A), 52 (61),52 (70), 52 (72), 52 (72A), 53 (57), 53 (62B), 62 (57), 63 (57), 68(61), 68 (62), 68 (72), 70 (57), 70 (58), 71 (57), 76 (57), 84 (57), 84(58), 89 (57), 124 (57), 124 (58), 144 (57), 150 (61), 152 (57), 157(57), 158 (57), 159 (57), 160 (57), 164 (57), 165 (57), 172 (57), 173(57), 176 (57), 178 (57), 180 (57), 198 (57), 200 (57), 202 (57), 209(57), 220 (62), 220 (82), 224 (61), 224 (83), 231 (57), 236 (57), 237(57),Pyricularia oryzae, compounds 12 (50), 12 (57), 12 (58), 35 (57), 35(58), 38 (58), 46 (57), 47 (57), 52 (57), 84 (57), 120 (57), 166 (57),189 (57), 200 (57);Botrytis cinerea, compounds 8 (57), 16 (61), 38 (61), 12 (67), 47 (62),12 (83a), 48 (57), 50 (57), 50 (62), 52 (50), 52 (57), 52 (67), 68 (62),68 (61), 68 (72), 120 (58), 122 (50), 124 (58), 133 (57), 164 (57), 169(57), 207 (57), 211 (61), 220 (61),Erysiphe graminis f.sp. hordei, compounds 4 (57), 6 (57), 8 (57), 12(1), 12 (13), 12 (15), 12 (50), 12 (57), 12 (58), 12 (61), 13 (57), 27(57), 33 (57), 35 (50), 35 (57), 35 (58), 38 (50), 38 (58), 38 (61), 39(57), 40 (57), 42 (57), 43 (57), 45 (57), 47 (57), 48 (57), 49 (57), 50(57), 52 (13), 52 (50), 52 (57), 52 (58), 52 (61), 52 (67), 53 (57), 59(57), 60 (57), 62 (57), 63 (57), 65 (57), 70 (13), 70 (50), 70 (57), 70(58), 71 (57), 84 (50), 84 (57), 84 (58), 85 (57), 89 (57), 102 (57),120 (58), 122 (57), 122 (58), 124 (58), 124 (61), 128 (58), 133 (81),144 (57), 150 (58), 150 (61), 152 (57), 153 (57), 157 (57), 158 (57),161 (57), 163 (57), 164 (57), 177 (57), 178 (57), 180 (57), 183 (57),185 (57), 189 (57), 189 (58), 192 (57), 198 (57), 200 (57), 211 (61),212 (57), 216 (57);Puccinia recondita f.sp. tritici, compounds 12 (58A), 12 (72A), 35 (50),47 (57), 47 (72), 52 (58A), 220 (72);Septoria nodorum, compounds 12 (50), 12 (61), 47 (57), 52 (50), 84 (50),84 (57), 120 (57), 133 (57), 198 (57);Septoria tritici, compounds 12 (1), 12 (36), 12 (44), 12 (47), 12 (55),12 (57), 12 (62), 12 (83A), 12 (83B), 16 (57), 16 (61), 16 (72), 47(62), 12 (58A), 12 (60), 47 (62), 12 (62A), 12 (62B), 12 (72a), 47 (72),50 (61), 50 (62), 50 (72), 52 (52), 52 (58A), 52 (61), 52 (62B), 52(72), 52 (72A), 68 (57), 68 (61), 68 (72), 220 (57), 220 (61), 220 (62),220 (72), 224 (57), 224 (61), 224 (62), 230 (50), 226 (57), 228 (57),230 (57), 235 (57), 236 (57), 237 (57).Fusarium culmorum, compounds 12 (58A), 12 (62), 12 (62A), 12 (62B), 12(72A), 16 (57), 16 (61), 16 (62), 47 (62), 47 (72), 50 (62), 50 (72), 52(58A), 52 (72A), 68 (62), 68 (57), 68 (61), 68 (72), 220 (57), 220 (61),220 (62), 220 (72), 235 (57).

The following compounds (number of compound first, followed by tablenumber in brackets) gave at least 60% control of the following fungalinfection at 20 ppm:

Pythium ultitnum, compounds 2 (57), 12 (1), 12 (13), 12 (15), 12 (47),12 (55), 12 (57), 12 (58), 12 (58A), 12 (59), 12 (60), 12 (62), 12(62B), 12 (65), 12 (70), 12 (81), 12 (83b), 12 (36), 12 (44), 13 (57),16 (72), 27 (57), 35 (57), 35 (58), 35 (81), 39 (57), 40 (57), 42 (57),43 (57), 47 (57), 47 (62), 47 (72), 48 (57), 49 (57), 50 (57), 50 (62),50 (72), 52 (57), 52 (58), 52 (58A), 52 (59), 52 (62B), 52 (72), 52(72A), 52 (81), 59 (57), 60 (57), 62 (57), 63 (57), 65 (57), 68 (57), 68(61), 68 (72), 70 (57), 70 (58), 70 (81), 82 (57), 84 (57), 84 (58), 89(57), 120 (57), 122 (57), 122 (58), 124 (57), 133 (57), 133 (58), 133(81), 185 (57), 189 (44), 189 (57), 189 (81), 220 (57), 220 (62), 224(57), 231 (57), 235 (57), 236 (57).

1. A compound of the general formula (1):

wherein Ar is aryl, heteroaryl, or a partially or fully saturated cyclyloptionally containing one or two heteroatoms independently selected fromN, O or S, the aryl, heteroaryl or partially or fully saturated cyclylbeing optionally substituted with one, two, three, four or fivesubstitutents independently selected from halo, cyano, nitro, azido,C₁₋₆ alkyl, halo(C₁₋₆)alkyl, C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl, halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl,halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆ alkenyloxy,halo-(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy, halo(C₂₋₆)alkynyloxy, aryl,aryloxy, aryl(C₁₋₆)alkyl, aryl-(C₁₋₆)alkoxy, heteroaryl, heteroaryloxy,heteroaryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkoxy, —SF₅,—S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2 and the alkyl group isoptionally substituted with halo, —OSO₂(C₁₋₄)alkyl where the alkyl groupis optionally substituted with halo, —CONR^(u)R^(v), —COR^(u),—CO₂R^(u), —CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v),—NR^(u)CO₂R^(v), —SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆alkyl optionally substituted with halogen and R^(u) and R^(v) areindependently H or C₁₋₆ alkyl optionally substituted with halogen, or,in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a 5-or 6-membered ring containing a single nitrogen atom, a single sulphuratom, saturated carbon atoms and optionally a single oxygen atom;wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl, arylor heteroaryl groups or moieties are optionally substituted; R¹ is C₁₋₄alkyl, halo(C₁₋₄)alkyl or C₃₋₄ cycloalkyl; R² is H, C₁₋₈ alkyl, C₃₋₄cycloalkyl, C₂₋₈ alkenyl, cyano(C₁₋₄)alkyl, C₁₋₄ alkoxy(C₁₋₄)alkyl, C₁₋₄alkoxy(C₁₋₄)alkoxy(C₁₋₄)alkyl or benzyloxy(C₁₋₄)alkyl in which thephenyl ring of the benzyl moiety is optionally substituted with C₁₋₄alkoxy; R³ is—(CR^(a)R^(b))_(p)(CR^(c)R^(d))_(q)(X)_(r)(CR^(e)R^(f))_(s)R⁴ whereinR^(a), R^(b), R^(c), R^(d), R^(e) and R^(f) are independently H, C₁₋₄alkyl, halo, cyano, hydroxy, C₁₋₄ alkoxy or C₁₋₄ alkoxycarbonyl, X is(CO), (CO)O, O(CO), O, S(O)_(t) wherein t is 0, 1 or 2, NH orN(C₁₋₆)alkyl, p, r and s are 0 or 1, q is 0, 1 or 2, R⁴ is C₁₋₆ alkyloptionally substituted with one, two or three substituents independentlyselected from halo, cyano or hydroxy, C₁₋₄ alkoxy(C₁₋₄)alkyl, C₁₋₄alkoxy-(C₁₋₄)alkoxy(C₁₋₄)alkyl, benzyloxy(C₁₋₄)alkyl, C₂₋₆ alkenyloxy,—S(O)_(x)(C₁₋₆)alkyl wherein x is 0, 1 or 2 and the alkyl group isoptionally substituted with halo, mono- or di-(C₁₋₆)alkylamino ortri(C₁₋₄)alkylsilyl, or R⁴ is C₂₋₆ alkenyl optionally substituted withone, two or three substituents independently selected from halo, cyano,hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylcarbonyl, C₁₋₆ alkoxycarbonyl or phenyloptionally substituted with C₁₋₄ alkoxy, or R⁴ is —CH₂—C≡C—R⁵, whereinR⁵ is H, C₁₋₈ alkyl, C₃₋₆ cycloalkyl or C₃₋₆ cycloalkyl(C₁₋₄)alkyl inwhich the alkyl or cycloalkyl group is optionally substituted with halo,hydroxy, C₁₋₆ alkoxy, C₁₋₃ alkoxy(C₁₋₃)alkoxy, cyano, C₁₋₄alkylcarbonyloxy, aminocarbonyloxy or mono- ordi(C₁₋₄)alkylaminocarbonyloxy, tri(C₁₋₄)alkylsilyloxy,—S(O)_(g)(C₁₋₆)alkyl where g is 0, 1 or 2, or R⁵ is optionallysubstituted aryl, optionally substituted aryl(C₁₋₄)alkyl, optionallysubstituted aryloxy(C₁₋₄)alkyl, optionally substitutedaryl(C₁₋₄)alkoxy(C₁₋₄)alkyl, optionally substituted heteroaryl oroptionally substituted heteroaryl(C₁₋₄)alkyl, optionally substitutedheteroaryloxy(C₁₋₄)alkyl or optionally substitutedheteroaryl(C₁₋₄)alkoxy(C₁₋₄)alkyl, in which the optionally substitutedaryl and heteroaryl rings or moieties of the R₅ values are optionallysubstituted with one, two or three substituents independently selectedfrom halo, cyano, nitro, azido, C₁₋₆ alkyl, halo(C₁₋₆)alkyl, C₃₋₆cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl, halo(C₂₋₆)alkenyl,C₂₋₆ alkynyl, halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆alkenyloxy, halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy, halo(C₂₋₆)alkynyloxy,aryl, aryloxy, aryl-(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, heteroaryl,heteroaryloxy, heteroaryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkoxy, —SF₅,—S(O)_(g)(C₁₋₄)alkyl wherein g is 0, 1 or 2 and the alkyl is optionallysubstituted with halo, —OSO₂(C₁₋₄)alkyl where the alkyl group isoptionally substituted with halo, —CONR^(g)R^(h), —COR^(g), —CO₂R^(g),—CR^(g)═NR^(h), —NR^(g)R^(h), —NR^(g)COR^(h), —NR^(g)CO₂R^(h),—SO₂NR^(g)R^(h) or —NR^(g)SO₂R^(i) where R^(i) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(g) and R^(h) are independently H or C₁₋₆alkyl optionally substituted with halogen, or, in the case of—CONR^(g)R^(h) or —SO₂NR^(g)R^(h), may join to form a 5- or 6-memberedring containing a single nitrogen atom, a single sulphur atom, saturatedcarbon atoms and optionally a single oxygen atom; wherein any of theforegoing alkyl, cycloalkyl, alkenyl, alkynyl, aryl or heteroaryl groupsor moieties are optionally substituted, or R⁴ is C₃₋₆ cycloalkyl, C₅₋₆cycloalkenyl, aryl, heteroaryl, or a partially or fully saturated cyclyloptionally containing one or two heteroatoms independently selected fromN, O or S, the aryl, heteroaryl or partially or fully saturated cyclylbeing optionally substituted with one, two or three substituentsindependently selected from halo, cyano, nitro, azido, C₁₋₆ alkyl,halo(C₁₋₆)alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆alkenyl, halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl, halo(C₂₋₆)alkynyl, C₁₋₆alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆ alkenyloxy, halo(C₂₋₆)alkenyloxy, C₂₋₆alkynyloxy, halo(C₂₋₆)alkynyloxy, —SF₅, —S(O)_(x)(C₁₋₆)alkyl wherein xis 0, 1 or 2 and the alkyl group is optionally substituted with halo,—OSO₂(C₁₋₄)alkyl where the alkyl group is optionally substituted withhalo, —CONR^(x)R^(y), —CON(OR^(x))R^(y), —COR^(x), —CO₂R^(x),—CR^(x)═NR^(y), —NR^(x)R^(y), —NR^(x)COR^(y), —NR^(x)CO₂R^(y),—SO₂NR^(x)R^(y) or —NR^(x)SO₂R^(z) where R^(z) is C₁₋₈ alkyl optionallysubstituted with halogen and R^(x) and R^(y) are independently H or C₁₋₆alkyl optionally substituted with halogen, or R² and R³ may join to forma saturated or unsaturated 5- or 6-membered ring optionally containingan O or S atom and optionally substituted with one, two or three halo,C₁₋₄ alkyl or mono- or di-(C₁₋₄)alkylaminocarbonyl, or optionallycontaining an N atom which is optionally substituted on the N atom withC₁₋₄ alkyl optionally substituted with halo, C₁₋₆ alkoxy or cyano, orphenyl optionally substituted with nitro, C₁₋₄ alkyl, halo(C₁₋₄)alkyl,C₁₋₄ alkylcarbonyl or heteroaryl, or R² and R³ may join to form a6,6-membered saturated bicycle; wherein any of the foregoing alkyl,cycloalkyl, alkenyl, alkynyl, aryl or heteroaryl groups or moieties areoptionally substituted; L is O or S; and n is 0, 1 or
 2. 2. Compounds(1) according to claim 1 wherein Ar is phenyl optionally substitutedwith one, two, three, four or five substitutents independently selectedfrom halo, cyano, nitro, azido, C₁₋₆ alkyl, halo(C₁₋₆)alkyl, C₃₋₆cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl, halo(C₂₋₆)alkenyl,C₂₋₆ alkynyl, halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆alkenyloxy, halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy, halo(C₂₋₆)alkynyloxy,aryl, aryloxy, aryl(C₁₋₆)alkyl, aryl-(C₁₋₆)alkoxy, heteroaryl,heteroaryloxy, heteroaryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkoxy, —SF₅,—S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2 and the alkyl group isoptionally substituted with halo, —OSO₂(C₁₋₄)alkyl where the alkyl groupis optionally substituted with halo, —CONR^(u)R^(v), —COR^(u),—CO₂R^(u), —CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v),—NR^(u)CO₂R^(v), —SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆alkyl optionally substituted with halogen and R^(u) and R^(v) areindependently H or C₁₋₆ alkyl optionally substituted with halogen, or,in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a 5-or 6-membered ring containing a single nitrogen atom, a single sulphuratom, saturated carbon atoms and optionally a single oxygen atom;wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl, arylor heteroaryl groups or moieties are optionally substituted. 3.Compounds (1) according to claim 1 wherein Ar is phenyl optionallysubstituted with one, two or three substituents independently selectedfrom halo, cyano and C₁₋₆ alkyl.
 4. Compounds (1) according to claim 1wherein Ar is 3,5-dichlorophenyl, 3,4,5-trimethylphenyl,4-bromo-3,5-dimethylphenyl or 4-cyano-3,5-dimethylphenyl.
 5. Compounds(1) according to claim 1 wherein Ar is pyridyl optionally substitutedwith one, two, three, four or five substitutents independently selectedfrom halo, cyano, nitro, azido, C₁₋₆ alkyl, halo(C₁₋₆)alkyl, C₃₋₆cycloalkyl, C₃₋₆ cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl, halo(C₂₋₆)alkenyl,C₂₋₆ alkynyl, halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆alkenyloxy, halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy, halo(C₂₋₆)alkynyloxy,aryl, aryloxy, aryl(C₁₋₆)alkyl, aryl-(C₁₋₆)alkoxy, heteroaryl,heteroaryloxy, heteroaryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkoxy, —SF₅,—S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2 and the alkyl group isoptionally substituted with halo, —OSO₂(C₁₋₄)alkyl where the alkyl groupis optionally substituted with halo, —CONR^(u)R^(v), —COR^(u),—CO₂R^(u), —CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v),—NR^(u)CO₂R^(v), —SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆alkyl optionally substituted with halogen and R^(u) and R^(v) areindependently H or C₁₋₆ alkyl optionally substituted with halogen, or,in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a 5-or 6-membered ring containing a single nitrogen atom, a single sulphuratom, saturated carbon atoms and optionally a single oxygen atom;wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl, arylor heteroaryl groups or moieties are optionally substituted. 6.Compounds (1) according to claim 1 wherein Ar is pyridyl optionallysubstituted with halo.
 7. Compounds (1) according to claim 1 wherein Aris 5-chloropyrid-3-yl.
 8. Compounds (1) according to claim 1 wherein Aris benzothiazolyl optionally substituted with one, two, three, four orfive substitutents independently selected from halo, cyano, nitro,azido, C₁₋₆ alkyl, halo(C₁₋₆)alkyl, C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl, halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl,halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆ alkenyloxy,halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy, halo(C₂₋₆)alkynyloxy, aryl,aryloxy, aryl-(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, heteroaryl, heteroaryloxy,heteroaryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkoxy, —SF₅,—S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2 and the alkyl group isoptionally substituted with halo, —OSO₂(C₁₋₄)alkyl where the alkyl groupis optionally substituted with halo, —CONR^(u)R^(v), —COR^(u),—CO₂R^(u), —CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v),—NR^(u)CO₂R^(v), —SO₂NR^(u)R^(v) or —NRUSO₂R^(w) where R^(w) is C₁₋₆alkyl optionally substituted with halogen and R^(u) and R^(v) areindependently H or C₁₋₆ alkyl optionally substituted with halogen, or,in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a 5-or 6-membered ring containing a single nitrogen atom, a single sulphuratom, saturated carbon atoms and optionally a single oxygen atom;wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl, arylor heteroaryl groups or moieties are optionally substituted. 9.Compounds (1) according to claim 1 wherein Ar is benzothiazolyloptionally substituted with halo.
 10. Compounds (1) according to claim 1wherein Ar is benzothiazol-6-yl.
 11. Compounds (1) according to claim 1wherein Ar is dibenzofuranyl optionally substituted with one, two,three, four or five substitutents independently selected from halo,cyano, nitro, azido, C₁₋₆ alkyl, halo(C₁₋₆)alkyl, C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl, halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl,halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆ alkenyloxy,halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy, halo(C₂₋₆)alkynyloxy, aryl,aryloxy, aryl-(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, heteroaryl, heteroaryloxy,heteroaryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkoxy, —SF₅,—S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2 and the alkyl group isoptionally substituted with halo, —OSO₂(C₁₋₄)alkyl where the alkyl groupis optionally substituted with halo, —CONR^(u)R^(v), —COR^(u),—CO₂R^(u), —CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v), —NRUCO₂R^(v),—SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆ alkyl optionallysubstituted with halogen and R^(u) and R^(v) are independently H or C₁₋₆alkyl optionally substituted with halogen, or, in the case of—CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a 5- or 6-memberedring containing a single nitrogen atom, a single sulphur atom, saturatedcarbon atoms and optionally a single oxygen atom; wherein any of theforegoing alkyl, cycloalkyl, alkenyl, alkynyl, aryl or heteroaryl groupsor moieties are optionally substituted.
 12. Compounds (1) according toclaim 1 wherein Ar is dibenzofuranyl optionally substituted with one,two or three substituents independently selected from halo and C₁₋₆alkyl.
 13. Compounds (1) according to claim 1 wherein Ar isdibenzofuran-2-yl.
 14. Compounds (1) according to claim 1 wherein Ar isquinolinyl optionally substituted with one, two, three, four or fivesubstitutents independently selected from halo, cyano, nitro, azido,C₁₋₆ alkyl, halo(C₁₋₆)alkyl, C₃₋₆ cycloalkyl, C₃₋₆cycloalkyl(C₁₋₄)alkyl, C₂₋₆ alkenyl, halo(C₂₋₆)alkenyl, C₂₋₆ alkynyl,halo(C₂₋₆)alkynyl, C₁₋₆ alkoxy, halo(C₁₋₆)alkoxy, C₂₋₆ alkenyloxy,halo(C₂₋₆)alkenyloxy, C₂₋₆ alkynyloxy, halo(C₂₋₆)alkynyloxy, aryl,aryloxy, aryl(C₁₋₆)alkyl, aryl-(C₁₋₆)alkoxy, heteroaryl, heteroaryloxy,heteroaryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkoxy, —SF₅,—S(O)_(u)(C₁₋₆)alkyl wherein u is 0, 1 or 2 and the alkyl group isoptionally substituted with halo, —OSO₂(C₁₋₄)alkyl where the alkyl groupis optionally substituted with halo, —CONR^(u)R^(v), —COR^(u),—CO₂R^(u), —CR^(u)═NR^(v), —NR^(u)R^(v), —NR^(u)COR^(v),—NR^(u)CO₂R^(v), —SO₂NR^(u)R^(v) or —NR^(u)SO₂R^(w) where R^(w) is C₁₋₆alkyl optionally substituted with halogen and R^(u) and R^(v) areindependently H or C₁₋₆ alkyl optionally substituted with halogen, or,in the case of —CONR^(u)R^(v) or —SO₂NR^(u)R^(v), may join to form a 5-or 6-membered ring containing a single nitrogen atom, a single sulphuratom, saturated carbon atoms and optionally a single oxygen atom;wherein any of the foregoing alkyl, cycloalkyl, alkenyl, alkynyl, arylor heteroaryl groups or moieties are optionally substituted. 15.Compounds (1) according to claim 1 wherein Ar is quinolinyl optionallysubstituted with one, two or three substituents independently selectedfrom halo, C₁₋₄ alkyl, halo(C₁₋₄)alkyl, aryl and heteroaryl. 16.Compounds (1) according to claim 1 wherein Ar is 3-bromoquinolin-6-yl,3-chloroquinolin-6-yl, 3-fluoroquinolin-6-yl, 3,8-dibromoquinolin-6-yl,3-bromo-8-chloroquinolin-6-yl, 3-bromo-8-methylquinolin-6-yl,3-phenylquinolin-6-yl or 3-pyrid-4-ylquinolin-6-yl.
 17. Compounds (1)according to claim 1 wherein Ar is 3-bromoquinolin-6-yl,3,8-dibromo-quinolin-6-yl, 3-bromo-8-chloroquinolin-6-yl or3-bromo-8-methylquinolin-6-yl.
 18. Compounds (1) according to claim 1wherein Ar is 3-bromoquinolin-6-yl, 3,8-dibromo-quinolin-6-yl,3-bromo-8-chloroquinolin-6-yl or 3-bromo-8-methylquinolin-6-yl. 19.Compounds (1) according to claim 1 wherein Ar is3,8-difluoroquinolin-6-yl, 3-fluoro-8 chloroquinolin-6-yl,3-fluoro-8-bromoquinolin-6-yl, 3-fluoro-8-iodoquinolin-6-yl,3-fluoro-8-methylquinolin-6-yl, 3,8-dichloroquinolin-6-yl,3-chloro-8-fluoroquinolin-6-yl, 3-chloro-8-bromoquinolin-6-yl,3-chloro-8-iodoquinolin-6-yl, 3-chloro-8-methylquinolin-6-yl,3,8-bromoquinolin-6-yl, 3-bromo-8-chloroquinolin-6-yl,3-bromo-8-fluoroquinolin-6-yl, 3-bromo-8-iodoquinolin-6-yl,3-bromo-8-methylquinolin-6-yl, 3,8-iodoquinolin-6-yl,3-iodo-8-chloroquinolin-6-yl, 3-iodo-8-bromoquinolin-6-yl,3-iodo-8-fluoroquinolin-6-yl or 3-iodo-8-methylquinolin-6-yl. 20.Compounds (1) according to claim 15 wherein Ar is 8-haloquinolin-6-yl or8-methylquinolin-6-yl.
 21. Compounds (1) according to claim 1 wherein R1is methyl.
 22. Compounds (1) according to claim 1 wherein R2 is H ormethyl.
 23. Compounds (1) according to claim 1 wherein R3 is tert-butyl,1,1,1-trifluoro-2-methylprop-2-yl, 2-cyanoprop-2-yl,1-methoxy-2-methylprop-2-yl, 1-methylthio-2-methylprop-2-yl,1-methoxy-3-methylbut-3-yl, 2-cyano-1-methoxy-prop-2-yl,2-methoxycarbonyl-prop-2-yl or 2-methylaminocarbonylprop-2-yl. 24.Compounds (1) according to claim 1 wherein R3 is2-hydroxymethyl-1-methoxy-prop-2-yl or1-methoxy-2-methoxymethyl-prop-2-yl.
 25. Compounds (1) according toclaim 1 wherein L is O.
 26. Compounds (1) according to claim 1 wherein nis
 0. 27. A process for preparing a compound according to claim 1 asherein described.
 28. A process for preparing a compound according toclaim 1 wherein n is 0, which comprises (a) reacting the compound of theformula (4) with a halogenating agent, (b) reacting the resultingcompound of the formula (5) in the presence of a base with a compoundAr—OH, where R is as defined in claim 1, to yield the compound of theformula (6), (c) converting this compound in the presence of a base tothe corresponding acid of the formula (7) and (d) reacting this acidwith an amine of the formula (8).
 29. A process for preparing a compoundaccording to claim 1 wherein n is 1 or 2, which comprises (a) reactingthe compound of the formula (4) with a halogenating agent, (b) reactingthe resulting compound of the formula (5) in the presence of a base witha compound Ar—OH, where R is as defined in claim 1, to yield thecompound of the formula (6), (c) treating this compound with anoxidising agent to obtain the compounds of the formula (9) or (10), (d)converting this compound in the presence of a base to the correspondingacid of the formula (11) or (12) and (d) reacting the compound of theformula (11) or (12) with an amine of the formula (8).
 30. A process forpreparing a compound according to claim 1 wherein n is 0, whichcomprises (a) reacting the compound of the formula (2) with ahalogenating agent, (b) converting the compound thus obtained of theformula (3) with an alkanethiol of the formula R1-SH, where R1 is asdefined in claim 1, to the compound of the formula (6), (c) convertingthis compound in the presence of a base to the corresponding acid of theformula (7) and (d) reacting this acid with an amine of the formula (8).31. A process for preparing a compound according to claim 1 wherein n is0, which comprises (a) reacting the compound of the formula (13) with anamine of the formula (8) to form the compound of the formula (14), (b)treating this compound with a halogenating agent to yield the compoundof the formula (16) and (c) reacting this compound in the presence of abase with Ar—OH, where Ar is as defined in claim
 1. 32. A process forpreparing a compound according to claim 1 wherein n is 0, whichcomprises (a) reacting the compound of the formula (15) in the presenceof a base with an amine of the formula (8) to form the compound of theformula (16) and (b) reacting this compound in the presence of a basewith Ar—OH, where Ar is as defined in claim
 1. 33. A fungicidalcomposition comprising a fungicidally effective amount of a compound offormula (1) according to claim 1 and a suitable carrier or diluenttherefor.
 34. A method of combating or controlling phytopatho-genicfungi which comprises applying a fungicidally effective amount of acompound of formula (1) according to claim 1 to a plant, to a seed of aplant, to the locus of the plant or seed or to soil or any other plantgrowth medium.